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Summary of Thesis 
 
Transglutaminase 2 (TG2) is an enzyme with a predominant role in cell stress 
response and tissue repair. Dramatically increased production of this enzyme is 
associated with early changes in arthritis, and the activity of the protein has been 
shown to directly contribute to both inflammatory and degenerative arthritis, 
although through distinct molecular mechanisms. Aberrant TG2 activity during joint 
disease might lead to protein modifications that are not normally present in 
extracellular matrix components. Those novel epitopes can possibly serve as a 
qualitative biomarker besides their potential role in disease pathogenesis. TG2 is 
released from cells via a non-conventional route, and this mechanism controls its 
extracellular activity. This pathway is likely to be shared with other proteins 
undergoing alternative secretion, many of which are potent biological signaling 
molecules.  
The aim of this project is to investigate whether non-classical secretion of 
TG2 is mediated by activation of the ligand-gated ion channel 7 (P2X7R) in analogy 
to interleukin-1β processing and release. Specifically, we are exploring whether 
ATP, a P2X7R agonist, which might be released from damaged cells at the sites of 
injury, triggers active release of TG2 from cells.   
To test this hypothesis we first employed macrophage and breast cancer cell 
models, where P2X7R is endogenously expressed, to look for involvement of ATP 
signaling in TG2 externalization through microvesicle shedding. By establishing 
HEK293 cells stably expressing P2X7R we show for the first time that introduction 
of functional P2X7R alone is sufficient to reconstitute rapid non-conventional TG2 
export in a cell model. P2X7R activation induced time-dependent release of TG2 but 
not other cytoplasmic proteins, and this response was blocked by a selective P2X7R 
inhibitor. TG2 release was dependent on Ca2+ influx triggered by P2X7R activation 
and might be related to P2X7R-dependent membrane pore formation. These results 
provide a mechanistic explanation for a link between active TG2 release and 
inflammatory responses. 
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Chapter 1 Introduction 
1.1 Common forms of arthritis  
Osteoarthritis (OA) is the most common form of joint disease in humans. According 
to data provided by Arthritis Research UK approximately eight million people in the 
United Kingdom have painful OA of the knee joint and more than one million adults 
consult their general practitioner each year with OA1. OA is strongly age related 
disorder and during ageing the prevalence to develop OA rapidly rises. Another 
important risk factor is joint injury or medical intervention such as joint surgery, 
which may lead to OA in later life. Other factors such as joint mal-alignment, obesity 
and gender also have a big impact on the outcome of the disease. OA is currently 
classified as a degenerative disease and the changes within the joint are manifested 
by cartilage loss associated with an increase in subchondral bone density and bone 
formation (Tab. 1.1).  
On the other hand rheumatoid arthritis is a chronic autoimmune inflammatory 
disease that affects not only one joint, but can drive systemic inflammation (Tab. 1.1) 
(Pratt et al. 2009). Around 400,000 adults in United Kingdom suffer from RA2. The 
major risk factor is thought to be genetic predisposition, as mutations in allels of 
major histocompatibility complex (MHC) class II or human leukocyte antigen (HLA) 
DR subregion increases risk of developing RA up to 1.5-fold (Klippel 2007). A 
higher prevalence is seen in women than men with a factor of 3:1. As for all 
inflammatory diseases, an unhealthy lifestyle, bacterial or viral infections through 
lifetime can irreversibly lead to the autoimmune response that starts in the joint. 
                                                
1 Information source: http://www.arthritisresearchuk.org/arthritis-information/data-and-statistics/osteoarthritis.aspx 
2 Information source: http://www.arthritisresearchuk.org/arthritis-information/data-and-statistics/rheumatoid-arthritis.aspx 
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Table. 1.1 Comparison of the main features in OA and RA. 
Osteoarthritis (OA) Rheumatoid arthritis (RA) 
Age-related degenerative disease Chronic autoimmune disease 
Gradual loss of cartilage and bone drive 
synovial inflammation 
Inflammation drives destruction of cartilage and 
bone 
Slow progression Moderate to rapid progression 
Primary target organ – cartilage Primary target organ – synovial membrane 
Focal dysregulation within joint Systemic inflammation  
Information in the table taken from Klippel 2007. 
 
1.2 Cells and mediators involved in pathology of OA and RA 
Although the pathology of OA and RA is different, the overall outcome for the 
patient can be similar (Loeser et al. 2012; Ademowo et al. 2013). Traumatic injury, 
aberrant joint loading or autoimmune reaction can lead to loss of articular cartilage, 
increase formation of the blood vessels and infiltration of immune cells into synovial 
fluid (Ademowo et al. 2013). Patients, which are affected by OA or RA, often feel 
tenderness, stiffness or pain within the joint. Different cell types are primary 
involved in the pathology of joint degeneration in OA (Goldring and Goldring 2007) 
and RA (Pratt et al. 2009) progression. 
RA is an autoimmune disease that is mostly driven by activated blood cells 
infiltrating the joint space (Ademowo et al. 2013). Monocytes are being attracted to 
the joint, where they differentiate into macrophages. They secrete proinflammatory 
cytokines such as interleukin-1β (IL-1β) that further recruits T cells, B cells and 
dendritic cells into the joint. However, synovial fibroblasts are also playing an 
important role as they release proinflammatory cytokines: tumor necrosis factor 
alpha (TNF-α) and interleukin-6 (IL-6), which drive destructive responses in 
cartilage and chondrocytes. At the site of inflammation, synovial fibroblasts secrete 
chemokines (such as IL-8) and matrix metalloproteinases (MMPs), which contribute 
to cartilage and bone destruction. Beside elevated levels of cytokines and infiltrating 
cells, new blood vessels forming in the synovial walls, invade the joint space, which 
makes the joint wall thicker and swollen (Klippel 2007). Pannus tissue is forming at 
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the site, where bone, cartilage and synovium meet. Pannus formation further induces 
underlying bone erosion and joint degradation. RA is very heterogeneous disease and 
it is not clear, what drives the inflammation that leads to the disease. Beside genetic 
predispositions, alcohol abuse, smoking, bacterial and viral infections are considered 
as risk factors (Pratt et al. 2009).  
OA is no longer considered as mainly a degenerative disorder as it is 
associated with both local (synovial) inflammation and potentially also low-level 
systemic inflammation (de Lange-Brokaar et al. 2012; van der Kraan 2012) (Fig. 1.1) 
Degradation of cartilage can cause synovitis and lead to changes in subchondral bone 
(Goldring and Goldring 2010). The chondrocytes respond to mechanical forces that 
deplete proteoglycan content, damage the collagen network and promote matrix 
degradation. As the main risk factor for OA is age, this disease develops due to 
changes in joint mechanics that ultimately cause cartilage surface thinning, cartilage 
extracellular matrix (ECM) reorganization, and loss of its elastic properties 
(Goldring 2000). The building blocks of articular cartilage are collagen, mainly type 
II, proteoglycans predominantly aggrecan and various glycoproteins, which upon OA 
progression change their composition. Chondrocytes in articular cartilage normally 
stay in the resting state but during OA progression undergo hypertrophy. 
Chondrocytes in OA cartilage are able to produce various inflammatory mediators, 
such as IL-1β and IL-1β converting enzyme (caspase-1) (de Lange-Brokaar et al. 
2012). This is accompanied with elevated expression of MMPs (1,3 and 13) 
(Goldring and Goldring 2010), aggrecanases (ADAMTS-4 and ADAMTS-5). Also 
proinflammatory cytokines can be present such as IL-6 or TNF-α coming from 
infiltrating cells or synovium. Increased levels of tissue markers for inflammation 
such as advanced glycation endproducts (AGE) and high-mobility group box 
chromosomal protein 1 (HMGB-1) were found in the synovium of spontaneous OA 
mouse model, which positively correlated with increased serum levels of 
proinflammatory cytokine IL-1β (Kyostio-Moore et al. 2011). Moreover, 
accumulation of components of the complement system (C3a and C5b-9) in synovial 
fluid collected from early OA patients, has previously been identified, using 
proteomic techniques and enzyme-linked immunosorbent assays (ELISA) (Wang et 
al. 2012). Fragments of degraded cartilage, which act on synovial fibroblasts to 
release inflammatory mediators, might initiate the presence of inflammation during 
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OA. Alternatively, synovium itself could play a role as source of infiltrating 
macrophages, which drive cartilage destruction (Berenbaum 2012). It is therefore 
important to investigate how chondrocytes respond to inflammatory mediators and 
danger signals present in the synovial fluid, in order to be able to understand the 
molecular mechanisms driving OA progression and to define potential targets for 
therapeutic intervention. 
 
 
Fig. 1.1 Joint destruction in OA and the main mediators involved. Excessive 
mechanical stress on quiescent chondrocytes leads to their differentiation and 
production of cytokines, chemokines and MMPs that drive cartilage degradation. 
Tissue disruption leads to production of damage-associated molecular patterns 
(DAMPs), fragments of degraded ECM and alarmin proteins that feeds back on 
residual macrophages, synovial fibroblasts and chondrocytes to secrete inflammatory 
molecules. This promotes further cartilage destruction, expression of proteolytic 
enzymes and an innate immune response. Reproduced from Sokolove and Lepus 
2013. 
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1.3 Biological markers for arthritis  
The diagnosis of OA is confirmed by x-ray or MRI, yet these scans detect gross 
structural changes, which occur late in disease, and there are currently no reliable 
diagnostic or prognostic biochemical markers for early diagnosis (Rousseau and 
Delmas 2007; Ademowo et al. 2013). Hence, there is an urgent need to identify 
biological markers for early diagnosis and/or patient stratification for therapy 
(Ademowo et al. 2013). The fast growing field of biological markers needs novel 
approaches to identify diagnostics indicators with higher specificity and/or 
sensitivity for distinct disease processes (Rousseau and Delmas 2007). Genetic, 
proteomic and metabolomic studies are in progress to improve the prediction and 
outcome of RA (Smolen et al. 2008) and OA (Goldring and Goldring 2007). For OA, 
it is likely that a combination of several biological markers in addition to imaging 
techniques will be needed to diagnose the stadium of joint disease (Goldring and 
Goldring 2007). As OA is a degenerative disorder affecting mainly joint tissues, 
molecules of bone, cartilage and synovial tissue turnover have been tested as 
potential biomarkers (Berenbaum 2013). Products of metabolism such as MMPs, 
TIMPs and products of cartilage breakdown have been thought to be good candidates 
for detecting pathological changes within joint (Sokolove and Lepus 2013). 
However, changes in protein turnover seem to have a low specificity to detect OA, as 
changes in protein turnover can occur for many reasons and this is particular problem 
in an aged population (Berenbaum 2013)). In the context of RA, mainly 
autoantibodies or cytokines were tested (Smolen et al. 2008). Many of them failed to 
be good candidates for biomarkers, as body fluids from patients showed highly 
variable levels of these molecules independently of disease status. As RA is a highly 
heterogeneous joint disease, which maybe influenced by a range of different gene 
products there are many variations in the pathogenesis of the disorder. 
Recent evidence suggests that diagnostic assays based on the detection of 
proteins or peptides with posttranslational modifications may have a higher 
specificity than assays detecting changes in protein levels (Doyle and Mamula 2002). 
Therefore these assays could potentially be a highly predictive to detect 
abnormalities in RA and OA cartilage. The biochemical modifications within the 
proteins might play an important role during initiation of the disease, compromise 
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protein function and potentially leading to the development of autoimmunity (Doyle 
and Mamula 2005).  
1.4 Post-translational protein modifications 
Protein synthesis is based on the 20 amino acids, which are the building blocks for 
newly synthesized proteins. However, these 20 amino acids can be further 
posttranslationally modified in various ways giving a total of 140 distinctive amino 
acids present in proteins (Doyle and Mamula 2002). The term “posttranslational 
modification” is generally used to describe any type of covalent modification that 
can be added to the synthesized protein/polypeptide in the intracellular or 
extracellular environment. This term can be used to describe the modification of a 
currently present amino acid that subsequently changes its nature through 
introduction of structural bridges within the protein. The covalent modifications 
either occur spontaneously or are enzymatically added to the proteins. There are up 
to 27 different types of protein covalent modifications and the most abundant 
include: N-linked glycosylation, phosphorylation, methylation, ubiquitylation, 
acetylation, citrullination, palmitoylation, sulfation and O-linked glycosylation 
(Khoury et al. 2011). Posttranslational modifications are important for the structure 
and function of proteins, as they can change protein conformation, and they are 
believed to modulate protein stability by acting as allosteric effectors (Xin and 
Radivojac 2012).   
During the inflammatory responses the nature of posttranslational 
modifications such as glycosylation, citrullination, glycation or deamidation is 
altered (Doyle and Mamula 2002). Infection or trauma also induces many 
posttranslational modifications, which are mediated by enzymes that can be released 
at the site of inflammation. Thus, not only protein modifications should be analyzed 
but also localization and catalytic activity of enzymes involved in regulation these 
modifications can provide initial clues of disease progression. Early OA disease-
specific modified peptides are likely to provide a sensitive biochemical indicator, if 
such peptides can be identified in the future, as exemplified by the association of 
citrullinated peptides with RA (Nijenhuis et al. 2004). Anti-citrullinated 
protein/peptide antibodies are a powerful biomarker for diagnosing RA (Szodoray et 
al. 2010). It was shown that anti-citrullinated peptide antibodies that can be detected 
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in the sera of patients with RA are the best disease indicator currently available and 
that they have strong prognostic significance (van Venrooij et al. 2006). Those 
antibodies can be found in RA patient samples with the established test called cyclic 
citrullinated peptide assay, which has a sensitivity reaching up to 80%. One of the 
enzymes that is responsible for mediating posttranslational modifications during 
inflammation is transglutaminase 2 – a member of the transglutaminase family of 
proteins. Transglutaminase 2 is upregulated in the stress response (Siegel et al. 2008) 
and represents a self-antigen during coeliac disease (Sollid 2002). Transglutaminase 
2 has a potential role in OA and is the candidate molecule studied in this project.  
1.5 Family of transglutaminases 
Transglutaminases (TGs) are a family of proteins that mediate post-translational 
protein modifications that are essential in diverse biological processes such as blood 
coagulation, extracellular matrix stabilization or skin barrier formation (Iismaa et al. 
2009). In man, there are nine members of the transglutaminase family described: 
TG1, TG2, TG3, TG4, TG5, TG6, TG7, Factor XIIIa (FXIIIa) and Band 4.2 protein. 
They are closely related to cysteine proteases and together they are classified into the 
superfamily of papain-like enzymes (Lorand and Graham 2003). The expression of 
the different transglutaminases varies between tissues, therefore the original 
nomenclature of the family members was derived form the tissue, where the presence 
and activity of a specific transglutaminase was first detected (Grenard et al. 2001) 
(Tab.1.2). Eight transglutaminases, TG1-7 and FXIIIa, are enzymatically active.  
Band 4.2 protein is the only member that lacks enzymatic activity and acts as a 
scaffolding protein in erythrocytes. Four family members are present as zymogens 
and proteolytic cleavage generates the fully active enzyme. This was reported for 
TG1 (Steinert et al. 1996), TG3 (Ahvazi et al. 2003), TG5 (Pietroni et al. 2008) and 
FXIIIa (Muszbek et al. 1996). All family members have a similar protein structure 
that consist of a N-terminal β-sandwich, α/β catalytic core domain that harbors the 
cysteine-histidine-aspartic acid active site residues together with tryptophan residues 
stabilizing the active site as well as two C-terminal β-barrels (Pinkas et al. 2007). 
TG1 and FXIIIa contain an additional pro-peptide before the N-terminal β-sandwich 
that is cleaved for enzyme activation (Iismaa et al. 2009).  
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Table. 1.2 Tissue expression, function and involvement in disease pathology of 
different members of transglutaminase family. 
 
Protein Other name Main 
distribution 
Biological function  Link with disease 
TG1 TGK, 
keratinocyte TG 
Keratinocytes, 
other tissues at 
low level 
Cornified-envelope 
formation  
Lammellar ichthyosis 
TG2 TGC, tissue TG Ubiquitous 
expression 
Cell adhesion and 
motility, matrix 
assembly,  
signal transduction, 
cell survival, 
apoptosis, cell 
differentiation and 
many others 
Coeliac disease, and many 
others suspected including 
Alzheimer’s disease, 
Parkinson’s disease, 
Huntington’s disease, 
osteoarthritis, breast and 
ovarian cancer 
TG3 TGE, epidermal 
TG 
Epithelium, 
brain,  
hair follicle 
Cell-envelope 
formation 
Dermatitis herpetiformis 
TG4 TGP, prostate 
TG 
Prostate, salivary 
gland 
Semen coagulation Unknown 
TG5 TGx Uterus, 
keratinocytes, 
osteoblasts, 
ovaries, 
mammary gland 
Cornified cell 
envelope formation 
Peeling skin syndrome 
TG6 TGY Testis, 
lungs,  
cerebral cortex, 
olfactory lobe, 
cerebellum, 
spinal cord, 
stratified 
epithelia 
Unknown gluten ataxia, cerebellar 
ataxia  
TG7 TGZ Testis,  
lung,  
and many other 
tissues 
Unknown Unknown 
FXIIIa Fibrin-
stabilizing 
factor 
Platelets,  
monocytes, 
macrophages, 
chondrocytes,  
dendritic cells 
Blood clot 
formation, wound 
healing, bone 
development, 
embryo 
implantation during 
pregnancy 
FXIIIa deficiency 
(= bleeding disorder) 
Band 4.2 B4.2 Erythrocytes, 
bone marrow, 
spleen  
Scaffolding protein 
in membrane of 
erythrocytes 
Unknown 
Table adapted from (Lorand and Graham 2003) and (Mehta and Eckert 2005). 
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1.6 Enzymatic reaction mediated by transglutaminases 
TGs are capable of catalyzing Ca2+-dependent acyl-transferase reactions, which can 
give rise to various posttranslational protein modifications (Aeschlimann and 
Thomazy 2000). The substrates of TGs are mainly the γ-carboxamide group of the 
side chain of the targeted glutamine (Q) residue normally localized within a flexible 
region of the protein (Mehta and Eckert 2005). Q accessibility seems to be more 
important than the sequence, which surrounds the Q residue although there is 
sequence specificity. On the other hand, TGs do not react with free amino acid Q. A 
unique crosslinking reaction is the most characteristic reaction catalysed by TGs and 
results in the formation of covalent Nε(γ-glutamyl)lysyl isopeptide bonds between 
proteins or within polypeptides (Lorand and Graham 2003). However, depending on 
the nature of the substrates available, TGs catalyze other reactions that can be 
grouped into: 1) transamidation – these reactions lead to protein crosslinking or 
amine incorporation; 2) esterification; 3) hydrolysis – involved in deamidation and 
isopeptide cleavage (Iismaa et al. 2009). The reaction starts, when the protein- or 
polypeptide-bound “acceptor” Q reacts with cysteine localized in the TGs active site 
(Fig. 1.2). At first, the thiol group of cysteine (C) together with histidine (H) and 
tryptophan (W) residues form an oxyanion intermediate with the γ-carboxyamide 
group of the Q in the substrate. Then the substrate transiently acylates the thiol group 
in the active site to form the acylenzyme intermediate with the Q-containing 
substrate. This step is rate-limiting and results in the ammonium or amine release and 
formation of a covalently bound transient γ-glutamylthioester (Lorand and Graham 
2003). The reaction can further proceed into transamidation, esterification or 
hydrolysis and depends on the nucleophile that provides the electron pair and all 
reactions ultimately lead to thioester bond cleavage in the enzyme active site and 
enzyme regeneration (Mehta and Eckert 2005) (Fig. 1.3). The transamidation begins 
with the nucleophilic attack of the amino group of the second “donor” substrate 
(Iismaa et al. 2009) (Fig. 1.2). The W residue stabilizes the oxyanion intermediate 
that is formed with the active site C through hydrogen bonding. If the second 
substrate is the ε-amino group of deprotonated lysine localized on another protein, 
the reaction results in protein crosslinking leading to γ-glutamyl-ε-lysine isopeptide 
bond formation between two proteins. Another possibility of transamidation is the 
amine or polyamine incorporation into the acceptor Q on the donor protein. The 
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esterification occurs when the second available substrate is an alcohol. However, in 
the absence of a second donor substrate, a H2O molecule can drive the reaction 
resulting in hydrolysis. This leads to deamidation of the protein-bound glutamine 
residue, i.e. replacement of the –NH2 group into –OH, which converts glutamine into 
glutamate. The hydrolysis can also occur in the presence of already crosslinked 
polypeptide, whereby the isopeptide bond is cleaved by TGs. This effectively 
constitutes the reverse reaction of the second step in the transamidation/esterification 
reaction. The reactions of transamidation compete between each other and with 
esterification and they are reversible (Lorand and Graham 2003). However, both 
reactions leading to hydrolysis proceed only into one direction. 
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Fig. 1.2 Mechanism of reactions catalyzed by transglutaminases. The active site 
of TGs relies on catalytic triad cysteine, histidine and aspartic acid residues, and the 
W involved in the transition state stabilization. The reaction begins when the γ-
carboxamide group in the side chain of Q residue in the first substrate transiently 
acylates the thiol group in the TG2 active site. This leads to the formation of the 
oxyanion intermediate that is stabilized by the hydrogen bonds on both C and W. 
Formation of the thioester acylenzyme intermediate results in release of ammonium. 
In the presence of the second substrate (e.g. an amine), the electron pair of the of the 
amino group enhances the formation of the second oxyanion intermediate stabilized 
by hydrogen bonding with C and W residues. This results in the crosslinking of both 
substrates and release of the product that is followed by enzyme regeneration. 
Reproduced from Iismaa et al 2009.  
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Fig. 1.3 Types of reactions catalyzed by transglutaminases. The Ca2+-dependent 
acyl-transfer reactions mediated by TGs can be classified into transamidation (a, b, 
c), esterification (d) or hydrolysis (e, f) depending on the second nucleophile donor. 
Q acceptor residue (blue rectangle); lysine donor residue (purple ellipse); R (side 
chain of primary amine); R’ (peptide with reactive Q); R’’ (ceramide); R’’’ and R’’’’ 
(the side chains of branched isopeptides). Reproduced from Lorand and Graham 
2003. 
 
1.7 Biological function of TG-mediated reactions 
The reactions catalyzed by transglutaminases have many important biological roles 
(Aeschlimann and Thomazy 2000). The deamidation reaction that preferably occurs 
in an acidic environment leads to the change of uncharged glutamine into negatively 
charged glutamate, which can dramatically affect protein behaviour. This is 
exemplified by the role of deamidation of peptides in the context of coeliac disease 
(Sollid 2002). Cross-linking of two proteins leading to covalent complexes is 
important for mediating tissue stability. TGs’ extracellular activity contributes to 
ECM stabilization by selectively crosslinking proteins (Aeschlimann and Paulsson 
1991; Raghunath et al. 1996; Raghunath et al. 1999). The formation of covalent 
Nε(γ-glutamyl)lysyl isopeptide bonds between or within polypeptides,  enhances the 
strength of the tissue and makes it more resistant to proteolytical or chemical  
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degradation (Aeschlimann and Thomazy 2000). This feature is also important in the 
process of wound healing, the stress responses and programmed cell death 
(Raghunath et al. 1996; Iismaa et al. 2009). For example, stabilization of the 
intracellular content by crosslinking during formation of apoptotic bodies is an 
important function of TG2. Stabilization of protein assemblies is also of importance 
during blood-clot formation and is mediated by FXIIIa (Komáromi et al. 2011). The 
FXIII protein present in plasma is a tetramer that consists of two FXIIIa subunits 
(with transglutaminase activity) and two FXIIIb subunits (belongs to distinct protein 
family and act as inhibitory proteins). In the last phase of the blood coagulation 
cascade, FXIII becomes cleaved by thrombin in the presence of Ca2+. The 
disassembly of the FXIIIb subunits from FXIIIa leads to transglutaminase activation 
and formation of the γ-glutamyl-ε-lysine bridges that stabilize the fibrin clot. This is 
important for avoiding delayed bleeding and the process of wound healing as it 
makes the elastic fibrin matrix resistant to lytic enzymes that can be used for the 
wound closure and infiltration of the repair cells (Iismaa et al. 2009). Thus, both 
FXIIIa and TG2 are important molecules in tissue repair, with specific roles in clot 
formation and angiogenesis. Additionally, the presence of TGs is important in 
differentiation of keratinocytes and their crosslinking activity is required for 
cornification of the epidermal cells (Mehta and Eckert 2005). The expression of TGs 
varies between the skin layers. TG2 is mostly expressed in the dermis and epidermal 
cell adjacent to the basement membrane (Rhgjamonth 1996). Both TG1 and TG5 can 
be detected in the upper layers of epidermis whereas TG3 is present in the outer part 
of granular layer and in the part corresponding to stratum corneum (John et al. 2012). 
It seems that TG2 is involved in stabilizing the junction between the dermal and 
epidermal layers (Candi et al. 2002). On the other hand TG1, TG3 and TG5 
introduce cross-links within the cornified envelope. In this case, not only protein 
cross-linking through transamidation but also anchorages of the protein scaffold to 
the underlying lipid membrane through esterification is of importance (Nemes et al. 
1999). 
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1.8 TG2 – the candidate molecule catalyzing posttranslational protein 
modifications 
1.8.1 TG2 protein expression 
One member of the TG family – transglutaminase 2 (TG2) is a ~80 kDa protein 
widely distributed throughout the body and in many instances expressed at much 
higher level than any of the other enzymes of the family (Thomázy and Davies 1999; 
Lorand and Graham 2003; Nurminskaya and Belkin 2012). As TG2 is the most 
abundantly expressed member of the transglutaminase family, it is also one of the 
most studied and as a consequence has been postulated to have many intra- and 
extracellular functions (Pinkas et al. 2007). Endothelial cells, smooth muscle cells 
and fibroblasts show constitutive expression of TG2 (Iismaa et al. 2009). Moreover, 
macrophages, hepatocytes and chondrocytes express TG2 at variable levels during 
cell differentiation with the highest levels at terminal differentiation (Aeschlimann 
and Thomazy 2000). Most of the protein localizes in the cytosol (80%) but it can also 
be found associated with the cell membrane (10-15%) and nuclear membrane (5%) 
(Lorand and Graham 2003). The TGM2 gene that encodes TG2 contains 13 exons 
and 12 introns and is localized on chromosome 20q11-12. Of the nine described TGs 
in man, TG2 evolved from the same branch as TG3 and TG6 (Grenard et al. 2001). 
TG3 and TG6 likely arose form a cluster of genes that was formed through tandem 
gene duplication of an ancestral tissue type protogene. The elements regulating gene 
expression differ between isoenzymes (Aeschlimann and Thomazy 2000). The 
TGM2 gene contains response elements for retinoic acid (ATRA) (Nagy et al. 1996), 
interleukine-6 (IL-6) (Suto et al. 1993), transforming growth factor β (TGF-β) (Ritter 
and Davies 1998) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) signaling pathways (Mehta and Han 2011a). 
1.8.2 TG2 protein structure and regulation of enzymatic activity 
Similarly to other members of the TG family, TG2 consists of four domains (Mehta 
and Eckert 2005). The first being the β-sandwich on the N-terminus. The catalytic 
core domain contains six β-strands and four α-helices. The active site cysteine 
(C277) is situated in a pocket formed by three α-helices. Two tryptophan residues 
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(W241 and W332), which stabilize the substrate in the active site are flanking the 
pocket. Two other residues of the catalytic triad: histidine (H335) and aspartic acid 
(D358) are localized on the neighboring β-sheets. The core domain is connected to β-
barrel 1 by a flexible loop. β-barrel 1 is created by six β-strands and one β-turn. Most 
distal domain forming the C-terminus is β-barrel 2, which is composed of seven β-
strands that are localized antiparallel to each other. TG2 is a protein with enzymatic 
activity that is allosterically regulated by guanine nucleotides (GTP/GDP) and Ca2+ 
ions (Achyuthan and Greenberg 1987; Begg et al. 2006). Guanosine-5'-triphosphate 
(GTP) serves as a potent allosteric inhibitor of TG2 that suppresses Ca2+-activated 
crosslinking activity. Thus, in the cytosol TG2 remains in a GTP-bound “closed” 
conformation, which lacks transamidation activity (Fig. 1.4). TG2 possesses GTPase 
activity and hydrolyses GTP to GDP (Nakaoka et al. 1994). GTP-binding decreases 
the accessibility of the TG2 substrate binding pocket by masking the active site (Di 
Venere et al. 2000). The GTP-bound conformation of TG2 can be changed by > 200 
µM of Ca2+, facilitating transition into the “open” conformation and inducing 
catalytic activity (Pinkas et al. 2007). Activation of TG2 requires binding of at least 
two Ca2+ ions and is associated with a large conformational change, whereby the two 
C-terminal β-barrels rotate almost 180˚ into the plane (120 Å from closed to open) of 
the core/β-sandwich domain of the enzyme. This rotation opens the active site and 
allows substrate access. Current understanding suggests that TG2 is rapidly 
converted into the activated form upon its release from cell in the presence of high 
extracellular Ca2+ concentrations. However, some reports suggest that secreted TG2 
remains in a GTP/GDP-associated closed conformation after externalization and 
beyond and that this depends on the microenvironment encountered (Johnson and 
Terkeltaub 2005).  
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Fig. 1.4 Schematic representation of the closed and open confirmation of TG2. 
A. closed conformation of TG2 with GDP bound; B. open confirmation after 
addition of a specific inhibitor, Ac-P(DON)LPF-NH2, trapping the transamidation 
intermediate; Blue – N-terminal β-sandwich, green – catalytic core domain, yellow 
and red – β-barrels. Reproduced from Pinkas et al. 2007. 
 
Before the TG2 crystal structure was solved in both the “closed” (GDP-
bound) and “open” (inhibitor-stabilized) state by Liu and colleagues (Liu et al. 2002) 
and Pinkas and colleagues (Pinkas et al. 2007), respectively. It was predicted that 
TG2 catalyzed crosslinking of two proteins with bulky residues would lead to drastic 
changes in TG2 conformation (Liu et al. 2002; Mehta and Eckert 2005). Thus, it was 
postulated that expansion of the TG2 structure is necessary for a internal “channel” 
to be formed, where both substrates could interact with the enzyme’s catalytic 
residues (Mehta and Eckert 2005). Although the GTP/GDP “closed” form seems to 
truly represent the TG2 inactive state, it is still debatable whether the inhibitor- 
bounded “open” structure is actually representing the activated TG2 or just one of 
the transition states (Király et al. 2011). TG2 can act as an ATPase as well and the 
crystal structure with adenosine-5'-triphosphate (ATP) bound has been solved (Han 
et al. 2010). This confirmed that ATP can bind to the same pocket as GTP, but 
showed that different residues coordinate the ATP molecule through hydrogen bonds 
and ionic interactions. However the affinity for ATP is several orders of magnitude 
lower compared to GTP (Achyuthan and Greenberg 1987; Schaertl et al. 2010). 
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The Ca2+ activated TG2 crystal structure is still missing and therefore, the 
presence of 3-6 Ca2+ binding sites proposed in the literature, based on calorimetric 
analysis and computational studies remains a matter of debate (Bergamini et al. 
2010; Király et al. 2013). The crystal structure of the closely related TG3 was solved 
in the presence of Ca2+, and the data set confirmed the existence of three Ca2+ 
binding sites (Ahvazi et al. 2002). The first of the Ca2+ binding sites seems to be 
constantly occupied and crucial for activity. Occupation of the second Ca2+ binding 
site induces small structural changes, but the ultimate conformational change and full 
enzyme activation is mediated by binding of Ca2+ ion into the third site. This allows 
for exposure of the two tryptophane residues and enables them to stabilize the active 
site and approach of the substrate. 
A recent study revealed the presence of an internal disulfide bond that 
situated between cysteine residues (C370-C371 and C230-C370) stabilizes the open 
conformation (Stamnaes et al. 2010). This modification occurs through oxidation in 
the extracellular environment and is regulated by redox conditions. The shift between 
those disulfide bonds is suggested to be a mechanism for regulation of the TG2 
enzymatic activity, whereby oxidation reversibly inactivates the enzyme. Thus, the 
level of active TG2 present in the extracellular milieu can be influenced by the local 
oxidation state and modulated by the presence of Ca2+ as well as substrate. 
An interesting and unusual feature of TG2 is the large conformational change 
for activation. TG2’s structural change to the “open” conformation could potentially 
expose self-epitopes normally not present within the tissue that drive immunological 
responses (Pinkas et al. 2007). In gluten sensitivity, the production of autoantibodies 
against TG2 is detected (Sollid 2002).  
1.8.3 Intracellular functions of TG2 
Inside the cell, where the concentrations of free GTP are fluctuating from 50 to 300 
µM (Király et al. 2011), TG2 efficiently binds and can hydrolyze GTP to GDP, and 
like other G proteins, participates in signaling pathways. Thus, inside the cell TG2 
acts as a high-molecular-weight G-protein involved in G-protein coupled receptor 
signaling, e.g. linking with α1B adrenergic receptor or oxytocin receptor for PLCδ 
signal transduction (Nakaoka et al. 1994). GTP binding probably also protects TG2 
from intracellular cleavage by calpain (Zhang et al. 1998). It is debatable whether 
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intracellular TG2 can catalyse reactions of transamidation (Nurminskaya and Belkin 
2012). Some reports suggest that intracellular TG2-catalysed transamidation 
reactions lead to modification of the small RhoA GTPases and that this promotes its 
binding to ROCK-2 protein kinase and its phosphorylation (Singh et al. 2001). The 
later acts on the cytoskletetal protein vimentin and induces cell adhesion. Also, the 
interaction of TG2 with the microtubule network and more specifically, β-tubulin 
was reported (Song et al. 2013). TG2 can be imported into the nucleus by nuclear 
transporter protein, importin-α3, and has been reported to modify histones (Peng et 
al. 1999). There is also strong evidence that indicates that TG2 mediates cell-matrix 
interactions that affect spreading and migration (Stephens et al. 2004). In fact it was 
shown that TG2 alters cell spreading on a number of ECM substrates such as 
fibronectin, collagen type I and laminin variants. This may involve both intracellular 
as well as extracellular activities of TG2. However, it has been shown TG2 plays a 
role in activation of PKC-α signaling and phosphorylation of FAK kinase that 
enables focal adhesion formation. 
1.8.4 Extracellular TG2 and its interaction partners in the ECM and on the cell 
surface 
 
TG2 interacts with many ECM and transmembrane proteins and this is known to 
affect cell adhesion, motility and spreading as well as signaling and cell 
differentiation (Stephens et al. 2004; Johnson and Terkeltaub 2005; Zemskov et al. 
2006). In many instances, those interactions have roles that are independent of TG2 
transamidation activity. TG2 was shown to interact with fibronectin (Gaudry et al. 
1999), integrins (Akimov and Belkin 2001; Zemskov et al. 2006), syndecan-4 
(Scarpellini et al. 2009); GPR56 (G-protein coupled receptor 56) (Xu et al. 2006), 
low density lipoprotein receptor-related protein 1 (LRP1) (Zemskov et al. 2007), 
MMP-2 (Stephens et al. 2004), platelet-derived growth factor receptor (PDGFR) 
(Zemskov et al. 2009) to name a few (Fig. 1.5). Hydrolysis of extracellular ATP by 
TG2 was postulated to be major function of cell-surface TG2 in osteoblasts and the 
hydrolysis product inorganic pyrophosphate is likely involved in promoting 
mineralization (Nakano et al. 2007).  
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Fig. 1.5 The main binding partners of TG2 present on the cell-surface and in the 
ECM and the effect of these potential interactions on downstream signaling. 
Reproduced from Belkin 2011. 
 
Fibronectin (FN) is a major component of the extracellular matrix (Mecham 
2011). It is a glycoprotein of high molecular weight that is abundantly synthesized by 
fibroblast and many other cell types. It forms an organized ECM. An alternative 
splice variant of FN is available as soluble form in plasma as well. FN is a key 
substrate for cell surface receptors, integrins, and this complex mediates cell 
adhesion, spreading as well as migration. Overexpression of TG2 in fibroblasts 
causes significant increases in crosslinking of FN (Verderio et al. 1998). However, 
TG2 activity is not crucial for FN polymerization into fibrils but enables binding of 
soluble FN and thereby initiate its incorporation into ECM (Akimov and Belkin 
2001). TG2 binds to FN and this interaction does not require catalytic activity 
(Gaudry et al. 1999). The interaction is mediated by a short sequence localized in the 
N-terminal β-sandwich domain. TG2 binds FN at the I6II1,2I7-9 modules that are 
localized in the gelatin-binding region of FN. This interaction does not restrict the 
interaction of FN with integrins. In fibroblasts, TG2 is co-expressed on the cell 
surface with α5β1 integrin (Akimov and Belkin 2001). In monocytes differentiated 
into macrophages cell-surface TG2 was proposed to be in a complex with integrins 
containing the β1, β3 and β5 subunits (Akimov and Belkin 2001). TG2 and β2 
integrin interaction possibly occurs in recycling endosomes as both proteins could be 
co-immunoprecipitated from perinuclear vesicles isolate from NIH3T3 fibroblasts 
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(Zemskov et al. 2011). The recruitment of TG2 into recycling endosomes may 
involve interaction of TG2 with phosphatidylinositol (3)-phosphate (PI(3)P), 
phosphatidylinositol (4)-phosphate (PI(4)P) and phosphatidylinositol (5)-phosphate  
(PI(5)P) through unique sequence (590KIRILGEPKQRKK602) (Zemskov et al. 2011).  
TG2 can be actively internalized from the cell surface and degraded 
intracellularly. It was shown that both PDGF and soluble FN induced TG2 
endocytosis and lysosomal degradation (Zemskov et al. 2009). TG2 internalization 
may require interaction with low density lipoprotein receptor-related protein (LRP1) 
for endocytosis, at least in some cell types (Zemskov et al. 2006). 
Syndecan-4 belongs to the family of heparan sulphate proteoglycans and is a 
transmembrane proteoglycan (Mecham 2011). The TG2 interaction with syndecan-4 
leads to protein kinase C α activation (Telci et al. 2008). Kinase activation 
transactivates inside-out signaling through β1 integrin. TG2 was shown to associate 
with heparan sulphate chains of syndecan-4 and binding was not affected by changes 
in the TG2 conformation and do not affect TG2/FN interactions (Scarpellini et al. 
2009). TG2 and syndecan-4 were co-localizing at the focal adhesions underlying the 
cell membrane of mouse fibroblasts. Wang and colleagues (2012) showed that TG2 
is interacting with heparan sulphate through a binding site 
(202KFLKNAGRDCSRRSSPVYVGR222). Binding of TG2 to syndecan-4 in the 
absence of interaction with FN could restore activation of protein kinase C α 
signaling, ERK1/2 phosphorylation and rescue ability of cells to spread. As MMPs 
are involved in the shedding of heparan sulphate from the cell surface, they proposed 
a model in which TG2-bound is to syndecan-4 in its “closed” form and is shed from 
the cell surface by MMPs and that this cleavage might induce TG2 “opening” and its 
activation. Another group has proposed that heparan sulphate is binding to TG2 in its 
“closed” form as they identified clusters of positively charged residues  (262RRWK265 
and 598KQKRK602) that is adopting a linear binding pocket when TG2 is in its 
compact conformation (Lortat-Jacob et al. 2012). Therefore it was suggested, that 
TG2 activation through Ca2+ leads to a reduced affinity for heparan sulphate and 
therefore TG2 “release” from this complex. 
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1.8.5 Studies using TG2 knock-out mice 
TG2 knock-out mice have been developed using homologous recombination to 
delete exon 6, that encodes catalytic the core domain (Laurenzi and Melino 2001). 
Surprisingly, TG2 deficient mice had no developmental abnormalities, no obvious 
changes within the organs and were reproducing normally. There was some residual 
TG activity detectable in liver and thymus extracts, probably due to TG1 
compensating for TG2 deficiency. The authors of that study showed that TG2 
expression is not necessary for the process of apoptosis as in both thymocytes and 
fibroblasts derived from knock-out animals apoptosis was occurring normally. 
However, the fibroblasts from TG2 deficient mice were less adherent, when 
transferred into cell culture. Another line of TG2 knock-out mice was established 
using the Cre/loxP site-specific system (Nanda et al. 2001). Here exons 6-8 were 
deleted, leading to the loss of the whole TG2 catalytic core. These mice lacking TG2 
were viable and normal in size as well as weight. However, in this study the thymus 
from tgm2-/- mice showed a significant increases in number of apoptotic cells 
induced by dexamethasone treatment indicating that crosslinking of cellular content 
by TG2 might be required for apoptotic cell clearance. As before, the fibroblasts 
isolated from TG2 knock-out mice were less adherent in cell culture than fibroblasts 
from wild-type mice. The lack of obvious abnormalities in TG2 deficient mice may 
be explained by the activity of other TGs (FXIIIa in particular) that partially 
compensate the absence of TG2 (Mehta and Eckert 2005). Many studies have been 
conducted using these mice and collectively, these show that deficiencies become 
apparent once the mice are subjected to different types of stress (Oh et al. 2011). The 
inflammatory response in particular is substantially different than in normal mice 
(Yoo et al. 2013). 
1.9 Involvement of TG2 in pathological processes  
The importance of studying the TGs pleiotropic functions emerged from the 
realization that this enzyme has a big impact on inflammatory, autoimmune as well 
as degenerative diseases (Iismaa et al. 2009). The involvement of TG2 has been well 
documented for different stages of a number of different diseases, where are 
upregulated or aberrant activity of the enzyme has been reported. Most evidence 
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exists for coeliac disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, osteoarthritis, cancer and fibrotic processes in different organs. The common 
link may be a function of T2 in inflammation and wound healing. While many of the 
non-catalytic actions of TG2 are important in the interaction with other molecules, 
however the Ca2+ dependent enzymatic activity is the function that enables TG2 to 
introduce novel post-translational protein modifications. Posttranslational protein 
modifications introduced by TG2 create neo epitopes within a target antigen, which 
could then be recognized by immune cells as foreign molecules (Sollid 2002). 
Therefore, TG2 is an interesting candidate molecule potentially driving reactions 
during inflammatory processes and associate fibrosis in a number of diseases 
including osteoarthritis. 
1.9.1 TG2 and development of autoimmunity  
Coeliac disease (CD) is a chronic autoimmune disorder caused by the ingestion of 
gluten, which is a major component of wheat, rye and barley (Sollid 2002). Gluten 
derived peptides that are resistant to further proteolytic cleavage by proteases due to 
its high proline content. In certain individuals those proteolysis resistant peptides that 
are observed can drive an aberrant immune response. The disease is manifested by 
the inflammation of the gut’s mucosa, ultimately leading to flattening and destruction 
of the intestinal villi and the presence of antibodies against gluten as well as the main 
auto-antigen TG2. Coeliac disease is present in certain individuals of genetic 
predisposition (HLA class II haplotype DQ2 or DQ8).  
The disease develops, when undigested fragments of gluten cross the lamina 
propria of the small bowel, where they become substrates for TG2 (Sollid and Jabri 
2013). Gluten is composed of gliadin and glutenin polypeptides that contain many 
prolines and glutamines in their structure. Therefore they are excellent targets for the 
TG2-dependent deamidation reaction, leading to conversion of glutamines to 
glutamic acid (Fig. 1.6A). Once the deamidated fragments are internalized by antigen 
presenting cells (APC), which residue in the gut, they can be presented to T-cells on 
the HLA DQ2 or DQ8 molecules on the surface of APC. T-cell population (CD4+) is 
responding to deamidated gluten fragments or covalent complexes of gluten peptides 
and TG2. This leads to the autoimmune reaction driven by those reactive T-cells. 
This is followed by activation of autoreactive B-cells, their differentiation into 
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plasma cells and production of antibodies against deamidated gluten or the TG2-
gluten complex. The stable complexes represent the TG2-substrate thioester 
intermediate state this complex has a long half life allowing detection as an antigen 
(Hadjivassiliou et al. 2010). The antibodies to TG2 belong to the immunoglobulin A, 
G and M isotypes (IgA, IgG and IgM) (Sollid and Jabri 2013). The antibodies for 
TG2 are mainly against the Ca2+ activated form of the enzyme (Iversen et al. 2013). 
Understanding of the pathology of coeliac disease helped to develop the novel 
benchmark tests to screen for CD that are widely used in clinics (Caja et al. 2011). 
The tests detect circulating IgA class antibodies against TG2 or antibodies to 
deamidated gliadin peptides. These tests were shown to have the highest sensitivity 
and specificity. This allows diagnosing up to 98% of untreated CD patients. These 
tests are currently the most powerful tools for CD diagnosis and have in some 
instances replaced the small intestinal biopsy that is highly invasive. 
There are some analogies to the situation in rheumatoid arthritis, where auto-
antibodies against citrullinated proteins are formed. The activated T-cells (CD45+) 
infiltrate synovium in patients of specific genetic background (Molberg and Sollid 
2006). The anti-citrullinated antibodies are formed due to activity of peptidyl 
arginine deiminase (PAD). This enzyme replaces the aldimine (=NH) group on the 
protein-bound arginine with a ketone group (=O) to form citrulline in Ca2+ dependent 
manner (Fig. 1.6B). One of the examples are autoantibodies found in RA patients 
specific for citrullinated fillagrin (an epidermal protein) (Nijenhuis et al. 2004). 
Autoantibodies against other citrullinated proteins (such as fibrin and vimentin) have 
been also detected in the synovium of rheumatoid arthritis patients (Szodoray et al. 
2010). It is possible that TG2 involvement in the process of autoimmunity 
development will be only restricted to CD but it is also possible that it occurs in other 
inflammatory conditions as well (Molberg and Sollid 2006; Sollid and Jabri 2013). 
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Fig. 1.6 Main enzymes involved in the development of autoimmunity during 
coeliac disease and rheumatoid arthritis. A) TG2-dependent deamidation in the 
presence of H2O transforms glutamine into glutamic acid by removal of amide. B) 
Deimination reaction catalyzed by PAD enzyme that converts arginine residue into 
citrulline. Reproduced from Molberg and Sollid 2006. 
1.9.2 Protein modifications mediated by TG2 in arthritis 
Once released from the cells, TG2 becomes catalytically active in the extracellular 
space and catalyzes reactions that might promote or contribute to pathology of RA 
and OA. During RA induction in a rat model, TG2 was shown to be secreted from 
the synoviocytes at the sites of collagen type II degradation and to become 
enzymatically active (Lauzier et al. 2012). Recent studies report that TG2 activity 
can enhance joint destruction in a rheumatoid arthritis mouse model (Dzhambazov et 
al. 2009). In this model for collagen-induced arthritis, TG2 was found to be 
responsible for modifying an immunodominant fragment of type II collagen (CII260-
270). TG2 crosslinking and/or deamidation of this epitope mediates a T-cell response 
to the fragment. Moreover, TG2 was shown to transamidate S100A11 calgranulin, 
which is a small protein involved in Ca2+ homeostasis and cytoskeletal 
rearrangement (Cecil and Terkeltaub 2008). Once the S100A11 is released by the 
cells it acts like an inflammatory cytokine and promotes chondrocyte 
differentiation/maturation. Mechanistically, TG2 that localizes in the conditioned 
medium of the mouse articular chondrocytes became enzymatically active when the 
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cells were treated with IL-1β. TG2-mediated crosslinking of the S100A11 molecule 
by forming γ-glutamyl-ε-lysine isopeptide bridges into a functional homodimer, 
which binds more efficiently to the cell surface receptor for advanced glycation end 
products (RAGE). This enhances outside-in signaling, the activation of p38 MAPK 
kinase and NFκB signaling pathways, and ultimately induced chondrocyte 
hypertrophy. 
1.9.3 TG2 expression and activation during chondrocyte 
differentiation/maturation 
Both, TG2 and cell-associated FXIIIa are present in bone and growth plate cartilage 
(Aeschlimann et al. 1996; Nurminskaya and Kaartinen 2006). The 
immunohistochemical staining for TG2 and FXIIIa showed its expression in the 
growth plate of human long bones. Both enzymes are expressed in normal articular 
cartilage, mainly in the superficial zone, deep zone as well as in the central part of 
menisci where maturation occurs (Johnson et al. 2001). Cellular FXIII is a a dimer of 
two FXIIIa subunits, present not only in platelets or monocytes but also in 
chondrocytes of the growth plate (Muszbek et al. 1996). Cartilage contains many 
substrates for TG2 (fibronectin, collagen II, III, V and XI, osteopontin, osteonectin, 
fibrilin) (Aeschlimann et al. 1996) as well as for FXIIIa (Muszbek et al. 2011). 
However, it was shown that besides some common substrates, where often different 
sites are targeted, the enzymes have a preference for distinct molecules (Watanabe et 
al. 2013). 
During embryonic development, chondrocytes of the growth plate undergoes 
terminal differentiation into the hypertrophic cells (Johnson et al. 2003). At a specific 
stage in chondrocyte differentiation, TG2 is upregulated and catalytically active in 
the ECM. Interestingly, the TG2 externalization precedes tissue mineralization 
(Aeschlimann et al. 1995). It is unknown which stimulus is responsible for triggering 
the sudden TG2 externalization. The released TG2 becomes enzymatically active, 
and this is an important stage in chondrocyte maturation and endochondral 
ossification. TG2-mediated crosslinking of the chondrocyte extracellular matrix is 
thought to contribute to formation of the scaffold for matrix calcification. During 
chondrogenesis, TG2 is regulating, through an autocrine pathway, the transition into 
the pre-hypertrophic stage and thereby to inhibit deposition of cartilaginous ECM. 
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Down regulation of TG2 expression increases synthesis of extracellular matrix rich 
in GAGs and promotes expression of early chondrogenic markers (Nurminsky et al. 
2011). Therefore, TG2 plays an active part in chondrocyte differentiation. 
1.9.4 TG2 expression in osteoarthritis 
At the site of injury, chondrocytes become hypertrophic and able to mineralize the 
local tissue (Nurminskaya and Kaartinen 2006). Therefore, hypertrophic 
chondrocytes are found in close proximity of hydroxyapatite and calcium 
pyrophosphate dihydrate crystal deposits. The development of chondrocyte 
hypertrophy close to the surface of the cartilage that ultimately leads to its 
destruction as well as superficial bone formation and remodelling of the subchondral 
bone plate are present in osteoarthritis (Goldring 2000). A characteristic feature of 
osteoarthritic articular cartilage is the presence of high levels enzymatically active 
TG2 that promotes chondrocyte hypertrophy (Tarantino et al. 2011). Thus, it is 
postulated that TG2 serves as a marker of cartilage remodelling in OA progression. 
Immunohistochemical staining reveals, that elevated expression of TG2 is induced in 
within clusters of hypertrophic chondrocytes in OA-affected human articular 
cartilage (Fig. 1.7), which is correlated with increased TG2 levels. A similar pattern 
of stronger TG2 staining is observed in mice after inducing knee instability, leading 
to upregulated TG2 expression. 
 
Fig. 1.7 TG2 expression in normal and osteoarthritic articular cartilage. The 
specimens of human femur head were stained with Hematoxylin-Eosin staining to 
visualize cells and detect extracellular matrix (a and c) and anti-TG2 antibodies to 
investigate its expression pattern (b and d). Reproduced from Tarantino et al 2011. 
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As both TG2 and FXIIIa can be found in the growth plate of the long bones, 
Tarantino and colleagues (2009) looked more closely, whether there are any skeletal 
differences between the knees of wild-type and TG2 deficient mice. Although there 
were no overt differences between wild-type and knock-out animals, they found a 
five fold higher expression of FXIIIa in cartilage. Hypertrophic chondrocytes from 
TG2 knock-out mice express FXIIIa, which is probably compensating for the 
absence of TG2. Also TGF-β1 expression, which has an anabolic role in cartilage 
and controls osteoblast differentiation, was increased when compared to the wild-
type. TG2 has been proposed to have a role in TGF-β1 activation (Telci et al. 2009) 
and hence, increased expression of TGF-β1 could be the result of feedback 
regulation and reduced active TGF-β1 levels in these mice. 
Induction of OA in the TG2 knock-out mice using surgery to cause joint 
instability revealed that in the absence of TG2, the severity of OA is reduced as 
indicated by grading the histological sections of the mice and there is more 
osteophyte formation (Orlandi et al. 2009). This may relate to differences in the 
inflammatory response between wild-type and TG2 -/- mice. 
Evaluation of TG2 as a biomarker was also reported and carried out using the 
Hartley guinea pig model (Huebner et al. 2009). Guinea pigs at 4, 7 and 12 month of 
age were analyzed as the OA develops spontaneously in this model over this time 
frame. In the early stages of OA, TG2 was mainly expressed in the superficial and 
middle zone of the cartilage. At later stages, TG2 staining was more disperse within 
the tissue and accumulated at the centre margin of the superficial layer. Enhanced 
expression of TG2 and formation of Nε(γ-glutamyl)lysyl isopeptide bonds was 
detected. TG2 upregulation was linked with MMP-13 and collagen type X 
expression in cartilage. TG2 levels measured in the synovial fluid from OA knees by 
ELISA correlated with the histological score of severity. Taken together, this 
indicates that TG2 is not only upregulated in OA cartilage but efficiently released 
into synovial fluid. Interestingly, a similar correlation was not found for FXIIIa.  
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1.9.5 Potential link between chondrocyte maturation, inflammatory mediators 
and TG2 
It has been proposed that the mechanism of upregulation of TG2 activity during 
stimulation with proinflammatory IL-1β is driven by nitric oxide (NO) (Johnson et 
al. 2001). Peroxynitrite donors significantly enhanced TG2 activity in meniscal cells 
derived from OA patients. CXCL1 and CXCLl8 chemokines were also stimulating 
TG2 activity (Merz et al. 2003). An organ culture of knee articular cartilage from 
healthy donors treated with TGFβ and IL-1β for 48h had increased TG2 expression 
(Johnson et al. 2001).  
TG2 is involved in the mechanism of tissue calcification promoted by cell 
differentiation and proinflammatory stimulation (Johnson et al. 2003). ATRA, which 
is a metabolite derived from vitamin A, directly upregulates TG2 expression and 
induces chondrocyte hypertrophy (Aeschlimann and Thomazy 2000). It has been 
shown that induction of TG2 promotes the expression of hypertrophic markers such 
as collagen type X, alkaline phosphatase (AP) or metalloproteinase-13 (MMP-13) 
suggesting of a direct link (Johnson et al. 2003). Moreover, treatment with both 
ATRA and IL-1β increases TG2 transamidation activity in articular chondrocytes 
isolated from murine and bovine knee explants, but not in those isolated form TG2-
knock-out mice (Johnson et al. 2003). However, the same treatment failed to induce 
residual transamidation activity from FXIIIa that is overexpressed in TG2 deficient 
animals as previously outlined (Huebner et al. 2009). Upregulation of TG2 
expression increased the levels of inorganic pyrophosphate and nucleotide 
pyrophosphatase phosphodiesterase that drive cartilage mineralization (Johnson et al. 
2003).  
Additionally, Johnson and colleagues (2005) proposed an interesting 
hypothesis suggesting that pathological changes in OA may at least in part be due to 
the presence of an inactive form of TG2 and not driven by its transamidation activity 
(Johnson and Terkeltaub 2005). They showed that cartilage hypertrophy and 
mineralization is mediated by the presence of the Mg-GTP bound form of TG2. They 
used the GTP binding mutant (TG2 K173L) in combination with the human 
chondrocytic cell line (CH-8) to show that addition of this mutant fails to induce 
matrix calcification and collagen type X upregulation. Moreover, they observed that 
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the GTP binding mutant was unable to be externalized from the cells in contrast to 
wild-type TG2 or C277S active site mutant.  
1.10 Non-conventional release of TG2  
Literature evidence indicates that TG2 is released by cells in specific context and that 
the products of its activity can promote chondrocyte hypertrophy (Tarantino et al. 
2011) and drive autoimmunity (Sollid 2002). Chondrocytes, osteoblasts, fibroblasts, 
macrophages and epithelial cells can actively externalize TG2, but the mechanism of 
TG2 externalization remains elusive (Lorand and Graham 2003). Current 
understanding of TG2 secretion is based on its well-documented interaction with 
ECM or cell membrane proteins. It is believed that when secreted, TG2 binds 
immediately to ECM proteins and interact with number of substrates such as 
fibronectin, collagen, syndecan, vitronectin, osteopontin or binds tightly to the cell 
surface (Belkin 2011). These interactions are thought to stabilize the ECM 
assemblies. However, it is not known whether TG2 becomes permanently associated 
with them.  
The structural features of TG2 suggest that it is secreted in a non-
conventional manner (Aeschlimann and Paulsson 1994; Nurminskaya and Belkin 
2012). The endoplasmic reticulum (ER)/Golgi-independent release pathway is 
predicted as TG2 lacks carbohydrate modifications despite the presence of potential 
N-glycosylation sites. TG2 lacks an amino-terminal signal sequence directing it to 
the ER and lacks disulfide bonds despite the presence of many cysteine residues 
(with exception of the disulfide bonds which regulate TG2 extracellular activity). 
Proteins that are not generated through the classical ER/Golgi secretory pathway 
share similar features such as the lack of a leader sequence and lack of specific 
posttranslational modifications (Nickel and Rabouille 2009). But many of them have 
a modified amino acid at the N-teminus (Aeschlimann and Paulsson 1994).  
1.11 Release of proteins via the conventional pathway  
Most secretory proteins synthesized in eukaryotic cells enter into the lumen of the 
rough endoplasmic reticulum and follow the ER/Golgi secretory pathway (Bruce et 
al. 2002). Those two compartments are part of a complex cellular machinery that 
controls protein folding, oligomerization, glycosylation and disulfide bond formation 
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prior to delivery of proteins to the cell surface (Trombetta and Parodi 2003). The 
synthesis of the proteins starts on the surface of ER but only for proteins that contain 
the ER signal sequence (Bruce et al. 2002) (Fig. 1.8). This is a short amino acid 
sequence, localized on the N-terminus of newly synthesized proteins. It is usually 
composed of hydrophobic amino acids (e.g. LLLVGILFWA) and this sequence is 
recognized by the signal recognition particle (SRP), expressed on the surface of ER 
membrane. Ribosomes with newly synthesized polypeptide attached are captured by 
SRP, which facilitates the translocation of the polypeptide chain into the ER lumen. 
After active translocation of the whole polypeptide, the signal sequence is cleaved 
off from the protein and proteolytically degraded inside the ER. The lumen of the ER 
is the location where the N-linked oligosaccharides are attached to asparagines. N-
linked glycosylation sites in proteins contain specific sequences: N-X-S or N-X-T 
(whereby X is any amino acid but not proline) that allow for the sugar attachment. 
The carbohydrate synthesis and remodeling is continued in the Golgi apparatus after 
exit of newly synthesized proteins from the ER and their translocation into Golgi in 
COPII-coated membrane vesicles. The COPII coat is composed of small GTPases 
(Sar1, Sec23-24 and Sec13-31) that interact with cargo receptors and concentrate 
proteins inside budding vesicles. After reaching the Golgi complex, proteins are 
further modified, folded and sorted in cis, trans and medial cisterns of the Golgi. 
Here further O-linked oligosaccharides might be added to S/T residues localized on 
proteins. Transport of proteins through the Golgi compartments in the direction of 
the cell surface and back to the ER is mediated by COPI vesicles, which contain 
ADP ribosylation factor 1 GTPase (Arf1). Arf1 is a protein that regulates the COPI 
coat association. The fusion events between membranes are dependent on 
transmembrane proteins called SNAREs (soluble N-ethylmaleimide-sensitive fusion 
(NSF) protein accessory receptors). The SNAREs complex localized on vesicles (v-
SNAREs) interact directly with target SNAREs (t-SNAREs) and when they are in 
minimal proximity with each other fusion occurs (Zhao et al 2008). This process is 
mediated by N-ethylmaleimide-sensitive factor (NSF) ATPase, which is necessary 
for intracellular membrane fusion and SNAREs recycling. Also transport of COPI- 
coated vesicles is dependent on transmembrane protein, syntaxin-5 that belongs to 
the t-SNAREs family (Nickel and Rabouille 2009) (Fig. 1.8). 
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Fig. 1.8 ER/Golgi-dependent pathway of protein secretion for proteins with an 
leader sequence. Reproduced from Nickel and Rabouille 2009. 
 
1.12 Emerging mechanism of non-conventional protein secretion 
Protein synthesis and transport through the ER/Golgi system is a highly controlled 
and effective process, which allows release of proteins with full biological activity 
(Bruce et al. 2002). It seems that non-conventional secretion is also a regulated event 
that applies to a smaller number of proteins (Nickel and Seedorf 2008). The reasons 
why some of the the proteins undergo non-classical export can vary and some 
hypotheses were proposed to explain the existance of classical and non-classical 
patways. Binding of substrates to their receptors that potentially might occur inside 
the ER or Golgi can potentially lead to aggregation and misfolding, therefore it is 
preferable that their synthesis and release is separated. This is important for signaling 
molecules such as TG2 as binding to the receptors can potentially induce autocrine 
signaling (Nickel and Seedorf 2008). Also some of the proteins that are sensitive to 
redox potential might be misfolded or inactivated in the oxidative environment of ER 
and Golgi. Therefore, the synthesis in the cytoplasm seems to be a safe option and it 
ensures proper protein folding and omits the need for re-folding during synthesis as 
evident in classical secretory pathway. The known mechanisms of non-conventional 
protein secretion can be grouped into two different types: 1) non-classical delivery of 
membrane proteins, which contain the leader sequence but are being supply to the 
cell surface via Golgi-independent pathway or 2) the release of cytoplasmic proteins 
that are lacking the signal peptide (Nickel and Rabouille 2009). Rabouille and 
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colleagues (2012) grouped them further into vesicular and non-vesicular non-
conventional release. The non-classical vesicular delivery of proteins to the outside 
of the cell can occur via secretion of proteins through vesicles bypassing the Golgi 
compartment or autophagy-mediated release (Deretic et al. 2012). The non-vesicular 
type of release involves direct translocation of proteins through the cell membrane or 
secretion of proteins or peptides with lipid modifications through ABC membrane 
transporters.  
 
1.12.1 Non classical protein transport bypassing the Golgi compartment 
COPII positive vesicles emerge from the ER and are involved in the subsequent 
transport of proteins to the Golgi, whereas COPI positive vesicles are mediating the 
movement through Golgi and from Golgi back to the ER (Nickel and Rabouille 
2009). However, some proteins bypass the Golgi compartments and are directly 
transported from the ER to the cell surface in COPII vesicles. This was reported for 
cystic fibrosis transmembrane conductance regulator (CFTR) (Wang et al. 2004) as 
well as for CD45 membrane receptor (Baldwin and Ostergaard 2002). CD45 receptor 
contains a glycosylation pattern characteristic for the ER (numerous N-glycan that 
are of high mannose type) and was shown to localize in the cell membrane of T 
lymphoma cells even in the absence of further branched oligosaccharides that should 
be added in Golgi compartments (Baldwin and Ostergaard 2002). Meanwhile, in 
CFTR trafficking to the membrane occurs in the absence of syntaxin-5, Sar1 GTPase 
or Arf1, which are all markers mostly associated with COPI vesicles (Rabouille et al. 
2012). However, CFTR delivery requires syntaxin 13 t-SNARE, which is involved in 
the formation of late endosomes, which suggests a different vesicular transport route. 
In some instances, the process of bypassing Golgi cisterns occurs in a COPII-
independent manner suggesting that membrane molecules are transported directly 
from ER to the cell surface via a distinct vesicular transport (Nickel and Seedorf 
2008). This is the case for the yeast heat-shock protein 150 (Hsp150), where 
secretion occurs in the absence of functional (Sec24p) protein of the COPII coat 
complex (Fatal et al. 2004). Other examples include Kv4 voltage-gated K+ channel in 
neurons that are delivered to the membrane through a non-COPII mediated pathway 
(Hasdemir et al. 2005). It was postulated that Golgi-independent secretion of proteins 
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can occur simultaneously to classical release and that this might be induced only 
during specific situations and/or in certain cell types (Nickel and Seedorf 2008). 
1.12.2 Release of proteins lacking the signal peptide 
Non-conventional export of cytoplasmic and nuclear proteins that lack an ER-signal 
peptide is being extensively studied as proteins secreted in this matter such as 
cytokines, growth factors and signaling molecules play an important role during 
inflammatory processes, cell differentiation, proliferation or oxidative stress (Nickel 
and Seedorf 2008). Even though the mechanism of their release can be different, all 
proteins share a few distinct features: lack of a classical signal peptide and lack of 
posttranslational modifications that occur during ER/Golgi protein maturation. Also, 
all of them were shown to be resistant to Brefeldin A treatment of cells – a drug that 
blocks Arf1 recruitment to Golgi and consequently vesicular transport trough 
ER/Golgi compartments. The possible mechanisms of non-classical export involving 
translocation across the membrane can be both vesicular and non-vesicular for 
leaderless secretory proteins (Rabouille et al. 2012) (Fig. 1.9). 
Examples of proteins that lack a signal peptide and function mainly outside 
the cell are members of interleukin family: IL-1α, IL-1β, IL-18 and IL-33 (Dinarello 
2009), fibroblast growth factor 2 (FGF2) (Seelenmeyer et al. 2005), galectin-1 (Zhu 
and Ochieng 2001), galectin-3 (Keller et al. 2008), high-mobility group box 1 protein 
(HMGB-1) (Gardella et al. 2002) or thioredoxin (Rubartelli et al. 1992). Soluble 
proteins secreted in an non-conventional way can have different biological functions 
intracellulary and extracellularly (Dinarello 2009). Interestingly, in many occasions 
non-conventional release is triggered by an external signal such as heat shock for IL-
1α (Tarantini et al. 2001), oxidative stress in T lymphocytes for thioredoxin (Kondo 
et al. 2004) lysophosphatidylcholine treatment for HMGB-1 (Gardella et al. 2002) or 
bacterial lipopolysaccharide (LPS) treatment followed by ATP stimulation in 
monocytes/macrophages in case of IL-1β (Qu et al. 2007). 
FGF2 is an example of a protein released by the non-vesicular route 
described as self-sustained membrane translocation (Nickel and Rabouille 2009). 
FGF2 is an important growth factor required in development, and for tissue repair 
and angiogenesis (Nickel 2011). A possible mechanism of FGF2 release involves its 
recruitment by the phosphoinositide phosphatidyl-inositol-4,5-bisphosphate 
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(PtdIns(4,5)P2) onto the inner side of the cell membrane,  followed by extracellular 
trapping by heparan sulphate proteoglycans (HSPGs) (Zehe et al. 2006). Interestingly 
FGF2 remains folded during the process of membrane translocation (Torrado et al. 
2009). FGF2 seems to directly insert into the lipidic membrane pore upon 
PtdIns(4,5)P2 oligomerization (Steringer et al. 2012). 
Thioredoxin, which is involved in maintaining the redox balance inside the 
cell, shows cytokine/chemokine activities when released (Nishinaka et al. 2001) and 
plays a role during inflammation (Bianchi and Agresti 2005). Eleveated levels of 
thioredoxin can be also found in RA (Xu et al. 2008). Once released, thioredoxin can 
activate transient receptor potential channels (TRPC) at the cell surface by breaking 
cyteine bridges on extracellular loops of TRPC and causing its activation. 
Autophagy based release is a novel emerging mechanism for export of IL-1β 
and HMGB-1 (Deretic et al. 2012). An example of a protein that is released after 
rapid environmental change is high-mobility group box 1 protein (HMGB-1). It has 
been shown that  in the nucleus HMGB-1 regulates gene expression (Bonaldi et al. 
2003). However, in monocytic cells, LPS stimulation leads to extensive transport of 
HMGB-1 from the nucleus to the lysosomes. Furthermore, the secretion of HMGB-1 
is potentiated by lysophosphatidylcholine released from monocytes at sites of 
inflammation (Gardella et al. 2002). Lysophosphatidylcholine is the metabolite 
formed due to the activity of phospholipase PLA2, and which is present at the later 
stages of inflammation. In the presence of inflammatory mediators and cytokines it is 
secreted into extracellular space and acts as chemotactic cytokine (Degryse and de 
Virgilio 2003). 
The most intensively studied leaderless protein over the last years is the 
proinflammatory cytokine IL-1β. It can be rapidly released from monocytes and 
macrophages upon LPS stimulation and extracellular ATP treatment, possibly 
through vesicular trafficking (Mackenzie et al. 2001). However, little is known about 
intracellular sorting of IL-β that preceeds its release. 
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Fig. 1.9 ER/Golgi-independent pathway of protein secretion for proteins lacking 
a leader sequence. 1. Non-vesicular mechanism (direct translocation of FGF2) 2. 
Lysosome-dependent pathway, 3. Microvesicle-dependent secretion, 4. 
Multivesicular bodies (exoxomes). Reproduced from Nickel and Rabouille 2009. 
 
1.13 Extracellular ATP – a trigger of non-classical protein secretion 
ATP (adenosine 5’-triphosphate) is the most widely used carrier of free energy 
within the cells and a fast-acting intercellular messenger (Bruce et al. 2002). Still, 
ATP remains an intracellular molecule harboring extracellular functions. It is 
debatable how ATP reaches the extracellular space, however a few mechanisms of 
its release have been proposed. Cell injury and death is not the only cause of ATP 
leakage (Jorgensen et al. 1997) because ATP can be released through nonlytic 
pathways, like fluid shear stress (Li et al. 2005) or mechanotransduction  (Garcia and 
Knight 2010). Moreover, in neuronal cells ATP is released in secretory vesicles 
(Burnstock 2008) or through channels formed by connexins or pannexins (Di 
Virgilio 2005). Cell manipulation causing mechanical stress such as cell stretching 
triggers ATP release (Solini et al. 1999). For a long time, ATP was not considered a 
signaling molecule. However, since the discovery that ATP can permeabilize cells 
(Cockcroft and Gomperts 1979) and is released by neuronal cells (Burnstock 1972), 
it has become one of the most important transmitters allowing for local cell-cell 
communication.  
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1.14 ATP as an inflammatory mediator 
It has been demonstrated that moderate release of ATP during chronic infection can 
play an anti-inflammatory role by activating dendritic cells and macrophages to 
secrete anti-inflammatory cytokines such as IL-10 and IL-1 receptor antagonist 
thereby inhibiting dendritic cell initiated Th1 responses (F Di Virgilio et al. 2009). 
The concentration of cytosolic ATP is 106-fold higher than in the extracellular milieu 
and ATP is present in a negatively charged form (ATP4-), which makes it a good 
candidate for alarming surrounding tissues about danger and trigger early events of 
inflammation (Di Virgilio et al. 2001). In addition, ATP released from activated 
monocytes or platelets can act through autocrine/paracrine pathways that amplify the 
danger signal (la Sala et al. 2003). A high dose of extracellular ATP (milimolar 
concentrations) initiates the immune response and stimulates antigen presenting cells 
to release pro-inflammatory cytokines such as IL-1β, IL-18, IL-6 or tumor necrosis 
factor α (Di Virgilio 1995; Falzoni et al. 1995; Ferrari et al. 2006). High ATP 
concentrations or prolonged stimulation can eventually lead to cell death, which 
occurs due to the massive upset of ion homeostasis, probably by colloido-osmotic 
lysis (Ferrari et al. 1997; Andrei et al. 2004). Initially, it was suspected that the 
extracellular increase of proinflammatory cytokines such IL-1β is simply due to the 
cytotoxic effect of ATP, but it has since become evident that cytokine maturation and 
release is mediated by a series of complex intracellular events (Jorgensen et al. 
1997). 
1.15 Extracellular ATP and its receptors  
It was shown that released ATP is quickly converted by ecto-enzymes to ADP, AMP 
and adenosine in order to terminate its action (la Sala et al. 2001) (Fig. 1.10). Those 
cell surface ecto-ATPases are called ectonucleotidases (Zimmerman 2000). 
Purinergic receptors are membrane proteins that respond to the extracellular 
nucleotides and form three classes of proteins. These are P1 (adenosine receptors), 
P2Y (G-protein-coupled receptors) and P2X (ligand-gated ion channels) (Surprenant 
and North 2009; Baroja-Mazo and Pelegrín 2012). Two subfamilies of them are 
transmembrane proteins, that respond to extracellular ATP: metabotropic P2Y and 
ionotropic P2X receptors (Di Virgilio 2007). Extracellular ATP acts via a signal 
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amplification system, to generate other inflammatory mediators and spread the alarm 
signal in the local milieu (Abbracchio and Burnstock 1994). The release of 
cytoplasmic ATP that occurs upon cell injury can lead to 5-10 mM local ATP 
concentrations in surrounding tissue (Di Virgilio et al. 2001). This high 
concentration of ATP is known to activate one member of the P2X family – P2X7R, 
which stimulates the release of non-conventionally secreted IL-1β. 
 
 
Fig. 1.10 Extracellular ATP activates ligand-gated ion channels (P2X) and G-
protein coupled receptors (P2Y) on the cell surface. Ectonucleotidases quickly 
hydrolyse ATP into ADP, AMP and adenosine. Adenosine acts as an agonist for P1 
receptors. Activation of P2X receptors leads to Na+ and Ca2+ influx and K+ efflux, 
which induces cell membrane depolarization. Activation of P2Y induces 
metabotropic responses, PLC activation, IP3 production and release of Ca2+ from 
intracellular stores. P1 activation also evokes metabotropic responses by stimulating 
or inhibiting cAMP production. Reproduced from Baroja-Mazo et al (2012). 
 
1.15.1 P2X receptors 
Up to now seven P2X receptors have been described (P2X1-7) and were shown to be 
widely expressed within different tissues in vertebrates (Khakh and North 2006; 
Kaczmarek-Hájek et al. 2012). Homologue receptors have been described in 
invertebrate organisms, such as in flatworm (Schistostoma mansoni), unicellular 
amoeba (Dictyostelium discoideum) or green algae (Ostreococcus tauri) 
(Kaczmarek-Hájek et al. 2012). However, there are no reports about P2X signaling 
in prokaryotic organisms (Fountain and Burnstock 2009). P2X are also not present in 
model organisms such as Drosophila melanogaster, Caenorhabditis elegans and 
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yeast. Therefore P2X evolution remains unclear. The P2X receptor expressed in D. 
discoideum was found to be localized on vacuoles and is thought to be responsible 
for osmoregulation. Therefore, it is likely that plasma membrane P2X found in 
vertebrates might have evolved from an intracellular channel.  
1.15.2 P2X receptor architecture  
P2X receptors are trimeric, nonselective cation channels that have a unique 
molecular structure when compared to other classes of ligand-gated receptors 
(Young 2010). The topology of the P2X is very similar to the acid-sensing receptors 
(ASICs), with which they might share a common ancestor. However, the lack of 
clear homology on the sequence level or 3D structure eliminates a close relation. All 
P2X receptors share a similar structural organization with both C- and N-terminus 
localized on the intracellular side of the membrane, two hydrophobic transmembrane 
domains (TM1 and TM2) and an extensively glycosylated extracellular domain with 
conserved disulfide bridges (North 2002; Browne et al. 2010). The transmembrane 
arrangement of the P2X receptor in its ATP-free resting state was confirmed in the 
zebrafish P2X4 receptor crystal structure, which has been solved at 3.1Å resolution 
(Kawate et al. 2009). The crystallization of the receptor was possible after 
introducing three point mutations and by excluding the N- and C-terminal 
intracellular domains (ΔzfP2X4-B). The crystal structure confirmed the trimmeric 
nature of P2X receptors and showed that assembly of three subunits, each of them 
spanning the plasma membrane twice, forms the functional receptor. The large 
extracellular chalice-like shaped domain composed mainly of β-strands is reaching 
up to 7 nm above the cell membrane plane whereas the transmembrane region is 
formed by six α-helices that are situated angled and antiparallel to each other and are 
approx. 2.8 nm in length (see Fig. 1.10 for a model of P2X2 based on this structure). 
On the extracellular portion, 3 non-canonical ATP binding sites where described. 
The extracellular domain mediates ATP, competitive antagonist and metal ion 
interactions whereas the transmembrane part takes an active part in channel opening 
(Browne et al. 2010). 
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1.15.3 P2X receptor subunit structure and their arrangement in the closed 
channel state 
In the resting state, the zfP2X4 structure was compared to the shape of a “dolphin” 
with the head, upper and lower body, both flippers and dorsal fin (Fig. 1.10B) 
(Kawate et al. 2009). The three β-sheets of the upper body are in contact with each 
other, while there are few contacts between the lower body domains of the subunits. 
The β-sheets of the body region are strictly conserved, suggesting that similar 
interactions are common to other P2X family members. The residues of the left 
flipper are less conserved; therefore they could be mediating receptor specific 
desensitization after ATP removal. The channel surface is formed out of the three 
TM2 α-helices and these are surrounded by three peripheral TM1 helices. In the 
resting state, both α-helical TM domains of each subunit are in tight contact, which 
prevents ion entry. 
1.15.4 ATP binding and P2X channel opening 
Members of the P2X ligand-gated ion channels act in the membrane as cell surface 
channels (North 2002). However, P2X7R has the additional function of mediating 
the formation of a membrane “pore”, which likely represents a more dilated state 
ATP binding allows the Na+, Ca2+, K+ and Cl- diffusion through the channel and the 
transport of the ions differs between P2X family members (Kawate et al. 2011). The 
ATP-bound crystal structure of the truncated ΔzfP2X4-C receptor resolved at 2.8 Å 
resolution showed for the first time how the receptor is changing its confirmation 
upon nucleotide binding (Hattori and Gouaux 2012) (Fig. 1.10A). Truncation of the 
receptor and removal of the intracellular domains was not ideal to fully understand 
the conformational changes. However, it allowed capturing the receptor in an open, 
but not fully dilated state, where ATP is bound to all available pockets (Jiang et al. 
2013). The structure confirmed the presence of the three non-canonical ATP-binding 
sites on the extracellular part of the receptor that were predicted (Ferrari et al. 2006; 
Kawate et al. 2009) (Fig. 1.11A). The ATP-binding pockets (“jaws”) are composed 
of positively charge amino acid residues localized approx. 4 nm from the cell 
membrane. ATP binding involves coordination of a few strictly conserved residues 
localized on head domain, body domain, right flipper and dorsal fin (Hattori and 
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Gouaux 2012). In the resting state, the receptors have empty “jaws” localized 
between head domain and dorsal fin. These adapt ATP via hydrophobic interactions. 
ATP is also recognized by the hydrophilic/charged residues of the upper and lower 
body domains, which form hydrogen bonds and salt bridges with the phosphate 
groups and adenine base of ATP. Upon binding to the P2X receptor subunit, ATP is 
becoming U-shaped by folding the α-, β- and γ-phosphates. Binding of ATP to the 
empty pocket tightens the  “jaws”, which shifts the head from the dorsal fin and 
flexes the lower body by approx. 0.8 nm in direction to the upper body. In fact the 
upper body of the receptor remains braced and less affected by the movement upon 
ATP binding. Widening of the extracellular vestibule is followed by movement of 
TMs domains. This movement creates a wider space in the canter of the 3 subunits. 
This type of movement is called “iris-like” motion, where TM domains of each 
subunit shift relative to the extracellular domain to open the cation channel. TM1 and 
TM2 turn anticlockwise (approx. 1 and 5.5 nm, respectively) to the cell membrane 
orientation and leave a space for ion flow of 1 nm in its widest place. It is likely that 
the antagonist bind to the same “jaws” as ATP (Jiang et al. 2013). However, more 
residues are involved in its coordination and binding of inhibitors prevents jaw 
closure that is necessary for ion conduction.
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Fig. 1.11 Model of the rat P2X2 trimeric channel based on the ΔzfP2X4 crystal 
structure. A) Model of rP2X2 receptor showing the change from closed to open 
conformation and movement in receptor vestibules. The lateral (left) and down 
(right) view of subunits (each shown in different colors) and the ATP (red spheres) 
are visualized. B) Representation of the one subunit of the trimeric P2X receptor 
with its “dolphin-like” structure. C) Trimeric receptor with the lateral portal for ion 
permeation and ATP binding “jaw”. Grey lines represent the layers of cell 
membrane. The receptor is shown in the expected arrangement relative to the 
membrane plane. Reproduced from Jiang et al 2013, with modifications. 
vestibules: 
upper 
central 
extracellular 
intracellular 
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1.15.5 Ion channel of P2X receptors 
 
Activation of P2X requires subunit motion that allows the channel expansion to 
create a gap for cations translocation (Kawate et al. 2011). There were two models 
proposed for the cation flow through the channel. 1) The central pathway that is 
formed between three-fold axis of subunits or 2) the lateral portal pathway localized 
in the region that connects the lower body with the TM helices (Fig. 1.11C). Based 
on the P2X4 crystal structure, computational studies revealed that the 0.8 nm wide 
lateral portals are preferable as there are less electrostatic barriers for ions to pass 
through the presumptive channel than in the central opening. Even in the closed 
receptor state the lateral windows are wide enough to facilitate ion entry through that 
route. The surface of lateral portal is composed of many cysteine residues and 
harbours a negative electrostatic potential necessary for Na+ and Ca2+ cation 
selection. It was also proposed that the acidic residues in the central vestibule and 
regions localized just above the lateral portal could participate in concentrating the 
cations before they enter the transmembrane gate, pass the channel and leave through 
the intracellular vestibule (Kawate et al. 2009; Hattori and Gouaux 2012). Similarly, 
on the other side of the membrane, the negatively charged glutamate residues could 
attract K+ ions before they diffuse through the channel. For some P2X receptors the 
cations may still penetrate the central vestibule region but this is thought to serve a 
modulatory mechanism rather than an ion flow pathway (Kawate et al. 2011). 
Studies with gadolinium ions (Gd3+) showed that the receptor can be allosterically 
regulated by ions (Kawate et al. 2009). Furthermore, Jiang et al (2013) suggested that 
Ca2+ or other ions that pass through the channel can bind to TM domains and further 
facilitate conformational changes that stabilize the channel. The driving force for ion 
transport are the pre-established concentration gradients across the membrane (North 
2002). 
1.16 P2X7 receptor (P2X7R) 
The P2X7R is an important molecule to study in the context of non-conventional 
protein secretion as it was shown to respond to high concentrations of extracellular 
ATP and trigger release of the proinflammatory cytokine IL-1β (Perregaux et al. 
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1992; Ferrari et al. 1997). The P2X7R sequence was originally cloned form rat brain 
was described in 1996 (Surprenant et al. 1996). The P2X7R is an ion gated channel 
similar to P2X4R. P2X4 and P2X7 are closely related and probably, were product of 
gene duplication (Kaczmarek-Hájek et al. 2012). P2RX7 gene encodes a full-length 
protein of approx. 77 kDa (Ferrari et al. 2006). The mRNA for P2X7R was found to 
be strongly expressed in liver, thymus, heart, skeletal muscles and pancreas and at 
lower lovers, was also detected in prostate, spleen and brain (Rassendren et al. 1997). 
Functional P2X7R is mainly present in murine and human monocytes, peritonel 
macrophages, leukocytes, B and T lymphocytes or dendritic cells (Di Virgilio et al. 
2001). P2X7R was also found to be expressed in neutrophils and is involved in the 
organism defence mechanism (Suh et al. 2001). Also cells of the nervous system like 
microglia, oligodendrocytes, astrocytes and Schwann cells express P2X7R (Coddou 
et al. 2011). Functional P2X7R activation can be evoked by high concentrations of 
ATP (1-4 mM) and much lower doses of its potent analogue BzATP (5-20 µM) 
(Jarvis and Khakh 2009; Coddou et al. 2011). Unlike P2X4R, P2X7R has a relatively 
large intracellular C-terminal domain, which is likely responsible for some unusual 
features (Costa-Junior et al. 2011). This will be discussed later. 
1.16.1 P2X7R as a membrane channel 
P2X7R channel formation is normally accompanied with fast Na+ and Ca2+ influx 
and K+ efflux along the chemical gradient, which induces cell membrane 
depolarization (Khakh and North 2006). P2X7R is adopting a trimmeric 
stoichiometry in the cell membrane, thus it is likely that changes in conformation 
upon ATP binding are going to be similar to those described for zfP2X4. Progressive 
increases in pore size can cause dramatic changes in membrane permeability and in 
cation concentration inside the cell. The recently proposed model of P2X receptor 
activation with its dynamic changes from the closed to the open channel 
configuration might potentially involve a few intermediary stages (Jiang et al. 2013). 
ATP gating that induces a shift in the subunits arrangement of subunits that leads to 
ion transport can be referred to the 2 conductivity types: O1 and O2 (Fig. 1.12). 
Sustained stimulation with ATP causes either a shift from open (O1) to the 
desensitized state (D), which is mainly observed for P2X1 and P2X3 receptor, or is 
follows further slow dilation described by O2 state, which is mainly seen for P2X2, 
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P2X4, and P2X7. It is thought that the O1 conducting state allows for small cations to 
be passed through the channel. Progression to the O2 state, however, is necessary for 
entry of the bigger organic cations, such as N-methyl-D-glucamine (NMDG) or 
fluorescent dyes like YO-PRO-1 and ethidium bromide. The O2 state can be referred 
to as a “pore dilation” receptor shape. The structural arrangement forming the 
channel for this state has, however, not been determined yet. It is still under debate if 
those larger molecules permeate P2X itself or whether other hemichannels are 
involved in this process (Jarvis and Khakh 2009; Jiang et al. 2013). Recently Khadra 
and colleagues (2013) proposed a revised model of P2X7R channel function that also 
includes a transitional desensitization step under certain conditions. They showed 
that stimulation of native rat P2X7R with agonist enables different responses 
depending on agonist concentration. Sustained stimulation of P2X7R with low 
amounts of potent agonist BzATP (3.2 µM) results in monophasic current and 
channel opening that is followed by receptor desensitization and its internalization 
from the membrane. However, when BzATP reaches saturating concentrations (320 
µM) the receptor activation is followed by its further dilation. The authors suggested 
that this might be the effect of three ATP/BzATP molecules binding to the receptor 
and be required for full receptor sensitization and its dilation into the “pore” state 
(Fig. 1.12). However, this would suggest that the ΔzfP2X4R structure with ATP 
reflects the “pore” state. As there are important differences between P2X7R and 
P2X4R in terms of receptor electrophysiology, the resolution of the receptor 
structure with the C-terminal domain is necessary. It was suggested that the state 
when two ATP molecules are bound to the receptor might represent the physiological 
responses mediated by P2X7R whereas the state with three ATP binding sites 
occupied and fully dilated might ultimately lead to cell death (Jiang et al. 2013). 
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Fig. 1.12 Allosteric regulation of P2X channel opening by ATP. Receptor is 
composed of the three subunits that surround the pore. ATP-binding induces a shift 
from the closed, resting state (R) to the open, conducting state (O1 and O2). The 
channel can be closed and move to desensitized state  (D) or further dilate by shifting 
to the O2 state. The primed state (F) when ATP is bound but the channel remains 
closed has been proposed for P2X2. Reproduced from Jiang et al 2013, with 
modifications. 
1.16.2 P2X7R-dependent “pore formation”  
There are many recent studies trying to understand the phenomenon of a dilated 
P2X7R membrane channel, as inferred from dye uptake through the “pore”. P2X7R 
as well as closely related P2X2 and P2X4 receptors have the ability to form a 
membrane pore in neuronal cells upon prolonged stimulation with ATP (Khakh et al. 
1999; Chaumont and Khakh 2008; Sun et al. 2013). However, there are differences 
in “pore” formation between these receptors and only P2X7R activation leads to 
membrane “blebbing”, cytoskeletal changes, cell death or lysis (North 2002). It was 
suggested that the sustained stimulation with ATP causes spontaneous aggregation of 
receptor subunits (of 6 or more) and leads to the formation of a large nonselective 
pore within the membrane (Di Virgilio et al. 2001). However, it is possible that other 
membrane hemichannels are involved in the formation of the membrane 
“pore”(Baroja-Mazo et al. 2012), activated by downstream signaling. P2X7R is 
widely expressed on monocytes/macrophages and microglia indicating a role in the 
release of proinflammatory mediators and inflammasome activation in macrophages. 
It is likely that P2X7R acts primarily as a membrane channel but the phenomenon of 
“pore” formation requires further investigation. Some recent evidence suggests that 
different activities of P2X7R may be involved in controlling inflammatory mediators 
and pain sensitivity (Khakh and North 2006; Sorge et al. 2012).  
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1.16.3 C-terminus of P2X7R 
The feature that distinguishes P2X7R from the other P2X family members is the long 
C-terminal tail, which has been implicated in its function (Costa-Junior et al. 2011; 
Sun et al. 2013). It has been proposed that the intracellular C-terminus is the key 
element that upon changes in membrane potential, can induce specific downstream 
signaling and is required for “pore formation” (Surprenant et al. 1996). Deletion of 
the C-terminus prevented dye uptake but did not change P2X7R channel function.  
The large C-terminus could possibly be involved in “pore formation” through 
interaction with some other proteins. It was reported that the C-terminus of P2X7R 
has a conserved LPS binding motif, that might modulate the inflammatory response 
in macrophages (Denlinger et al. 2001). It was suggested that this conserved binding 
domain binds LPS and inhibits downstream signaling events in macrophages, such as 
ERK1/2 phosphorylation and ΙκBα degradation. Moreover, the C-terminus is 
important for P2X7R activation and proper cell surface localization. Recently a 
R578Q point mutation in the C-terminus was shown to have reduced ability to form a 
pore (Wickert et al. 2013). Likewise, signaling through ERK1/2 phosphorylation was 
shown to be impaired. This mutation abolished receptor oligomerization and affected 
proper delivery to the cell surface due to altered N-glycosylation of receptor 
monomers. Therefore oligosaccharide modification of P2X7R is necessary for the 
trimmer assembly and membrane trafficking.  
Ion flow through open rat P2X7R is modulated by Ca2+ (Roger et al 2008). 
The presence of calmodulin enhanced and prolonged Ca2+ entry. Calmodulin can 
interact with the C-terminus of rat P2X7R through a unique binding motif. 
Calmodulin and P2X7R association is constitutive and occurs in the absence of ATP 
stimulation but is enhanced upon agonist addition. However, the same was not true 
for the human P2X7R (Roger et al. 2010). Human P2X7R hat a reduced ion transport 
capacity compared to rat P2X7R, which might be due to a lack of its interaction with 
calmodulin affecting channel function and linking it with downstream events.  
1.16.4 Cytoskeleton re-arrangements upon P2X7R activation 
Cell morphological changes upon agonist treatment are remarkable in cells 
expressing P2X7R such as extensive formation of membrane protrusions on the cell 
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surface (Solle et al. 2001).  The physiological agonist is believed to be ATP. 
However, in humans, it is still unclear if P2X7R is regulated by agents other than 
ATP (Ferrari et al. 2006). Little is known about the downstream signaling molecules 
that are activated upon P2X7R stimulation. However, P2X7R activation leads to 
significant cytoskeleton re-arrangement (Mackenzie et al. 2005). The polymerized F-
actin fibril network is disrupted and G-actin, which can freely move in the cytosol is 
translocated into newly formed membrane protrusions. Likewise, vinculin is also 
shifted into cell protrusions and accumulates at the edge of the cell membrane. 
Moreover, α-tubulin is detected at the periphery of newly formed membrane “blebs”. 
A number of inhibitors that disturb the cytoskeletal rearrangement were tested but 
only inhibitor of ROCK-1 kinase increased cell blebbing and changed the timing of 
events, suggesting its involvement (Morelli et al. 2003). 
1.17 The “Inflammasome” assembly upon P2X7R activation 
The term “Inflammasome” was established to describe a multiprotein complex that is 
involved in the regulation of the innate immune response associated with activation 
of inflammatory caspases (Martinon et al. 2009). The inflammasome relies strongly 
on intracellular sensors, such as NOD-like receptors (NLRs), which can recognize 
both microbial or nonmicrobial danger signals. ATP activated P2X7R induces rapid 
efflux of K+ from the cell, which stimulates inflammasome assembly driven by 
caspase-1 autoprocessing and leading to final maturation of IL-1β (Dinarello 2004). 
As the activation of the inflammasome in cells of hematopoetic origin has been 
directly linked to proteolytic cleavage of pro-IL-1β by caspase-1, the inflammasome 
is likely to be a crucial element in autoimmunity and rheumatic diseases (Martinon et 
al. 2009). 
The inflammasome requires the assembly of a cytosolic protein scaffold that 
consist of the sensor (NLR protein), adaptor (ASC protein) and effector protein such 
as a specific caspase that activates proinflammatory cytokines (Sidiropoulos et al. 
2008). The mechanism of ligand selective NLR activation remains unknown but 
specific stimuli can promote assembly of different types of inflammasomes: NALP1, 
NALP3, IPAF or NAIP (Martinon et al. 2002). NALP1, NALP3 and IPAF are 
expressed in human tissues (Martinon et al. 2009). All of them have been found to 
effectively recruit caspase-1 (Sidiropoulos et al. 2008; Dinarello 2009; Martinon et 
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al. 2009). The leucine-rich repeats (LRR) in NLRs are proposed to sense pathogen-
associated patterns and drive oligomerisation of its NACHT domains (Martinon et al. 
2009). Activation of the NALP3 inflammasome after NLRs-dependent ligand 
sensing occurs through the NLRs effector domains. The pyrin domain (PYD) and 
caspase recruitment domain (CARD) become activated through close homotypic 
complex formation. The protein assembly leads to engagement of PYD or CARD-
containing molecules such as pro-caspase-1 into the complex. The oligomerisation of 
inflammasome initiates the processing of pro-caspase-1. Active caspase-1 processes 
the pro-IL-1β, which is released from the cells as a mature IL-1β (Khakh and North 
2006) (Fig. 1.13).  
 
 
 
Fig. 1.13 Structural organization of the NALP3 inflammasome. The NOD-like 
receptors (NLRs) are consisting of three important domains: C-terminal leucine-rich 
repeat (LRR), multihistocompatability complex transcriptor (NACHT), NAD and N-
terminal pyrin domain (PYD). PYD-PYD and caspase recruitment domain CARD-
CARD interactions are needed for caspase-1 recruitment by the NALP3 
inflammasome. Reproduced from Martinon et al. 2009, with modifications. 
 
The process of inflammasome formation and the recruitment steps require 
further study (Dubyak 2012). However, the link between ATP mediated P2X7R 
activation and inflammasome assembly indicates that the inflammasome is regulated 
largely by this pathway. Opening of the cation selective channel after ATP binding 
and effective IL-1 β release may be connected by P2X7R activating a novel 
downstream protein, which links the two pathways. However, the most plausible 
scenario is that cell membrane permeabilisation and P2X7R formation leads to 
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cytosolic K+ depletion. This promotes activation of NALP3 by stabilizing the 
inflammasome protein complex (Perregaux and Gabel 1994) (Fig. 1.14)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.14 Complexity of the IL-1β and IL-18 synthesis and secretion in response 
to exogenous signals.  There are two signals required for IL-1β maturation and 
release. In immune cells, activation of Toll-like receptors (TLR) by LPS priming 
drives NF-κB downstream signaling and thereby pro- IL-1β, pro-caspase 1 and pro-
caspase 11 production. The second signal triggered by ATP activation of P2X7R and 
induces rapid efflux of K+ from the cell, which stimulates inflammasome assembly. 
Inflammasome complex formation initiates the processing of pro-caspase 1 that after 
being cleaved into caspase-1 can process pro- IL-1β into mature IL-1β. Reproduced 
from Sidiropoulos et al. 2008. 
 
1.18 Mechanism of interleukin-1β secretion – a prototypic non-conventionally 
secreted protein 
There are many hypotheses on how IL-1β could be trafficked into the extracellular 
space. In human blood monocytes, LPS stimulation leads to accumulation of 
intracellular pro-IL-1β and only 10% of it is released into the extracellular space (C 
Andrei et al. 2004). The first model suggests that pro-IL-1β and pro-caspase 1 are 
directed into a specific lysosomal compartment from which proteins are secreted by 
exocytosis from activated monocytes. This idea is supported by results showing co-
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localisation of lysosomal cathepsin D with the inactive precursors of IL-1β and 
caspase-1 (Bianco et al. 2005). ATP-induced K+ depletion caused activation of 
lysosomal specific phospholipases C and A2, which potentially regulate IL-1β 
secretion. Lysosomes could represent possible storage vesicles for pro-IL-1β and 
additionally provide a suitable microenvironment for its processing (Mackenzie et al. 
2001; Bianco et al. 2005). However, membrane translocation of pro-IL-1β into the 
lysosomal compartments remains to be explained. 
An alternative pathway of cytokine externalization involves the formation of 
microvesicles at specific sites of the plasma membrane (Mackenzie et al. 2001; 
Thomas and Salter 2010). These microvesicles contain pro- and mature IL-1β and 
are directly shed from the cell surface into the conditioned medium. Microvesicle 
shedding from LPS-treated THP-1 monocytes occurs within the first 2 min after 
BzATP stimulation (Mackenzie et al. 2001). Therefore, this mechanism could 
explain the rapid release of mature bioactive IL-1β. However, it is possible that there 
is more than one mechanism of release involved, as the microvesicle pathway is not 
effective after prolonged stimulation with BzATP. It has also been shown that IL-1β 
can be directly secreted into the medium without microvesicle involvement (Qu et al. 
2007).  
Another model suggests the possible role for exosomes derived from 
multivesicular bodies (MVB) as a main pathway for rapid co-release of IL-1β, 
caspase-1 and inflammasome components from murine macrophages (Théry et al. 
2002). Exosomes are small membrane vesicles that are released by most types of 
cells. They contain a specific subset of proteins that represent cytoplasmic 
components enclosed within the bi-layer membrane (Qu et al. 2007). The finding that 
IL-1β can be associated with MHC class II molecules may suggest cytokine 
incorporation into recycling endosomes and MVBs. 
1.19 Link between P2X7R and arthritis 
ATP signaling acts as an additional element of innate immunity, as P2X7R is a 
sensor of early microbial infection or tissue injury (Dubyak 2012). Studies with 
P2X7R-deficient mice show reduced IL-1β release after LPS-priming and ATP 
stimulation. Peritoneal macrophages derived from those animals are unable to secrete 
the mature 17 kDa form of IL-1β (Labasi et al. 2002). Moreover, P2X7r knockout 
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mice developed less severe collagen induced arthritis. Cartilage destruction was 
significantly reduced when compared to wild-type mice. Cathepsins that are 
lysosomal proteins involved in joint destruction can be released form mouse 
macrophages upon P2X7R activation (Lopez-Castejon et al. 2010). P2X7R-/- 
macrophages were unable to secrete cathepsins, thus indicating that P2X7R directly 
contributes to non-inflammatory arthritis (Lopez-Castejon et al. 2010). Interestingly, 
citrullinated peptides, to which antibodies are formed in patients with RA (Szodoray 
et al. 2010) were recently shown to be formed after challenging murine mast cells 
with the P2X7R agonist ATP (Arandjelovic et al. 2012).  
The P2X7R is highly polymorphic (Fuller et al. 2009). Analysis of the single 
nucleotide polymorphisms in RA cohort revealed presence of P2X7R gene mutations 
that impair receptor function and correlated with the presence of rheumatoid factor in 
patients carrying those alleles (Al-Shukaili et al. 2011). Recent findings suggest that 
mutation in P2X7R coding sequence that disables membrane pore formation are 
related to the reduced chronic pain in OA patients (Sorge et al. 2012). It is therefore 
interesting whether inhibiting only P2X7R-mediated pore formation but not the 
channel activity could be a possible therapy to reduce severe pain in those patients. 
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1.20 The aims of the project 
 
Disease-specific modified peptides are likely to provide a sensitive qualitative 
indicator of early arthritis. Our candidate molecule that mediates posttranslational 
modification and produces self-antigens during the cellular stress response is TG2. 
Little is known about the mechanism that triggers TG2 release, which is critical step 
in regulating extracellular enzyme activity. The specific aim of this project is 
therefore to identify the signaling pathway that regulates TG2 externalization. 
 
Within this context, I am setting out to answer the following main questions: 
 
1) Can TG2 be secreted through a non-classical mechanism in the same manner as 
IL-1β? 
2) Does exogenous ATP trigger TG2 release through P2X7R-dependent signaling 
and does it require pore formation? 
 
Answering those questions would widen our understanding of aberrant release and 
activation of TG2. These events might drive protein modification initiated by TG2 
activity in the matrix or at the cell surface. This knowledge could later be used to 
identify TG2 modified proteins in articular cartilage. It is likely that specific products 
accumulate in OA and RA patients due to high levels of TG2 seen in pathology.
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Chapter 2 Materials and methods 
General materials and methods 
2.1 Cell culture  
The human embryonic kidney host cell line with an Flp-In site (HEK293 Flp-In) and 
human epithelial adenocarcinoma cells from mammary gland (MDA-MB-231) were 
kindly donated by Dr Vera Knäuper. The human monocytic leukemia cells (THP-1) 
were kindly donated by Dr Xiaoqing Wei.  A HEK293 Flp-In cells, HEK293 cells 
stably expressing wild-type P2X7 receptor (HEK293 P2X7R), HEK293 cells stably 
expressing P2X7R with V5-His tag (HEK293 P2X7R-V5-His) and MDA-MB-231 
cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen) 
containing 10% heat inactivated fetal bovine serum (FBS) (Invitrogen) and 
antibiotics (100 µg/ml streptomycin, 100 U/ml penicillin) (Invitrogen). The HEK293 
Flp-In cells were grown in the presence of 100 µg/ml Zeocin to maintain the 
expression of Flp-In site (Invitrogen). The culture medium for HEK293 P2X7R and 
HEK293 P2X7R-V5-His cells was supplemented with 100 µg/ml Hygromycin B to 
maintain the expression the transgene (Invitrogen). THP-1 cells were grown in 1640 
RPMI medium (Sigma) containing 10% FBS (Gibco), 2 mM L-glutamine (Gibco) 
and antibiotics (100 µg/ml streptomycin, 100 U/ml penicillin) (Gibco). Cells were 
maintained at 37 °C in a humidified incubator at 5% level of CO2. 
2.1.1 Cells passaging 
Adherent cells were split 1:7 and transferred into fresh 75 cm2 flask (Starstedt) when 
they reached 80% confluence. Briefly, cells were detached from the surface with 1 
ml trypsin/EDTA solution (0.05%) (Invitrogen) and left for 2-5 min at 37 °C. 
Trypsin was ‘inactivated’ by addition of 5 ml of medium containing 10 % FBS and 
cells were collected by centrifugation for 5 min at 400 x g. Cell pellet was re-
suspended in 7 ml of fresh medium and 1 ml was transferred into new 75 cm2 flask. 
The non-adherent cells were collected from flask and centrifuged for 5 min at 400 x 
g. Cell pellet was re-suspended in 7 ml of fresh medium and 1 ml was transferred 
into new 75 cm2 flask. 
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2.1.2 Cell counting 
After trypsinization cells were suspended in the medium containing 10% FBS. 
Desired volume of cell suspension was mixed with Trypan Blue solution (0.4%) 
(T8154, Sigma) in 1:1 ratio. 10 µl of cell suspension was loaded into Neubauer 
counting chamber and unstained cells counted according to the manufacturers 
protocol in order to obtain the cell number per 1 ml of medium. 
2.3 Sample processing for Western blotting 
2.3.1 Protein extraction 
Cells were lysed in Cell Extraction Buffer (CEB) containing 20 mM HEPES, pH 7.4, 
150 mM NaCl, 1 mM EGTA, 1% Triton X-100 and 0.25% deoxycholic acid. To the 
CEB 10% glycerol, 1 mM PMSF and 1 mM NEM were added just before protein 
extraction. Cells were lysed on ice for 10 min and the obtained extract was cleared 
by centrifugation at 15, 000 x g for 10 min, 4 °C. The supernatant was collected and 
frozen at -20 °C for further analysis. 
2.3.2 Protein concentration determination 
BCA protein assay was performed according to the protocol provided by the 
manufacturer (Thermo Scientific). In order to calculate protein concentrations, BSA 
was used as a standard (20 – 2000 µg/ml). 25 µl of each standard and sample as well 
as appropriate blanks were placed into wells of a 96-well plate and 200 µl of working 
solution/well was added (working solution: Reagent A with Reagent B at a ratio of 
50:1). The plate was sealed and agitated thoroughly for 30 sec, and incubated at 37 
°C for 30 min. After equilibrating plate to RT, the absorbance was read at 590 nm 
using a plate reader. The standard curve for BSA was derived by linear regression 
and protein concentrations were calculated from the standard curve. 
2.3.3 SDS polyacrylamide gel electrophoresis 
Protein samples were mixed with an equal volume of 2x sample buffer (25 mM 
Tris/HCl, pH 6.8, 39 mM EDTA, 4 % w/v SDS, 30 % v/v glycerol, 0.3 % w/v 
bromophenol blue) containing 2 % β-mercaptoethanol and boiled for 3 min at 98 °C. 
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A set amount of protein was loaded per lane (10 – 50 µg as indicated). As a 
molecular weight standard, 30 µg of the Amersham Low Molecular Weight Marker 
(LMW) (GE Healthcare) was used. Proteins were separated on Novex 4-20% Tris-
glycine polyacrylamide gels (Invitrogen) for 2 hours using 125 V constant voltage 
(~35 mA). The electrophoresis was performed in running buffer (25 mM Tris/HCl, 
pH 8.8, 192 mM glycine, 0.1 % w/v SDS). 
2.3.4 Western blotting 
The sponges, blotting paper (Whatman) and nitrocellulose membrane (Schleicher & 
Schuell) was soaked in the transfer buffer (25 mM Tris/HCl, 192 mM glycine, 20 % 
v/v methanol). Then the “blotting sandwich” containing sponges, blotting paper, 
polyacrylamide gel and nitrocellulose membrane was prepared and placed in the 
transfer chamber. Proteins were transferred onto the nitrocellulose membrane for 2 
hours using 125 mA constant current (∼25 V) in transfer buffer. After transfer, the 
nitrocellulose membrane was stained with Ponceau S solution (5 % acetic acid v/v, 
0.1 % w/v Ponceau S in H2O) to visualize transfer efficiency and to mark the protein 
marker position. After washing with TBS, the membrane was blocked with 5% 
skimmed milk in TBS for 1 hour to prevent non-specific binding. Primary antibodies 
(Table 2.1) were diluted in 5% skimmed milk/TBS to the indicated concentration and 
incubated with the membrane at RT for the indicated time while shaking. The 
membrane was then washed 3 x 5 min in TBS containing Tween-20 (0.05%) 
(TBST). Secondary antibodies conjugated to HRP (Table 2.2) were diluted 1:500 in 
5% skimmed milk/TBS before addition to the membrane. Following a 1 hour 
incubation period, the membrane was washed 3 x 5 min with TBST and once with 
TBS before addition of HRP-substrate. Antibodies binding was visualised using 
Amersham ECL Plus or Amersham ECL Prime Western Blotting Detection 
Reagents. The membrane was exposed to Amersham Hyperfilm (GE Healthcare). 
Film exposure time was adjusted from a few seconds up to 10 min. 
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Table. 2.1 List of primary antibodies used for immunostaining and Western 
blotting 
Name Clone Species Antigen (amino 
acids (aa)) 
Final concentration Catalog 
number and 
manufacturer 
    WB Immunostaining  
Anti-
TG2 
 
CUB 
7402 
Mouse 
monoclonal 
aa 447-478 
between 
catalytic core 
and β barrel-1 
200 ng/ml 
(1:1000) 
1.5h, RT or 
ON, 4°C  
2 µg/ml 
(1:100)  
MS-224-P1, 
Thermo 
Scientific 
Anti-
P2X7R 
 
- Rabbit 
polyclonal 
 
aa 331-595 on 
the C-terminus 
of human 
P2X7R 
1 µg/ml 
(1:200)  
2h, RT or 
ON, 4°C  
2 µg/ml 
(1:100) 
sc-25698, 
Santa Cruz 
Anti-V5 - Mouse 
monoclonal 
14 aa sequence:  
G-L-P-I-P-N-P- 
L-L-G-L-N-S-T  
20 ng/ml 
(1:5000) 
1h, RT 
1 µg/ml 
(1:100) 
R96025, 
Invitrogen 
Anti β-
tubulin 
TUB 
2.1 
Mouse 
monoclonal 
aa 281-446 on 
the C-terminus  
2.6 µg/ml 
(1:1000) 
1h, RT 
- T4026, 
Sigma-
Aldrich 
Anti-
actin 
- Rabbit 
polyclonal 
11 aa sequence 
on the C-
terminus:  
S-G-P-S-I-V-H-
R-L-C-F 
 
3.15 µg/ml 
(1:200)  
1h, RT 
 
- A2066, 
Sigma-
Aldrich 
Anti-
Flotillin-
2 
29/Floti
llin-2 
Mouse aa 122-379 500 ng/ml 
(1:500) 
1h, RT 
- 610383, BD 
Biosciences 
Anti- 
IκBα 
 Rabbit 
polyclonal 
 
peptide on the 
C-terminus  
1 µg/ml 
(1:200)  
2h, RT  
- sc-371, 
Santa Cruz 
Anti-
GAPDH 
GAPD
H-71.1 
Mouse 
monoclonal 
not specified 200 ng/ml 
(1:5000) 
1h, RT 
- G8795, 
Sigma 
Anti-IL-
1β 
CRM5
6 
Mouse  not specified 500 ng/ml 
(1:1000) 
ON, 4°C 
- 14-7018-81, 
eBioscience 
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Table 2.2 List of secondary antibodies used for immunostaining and Western 
blotting 
 
 
 
 
 
 
 
 
 
 
2.4. Statistical analysis 
Data were analyzed using the GraphPad Prism software version 4.0a. The data 
presented are the mean ± standard error of the mean (SEM) or mean ± standard 
deviation (SD) as appropriate. For multiple pairwise comparisons, one-way analysis 
of variance (ANOVA) using the Tukey pair test was conducted. A p value of ≤0.05 
was considered as significant.    
Conjugate Species Final concentration Cat No and 
manufacturer 
  WB Immunostaining  
Alexa 
Fluor 594 
Donkey 
anti-mouse 
- 10 µg/ml 
(1:200) 
A21203, 
Invitrogen 
Alexa 
Fluor 488 
Donkey 
anti-rabbit 
- 10 µg/ml 
(1:200) 
A21206, 
Invitrogen 
HRP Rabbit anti-
mouse 
2 µg/ml 
(1:1000) 
- P0260, Dako 
HRP Swine anti- 
rabbit  
2 µg/ml 
(1:1000) 
- P0399, Dako 
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Materials and methods in Chapter 3 
2.5 TG2 storage and determination of protein concentration using the 
spectrophotometer 
Transglutaminase 2 was purified from E.coli by our laboratory as previously 
described (Hadjivassiliou et al. 2008). After purification TG2 was stored at -20°C in 
a buffer containing 300 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.5. During 
the time course of the experiments TG2 was defrosted and kept at 4°C. In order to 
estimate protein concentration the sample was cleared by centrifugation at 14000 x g 
for 30 min at 4˚C and absorbance was measured with the spectrophotometer 
(Beckman Coulter, DU 800). Concentration was derived from the OD280 reading 
using the Beer-Lambert law and the extinction coefficient of ε = 1352 cm2/g. Some 
experiments were performed using commercially available TG2 (T002, Zedira). 
2.6 Excitation and emission spectra determination of Abz-APQQEA and Abz-
APE(γ-cad-Dnp)QEA  
The excitation and emission spectra of the quenched Abz-APE(γ-cad-Dnp)QEA 
substrate and unquenched Abz-APQQEA peptide were first determined in the 
absence of Ca2+ and TG2. Solutions of 0.5 µM Abz-APQQEA peptide (Zedira) or 5 
µM Abz-APE(γ-cad-Dnp)QEA quenched peptide (A102, Zedira) in Assay Buffer 
containing 50 mM Tris/HCl, pH 7.4, 50 mM glycine methylester, 100 mM NaCl, 1 
mM dithiothreitol (DTT) and lacking Ca2+ were measured in a FluoroMax-3 
Spectrofluorometer (HORIBA Jobin Yvon) using a 10x2 mm quartz microcell 
(Hellma Analytics, 104.002F-QS). Slits were set at 1 nm/2 nm for excitation and 
emission, respectively. The emission spectra were obtained by exciting samples at 
λ=320 nm and reading emission between 335 – 600 nm. Samples were scanned from 
200 – 400 nm and the emission was read at λ=417 in order to determine the 
excitation spectra. For each sample and appropriate control 5 independent scans were 
taken and then averaged. The fluorescence of the control (buffer alone) was 
subtracted form the curves in order to obtain the final spectrum. In order to monitor 
the formation of the fluorescent reaction product the emission spectra of Abz-APE(γ-
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cad-Dnp)QEA were determined in Assay Buffer containing 2 mM Ca2+. The 
cleavage of 5 µM of Abz-APE(γ-cad-Dnp)QEA substrate was initiated with the 
addition of 20 µg/ml TG2. The reaction was incubated at 37°C and the emission of 
the sample was read at different time points using the same settings as above. 
2.7 Real-time fluorescence assay for monitoring of transglutaminase activity by 
determining isopeptidase activity 
TG isopeptidase activity was quantified by measuring changes in fluorescence 
intensity over time, resulting from transglutaminase-mediated cleaveage of Abz-
APE(γ-cad-Dnp)QEA (A102; Zedira, Darmstadt, Germany). Reaction kinetics were 
captured at 37˚C in black optical bottom 96-well plates (165305, Nunc) using a 
FLUOstar Optima or OMEGA plate reader (BMG LABTECH). The reaction was 
carried out in 100 µl Assay Buffer containing 50 mM Tris/HCl, pH 7.4, 10 or 55 mM 
glycine methylester, 100 mM NaCl, 50 µM Abz-APE(γ-cad-Dnp)QEA, 5 mM DTT, 
and indicated concentration of TG2. The cleavage of quenched substrate Abz-
APE(γ-cad-Dnp)QEA was initiated by automated injection of Ca2+. Briefly, after 
measuring baseline fluorescence for 400 s (10 x 40 s interval), 10 µl CaCl2 (2 - 50 
mM) or H2O as a control was injected. Where indicated 2 mM MgCl2 injection was 
used as a control. The fluorescence was measured using the 320ex nm excitation 
filter and the 440 nm emission filter (top optics, gain set to 2450) and using a plate-
mode protocol. The change in fluorescence was measured for a 1 h period (90 cycles 
of 40 s measurement intervals in total). Nucleotides (GTP, GTPγS, GDP, GMP, ATP 
and BzATP) (all from Sigma) were added at the desired concentration and reaction 
mixtures were incubated at 37°C for 15 min prior to enzyme activation with CaCl2. 
To inhibit TG2 activity the TG2 inhibitor Boc-DON-QIVMeEs was used (B003, 
Zedira). Background fluorescence of reaction in the absence of Ca2+ was subtracted 
form the curves obtained after Ca2+-mediated TG2 enzyme activation. The enzymatic 
reaction rates were derived by linear regression.  
2.8 TG2 isopeptidase activity assay using live cells 
Human embryonic kidney cells stably expressing P2X7 receptor  (HEK293 P2X7R) 
and breast cancer cells (MDA-MB-231) were used to optimize the TG2 isopeptidase 
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assay in live cells. Black optical bottom 96-well plates (165305, Nunc) were coated 
with 100 µg/ml Poly-L-lysine (mol. weight 150000-300000, P4832, Sigma), washed 
with PBS and air-dried. HEK293 P2X7R cells or MDA-MB-231 cells were re-
suspended in DMEM containing 10 % FBS and lacking antibiotics. Cells were 
seeded at a density of 6 x 104 cells/well and grown overnight. The next day cells 
were washed with pre-warmed PBS (37°C) following by addition of 80 µl Ca2+ -free 
PSS buffer containing 10 mM HEPES/NaOH, pH 7.4, 147 mM NaCl, 12 mM 
glucose, 2 mM KCl, 1 mM MgCl2 and supplemented with 50 µM Abz-APE(γ-cad-
Dnp)QEA and 55 mM glycine methylester, To some of the wells 10 µg/ml TG2 was 
added. The isopeptidase cleavage was initiated by automated injection of 2 mM 
CaCl2 or 2 mM MgCl2 as a control. To assay for TG2 intracellular activity, cells 
were permeabilized by addition of Triton X-100 at 0.1% v/v to the PSS buffer where 
indicated.  
Materials and methods in Chapter 4 
2.9 THP-1 differentiation with IL-6, TPA and ATRA  
THP-1 cells were seeded in RPMI medium with 10% FBS. The next day, medium 
was supplemented with interleukin-6 (IL-6) (0.8 nM in PBS) (human recombinant, 
Sigma, I1395), 12-O-Tetradecanoyl-phorbol-13-acetate (TPA) (0.5 µg/ml in 
dimethyl sulfoxide (DMSO)) (Merck Millipore, 524400) or all-trans retinoic acid 
(ATRA) (1 µM in DMSO) (Sigma, R2625). The same volume of PBS or DMSO, 
respectively, was added as vehicle control. For IL-1β upregulation, half of the wells 
were simultaneously treated with 0.1 µg/ml bacterial lipopolysaccharide (LPS) from 
Salmonella sp. (kindly donated by Dr Xiaoqing Wei) or LPS was added after 48h of 
differentiation. Cells were left to differentiate for 48h or 72h as indicated. Medium 
was collected from the wells and centrifuged for 10 min at 1500 x g. The supernatant 
was transferred into a fresh tube and Tris/HCl, pH 7.4 was added up to 5 mM before 
storage at -20 °C. The cell pellet and cells remaining in the wells were lysed with 35 
µl Cell Extraction Buffer (CEB) (see section 2.2.3.1 for details) and combined.  
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2.10 THP-1 cell culture on different substrates  
THP-1 cells were suspended in RPMI containing 10% FBS and no antibiotics. Cells 
were seeded at a density of 1x106 cells/well in a 24-well plate on plastic, glass 
coverslips or coverslips coated with collagen type I at 44 µg/ml (from rat tail, 
neutralized by 20 mM Tris/HCl, pH 7.4), fibronectin at 40 µg/ml (Sigma, F2006) or 
poly-L-lysine at 40 µg/ml (mol. weight 70000-150000, Sigma, P1274). Cells were 
grown on respective surfaces for 3 days and then washed once with PBS. To the cells 
Physiological Salt Solution (PSS) containing 10 mM HEPES/HCl, pH 7.4, 147 mM 
NaCl, 12 mM glucose, 2 mM CaCl2, 2 mM KCl, 1 mM MgCl2 was added. Cell 
morphology and attachment was assessed with inverted microscope and phase 
contrast optics (Nikon Eclipse TS100). Pictures of the cells were taken using a 
Panasonic Lumix (DMC-G1) camera.  
2.11 THP-1 cell differentiation with ATRA in parallel with LPS priming 
THP-1 cells were seeded in a 24-well plate on glass coverslips coated with poly-L-
lysine as above at a density of 1x106cells/well in RPMI with 10% FBS. On the next 
day, RA (1 µM) and LPS (0.1 µg/ml) were simultaneously added to the cells. After 
48h, medium was gently aspirated, centrifuged for 10 min at 1500 x g and after 
transferring into fresh tube and buffering, frozen at -20 °C. Cells were washed with 
PBS and 0.5 ml PSS was added. Cells were then incubated in PSS with or without 1 
mM ATP for 30 min or 1 hour in the incubator. Following ATP stimulation, the cell 
supernatant was cleared by centrifugation at 1500 x g for 10 min and after 
transferring into fresh tube and buffering, frozen at -20 °C.  
2.12 THP-1 cell differentiation with ATRA followed by LPS priming 
THP-1 cells were seeded in a 6-well plate at a density of 1x106cells/well in 1 ml of 
RPMI with 10% FBS. Additionally, THP-1 cells were seeded in a 24-well plate at 
the density of 0.5x106cells/well in 0.5 ml of RPMI with 10% FBS. The next day, 1 
µM of ATRA or DMSO as a vehicle control was added to the wells. Cells were then 
differentiated for 48h. After that, the conditioned medium from the 24-well plate was 
collected, processed as above and frozen at -20 °C. The cell pellet was lysed on ice in 
50 µl of CEB and then frozen at -20 °C. This represents the 48h time point samples. 
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The cells in the remaining set of wells of the 24-well plate and the ones in the 6-well 
plate were kept for another 24h +/- ATRA and in the absence or presence of 0.1 
µg/ml LPS. The conditioned medium and cell extract fraction was prepared from the 
24-well plate as previously. This represents the 72h time point samples. The cells in 
the 6-well plate were used for stimulation to induce IL-1β release. Cells were 
collected from the 6-well plate and were washed once with pre-warmed (37°C) PBS. 
The suspension cells was then centrifuged for 10 min at 1500 x g and the cell pellet 
was dissolved in 2 ml of PSS. The now fully differentiated cells were then 
transferred into a 24-well plate and stimulated +/- 1mM ATP in PSS for 30 min or 1 
h in the incubator. After that, the cell supernatant and cell extract fraction was 
prepared as above and frozen at -20 °C. 
2.13 Enzyme-linked immunosorbent assay (ELISA) for IL-1β 
Measurements of cytokine concentration in conditioned medium from THP-1 
experiments were performed using human IL-1β Ready-Set-Go reagent set 
(eBioscience) following the protocol provided by the manufacturer. Briefly, capture 
antibodies (anti-human IL-1β, CRM56) was diluted in the appropriate amount of 
Coating Buffer (1:250). To each well, 100 µl of capture antibodies was added and 
the plate incubated overnight at 4 °C. The plate was washed 5 x with TBS/Tween-20  
(0.01%). In the next step wells were blocked for 1 hour with Assay Diluent (200 
µl/well) to prevent non-specific binding. A 2-fold serial dilution of IL-1β standard 
was prepared starting from 500 pg/ml and either 100 µl of standard or 100 µl of 
conditioned medium/PSS transferred to the appropriate wells. Samples were 
incubated overnight at 4 °C, washed with TBST, and subsequently 100 µl of 
detection antibodies (biotin-conjugated anti-human IL-1β, CRM57) (1:250 in assay 
diluent) was added and the plate incubated for 1 hour at room temperature. After 
washing with TBST, 100 µl/well of Extravidin-peroxidase (Sigma) (1:1000 in assay 
diluent) was added. After 30 min, plate was washed 7 times TBST, followed by 
addition of 100 µl/well of Tetramethylbenzidine as substrate. The plate was left for 
15 min to develop. The reaction was stopped by addition of 50 µl 1M ortho-
phosphoric acid. The absorbance of the substrate at 450 nm was measured and a 
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background reading taken at 540 nm was subtracted. IL-1β concentrations were 
calculated from standards using linear regression analysis.  
2.14 Stimulation of MDA-MB-231 cells to detect TG2 in the media 
MDA-MB-231 cells were seeded in 24-well plates at a density of 3 x 104 cells/well 
in 1 ml of DMEM/10% FBS without antibiotics. After 2 days when the cells had 
reached approx. 70% confluence, cells were washed 1 x with serum free DMEM and 
then serum-starved for 18h. Cells were washed once with 200 µl of modified Eagle's 
Minimum Essential Medium (OptiMEM) (Invitrogen). The washing step was 
extended to 10 min when P2X7R inhibitor (A740003, Tocris) or P2X4R inhibitor (5-
BDBD, Tocris) was added. Cells were stimulated with 250 µl OptiMEM containing 
indicated stimuli in the incubator for the indicated time. 200 µl of conditioned 
medium was taken from each well and then centrifuged for 10 min at 1500 x g to 
remove any remaining cells. Cell free supernatant from 2 wells was combined and 
350 µl was transferred into a new tube. To each tube 1M Tris/HCl, pH 7.4, was 
added up to 5 mM final concentration before freezing at -20°C. Media were 
lyophilized and reconstituted in 40 µl of 8M urea and 2 x reducing sample buffer 
(mixed 1:1). 40 µl of conditioned medium was loaded per lane in a 10 well Tris-
Glycine gel (4-20%). To visualize changes in intracellular protein levels, stimulated 
cells were washed once with PBS and lysed with 35 µl of CEB. Cell lysate was 
centrifuged for 10 min at 15, 000 x g and the supernatant was frozen at -20°C. 
Samples were boiled 3 min at 97 °C and 10 µg of cell lysate was loaded per lane. 
Proteins were resolved by electrophoresis followed by Western Blotting. 
2.15 Intracellular calcium measurements in MDA-MB-231 cells  
MDA-MB-231 cells were seeded at 5 x 104 cells/compartment in glass bottom dishes 
(Greiner Bio-One), pre-coated with 100 µg/ml poly-L-lysine (mol weight, 150000-
300000, Sigma), washed once with PBS and air-dried before cell seeding. Fluo-4 
AM (acetomethylester) (Invitrogen) calcium indicator was dissolved in DMSO 
containing 20% (w/v) Pluronic F-127 (Invitrogen). Cells were loaded with 3 µM 
Fluo-4-AM in OptiMEM for 20 min at 37°C and the medium was replaced with 200 
µl fresh OptiMEM. Cells were monitored for 1 min under the confocal microscope 
prior to stimulation with an equal volume (to the volume in the dish) of OptiMEM 
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containing ATP or BzATP. The medium was carefully added to the cells to obtain a 
final concentration of 1 mM ATP or 100 µM BzATP. Cells were stimulated in an 
atmospheric control chamber kept at 37°C with 5% CO2. The time lapse videos were 
recorded using the Leica SP5 confocal microscope and a 63x/1.4 NA oil objective 
(HCX PL Apo CS) for approx. 10 min. Sequential scanning (xyt scanning mode) was 
employed at a scanning rate of 2,62 s/frame. The argon laser was used to excite the 
Fluo-4 calcium indicator and the fluorescence emission was monitored using the 
FITC channel (excitation at 488 nm, emission 500-535 nm). Pictures were analyzed 
and exported using the LAS AF Lite program (Leica Microsystems). 
2.16 Immunolocalization of TG2 in MDA-MB-231 cells  
In order to investigate TG2 localization, MDA-MB-231 cells were seeded into a 24-
well plate at 3 x 104 cells/well on sterile glass coverslips precoated with 100 µg/ml 
poly-L-lysine (mol weight, 150000-300000, Sigma). Cells were cultured in 1 ml of 
DMEM/10% FBS without antibiotics. After 2 days when cells reached approx. 70% 
confluence, cells were washed once with serum free DMEM and then were serum-
starved for 18h. Cells were washed with 200 µl OptiMEM, followed by addition of 
250 µl OptiMEM containing 1 mM ATP or 300 µM BzATP. As a control fresh 
OptiMEM without agonist was used. Cells were left in the incubator for 1h. Cells 
were then washed once with PBS, fixed with 4% PFA for 10 min at RT followed by 
extensive washing with PBS. To also detect intracellular TG2 cells were 
permeabilized with Triton-X-100 (0.1% in PBS) (Sigma) for 5 min where indicated. 
After washing, coverslips were blocked with 1% BSA (Cohn Fraction V, Fisher 
Scientific) in PBS for 60 min to prevent unspecific binding of antibodies. Coverslips 
were incubated for 2 h in a humidified chamber with specific mouse anti-TG2 
antibodies (CUB 7402, 2 µg/ml, Thermo Scientific) diluted in PBS with 1% BSA 
(details of antibodies used can be found in Table 2.1 and 2.2). Diluted antibody 
solutions were centrifuged for 5 min at 10, 000 x g to remove any protein 
precypitates/aggregates prior to application to the sections. Coverslips were washed 
three times with PBS. Anti-mouse Alexa Fluor 594 secondary antibodies (10 µg/ml 
in PBS with 1% BSA) were added to the corrsponding coverslips. Incubation was 
performed in a humidified chamber in the dark for 1 hour. Control coverslips were 
incubated with only the secondary antibodies in the same manner. After washing 
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three times with PBS, coverslips were mounted using Vectashield with DAPI stain 
(Vector Laboratories) to visuallize the nucleus. Images were taken using the Leica 
SP5 confocal microscope and 63x objective. Sequential scanning (xy scanning 
mode) was adopted to collect the fluorescence from each channel. The helium-neon 
543 nm laser source was used to excite Alexa Fluor 594 at 543 nm and the emission 
was collected at 555-620 nm. Nuclear staining was visualized by exciting the 
specimen at 405 nm using the diode405 laser and collecting the emmison between 
430-512 nm. Pictures were analyzed and exported using the LAS AF Lite program 
(Leica Microsystems). 
Materials and methods in Chapter 5 
2.17 Cloning the P2X7R coding sequence into pcDNA 5/FRT/V5-His expression 
vector 
Image clone (ID:4298811) containing the full-length sequence for P2X7R was 
purchased from GeneService, Cambridge, and was received as an E.coli stabculture. 
To prepare stocks and isolate DNA, bacteria were grown overnight in 3 ml LB 
medium (10 g Tryptone, 5g Yeast Extract, 10 g NaCl for 1liter) supplemented with 
chloramphenicol (34 µg/ml) at 220 rpm and 37 ˚C. The next day bacterial cells were 
collected by centrifugation at 3000 x g for 3 min and DNA was extracted using 
QIAprep Spin Miniprep Kit (Qiagen) according to manufacturers instructions. 
Plasmid DNA was finally eluted in 50 µl EB buffer (10 mM Tris/HCl, pH 8.5) and 
stored at -20 °C. In order to prepare glycerol stocks of transformed bacteria, 0.85 ml 
overnight culture was mixed with 0.15 ml glycerol and stored at -80 °C. 
2.17.1 Amplifying P2X7R coding sequence by PCR 
The 1.8 kb fragment encoding P2X7R was amplified using polymerase chain 
reaction and a forward and reverse primers (Eurofins MWG Operon) which 
introduced unique restriction sites into the amplified product (Tab. 2.3). For 
subsequent cloning, the forward primer (P2X7R-kpn-for2) was designed to add a 
KpnI restriction site at 5’ end. Reverse primers were designed to introduce a XhoI 
restriction site at 3’ end. Two different reverse primers were used in order to design 
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two distinct P2X7R amplicons. One that contains the natural stop codon (*) of the 
P2X7R sequence (P2X7R-xho* primer) and a second primer that inserts the XhoI site 
immediately downstream of the coding sequence where the XhoI site replaces the 
stop codon and therefore allows for the V5-His tag to be added within the reading 
frame C-terminal of the P2X7R sequence (P2X7R-xho-rev primer) (Tab. 2.3). When 
cloned into pcDNA5/V5-His vector a C-terminal fusion protein will be producd 
containing a V5-is tag. 
 
Table. 2.3 Primers used for P2X7R amplification 
Name Sequence Melting 
temp. 
P2X7R-kpn-for2 5’- TTAGGTACCTTCACCATGCCGGCCTGCTGC - 3’ 72.2 ˚C 
P2X7R-xho-rev 5’- TTTCTCGAGGTAAGGACTCTTGAAGCCACTGTACTG - 3’ 70.6 ˚C 
P2X7R-xho* 5’- TTTCTCGAGTCAGTAAGGACTCTTGAAGCCACTGTA - 3’ 69.5 ˚C 
 
The P2X7R fragment was amplified using 25 cycles in a total volume of 50 µl of 
reaction. The amplification was performed using 1U of Phusion DNA polymerase 
(Finnzymes, 2U/µl) and 1 µl of each primer in the presence of 10 µl HF buffer 
(Finnzymes) containing 10 mM dNTPs (New England Labs) and 0.5% DMSO (Tab. 
2.4). 
Table. 2.4 Details of PCR program used for P2X7R amplification 
PCR program 
 temperature time 
 98 ˚C 30 sec 
denaturation 98 ˚C 10 sec 
annealing 65 ˚C 20 sec 
elongation 72 ˚C 1’30 min 
 72 ˚C 10 min 
 4 ˚C  
 
For analysis, the amplified PCR fragments were separated on a 1 % agarose gel 
containing 1.25 mM ethidium bromide in TAE running buffer (40 mM Tris/acetate, 
pH 8.5, 2 mM Na2EDTA) The agarose electorphoresis was performed under constant 
25 x 
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voltage (100V). The PCR products were excised from the gel and extracted using 
QIAquick PCR Purification Kit (Qiagen). P2X7Rstop and P2X7R fragments were 
digested overnight at 37°C with KpnI and XhoI restriction enzymes in NEBuffer 1 
(Promega) containing 1% BSA (New England BioLabs). Digested fragments were 
separated using a 1% agarose gel, specific bands cut out from the gel and purified 
using the QIAquick GelExtraction Kit (Qiagen) according to manufacturers 
instructions. 
2.17.2 Construction of P2X7R expression vector 
A modified version of pcDNA 5/FRT vector (Invitrogen) containing the multiple 
cloning site from pcDNA 4/V5-His (version A) was used. This vector allows for site-
specific recombination and transgene expression under the human CMV promoter, 
which ensures high level of constitutive expression. The vector was triple digested 
for 1 hour at 37°C with KpnI, BamHI and XhoI restriction enzymes in NEBuffer 2 
(Promega) containing 1% BSA (New England BioLabs) to reduce re-ligation of the 
linearised vector. The linearised plasmid was purified using the gel extraction 
procedure as outlined above for the P2X7R coding sequence.  
The digested P2X7Rstop, P2X7R DNA fragments and linearised pcDNA 
5/FRT/V5-His plasmid were separated using a 1% agarose gel in order to estimate 
DNA concentration of each fragment. The P2X7Rstop fragment or P2X7R fragment 
was mixed with linearized and digested pcDNA 5/FRT/V5-His plasmid at a ratio of 
3:1 and ligated using 1U of T4 DNA ligase (Invitrogen) in the presence of 5 µl T4 
DNA ligase buffer. The ligation was performed for 1 hour at RT in the total volume 
of 10 µl.  
The ligation mix was added to 50 µl of chemically competent E.coli 
(NovaBlue GigaSingles Competent Cells, Novagen) and incubated on ice for 20 min. 
In the next step, bacterial cells were subjected to heat shock (42°C, 1 min) diluted in 
150 µl LB, spread on agar plates containing 50 µg/ml carbenicillin (Sigma) and 
grown overnight at 37°C. On the following day, the bacterial colonies were 
transferred to 3 ml LB medium with carbenicillin (50 µg/ml) using a sterile tip and 
grown overnight at 37°C and 220 rpm.  
Bacteria from overnight cultures were collected by centrifugation at 3000 x g 
for 3 min and bacterial DNA was extracted using QIAprep Spin Miniprep Kit 
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(Qiagen). DNA from selected colonies was digested for 1h in 37°C with KpnI and 
XhoI restriction enzymes in NEBuffer 2 (Promega) containing 1% BSA (New 
England BioLabs). The digests were analyzed using 1% agarose gel electrophoresis. 
Clones containing the plasmid with the insert were transferred into 100 ml LB 
medium with carbenicillin (50 µg/ml) and grown overnight at 220 rpm, 37°C. Half of 
the overnight culture was used to extract DNA using GenElute HP Plasmid Midiprep 
Kit (Sigma). Glycerol stocks of the positive clones were prepared and stored at -80°C 
(as in subsection 1). Plasmid DNA from 2 clones for each construct was sent for 
sequencing (Value Read Tube, Eurofins MWG, Germany). In order to sequence the 
entire P2X7R insert, 4 primers were used: vector primers T7, pCR3.1-BGHrev 
provided by Eurofins MWG and two internal primers P2X7R-for-3, P2X7R-rev-3 
primers that were de novo designed (Eurofins MWG) (Tab. 2.5). 
 
Table. 2.5 Primers used for P2X7R-V5-His and P2X7Rstop sequencing 
Name Sequence Melting 
temp. 
P2X7R-for-3 5’- GTGCTCATCAAGAACAATATCGAC- 3’ 59.3 ˚C 
P2X7R-rev-3 5’- CTCCCTAGTAGCTGCTGGTTCA - 3’ 62.1 ˚C 
 
2.18 Transfection of HEK293 cells with P2X7R and P2X7R-V5-His constructs 
and selection of stably transfected colonies 
A HEK293 host cell line that contains a Flp-In site (pFRT/lacZeo cassette) for site 
specific insertion using recombinase was used to generate stable cell lines 
(Invitrogen). This system is based on the homologous recombination that occurs 
between the FRT site present in the host cells and in the pcDNA 5/FRT/V5-His 
vector when co-expressed with Flp recombinase (Chapter 5, Fig. 5.2A). This process 
produces a functional hygromycin resistance cassette for selection. Integration of the 
expression construct into the genome is mediated by the Flp recombinase. The 
recombination brings the SV40 promoter and ATG initiation codon into proximity 
with the rest of the hygromycin gene carried by pcDNA5/FRT/V5-His, which allows 
for selection of cells. As the hygromycin gene transcribes the kinase that inactivates 
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Hygromycin B antibiotic by phosphorylation, only cells in which the integration was 
successful are able to grow in medium supplemented with Hygromycin B.  
For generation of the stable cell line, wells in a 6-well tissue culture plate 
(Sarstedt) were coated with poly-L-lysine (40 µg/ml) (Sigma). HEK293 Flp-In cells 
were seeded at the density of 7.6 x 105 cells/well in 3 ml of DMEM medium 
supplemented with 10% FBS and antibiotics. For each construct 2 replicates were 
prepared. The next day, medium was replaced with 3 ml antibiotics free medium 
containing 10% serum. 12 µl of FuGENE 6 Transfection Reagent (Promega) reagent 
was added to 200 µl serum free DMEM and incubated for 5 min at RT. Meanwhile 
3.6 µg of pOG44 vector encoding Flp recombinase was mixed with 0.4 µg of 
plasmid DNA from clone 3 or 6 of P2X7R and clone 3 or 6 of P2X7R-V5-His in a 
total volume of 100 µl serum free DMEM. Then each DNA mix was added into a 
tube containing medium and FuGENE 6 in order for the transfection reagent:DNA 
complexes to be formed (3:1 ratio). The incubation was continued for 30 min at RT. 
150 µl of transfection reagent:DNA complex was added drop-wise into each well. 
The plate was gently swirled in order to evenly distribute the lipid DNA complexes. 
After 24h, growth medium was replaced with 5 ml antibiotics free medium with 10 
% FBS containing 100 µg/ml Hygromycin B (Sigma). Growth medium 
supplemented with Hygromycin B was changed every day for two weeks to select 
transfected cells and once colonies had formed it was replaced every two days. 
Selection of stably transfected cells was performed for four weeks in total. Cell 
colonies were washed with PBS, trypsinized and transferred to a 25 cm2 flask. After 
expansion in the cell culture of the HEK293 expressing P2X7R cells and HEK293 
P2X7R-V5-His cells were frozen in DMEM medium containing 50% FBS and 10% 
DMSO. Stocks were kept in liquid nitrogen for long-term storage. 
Potential changes in cell morphology were investigated using an inverted 
microscope (Nikon Eclipse TS100) with 20x or 40x objective and phase contrast 
illumination. Pictures of the stably transfected cell colonies were taken with a 
Panasonic Lumix (DMC-G1) camera. 
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2.19 Characterization of HEK293 cells stably expressing P2X7R 
2.19.1 Immunolabelling of P2X7R in stably transfected HEK293 cells  
In order to investigate P2X7R localization, the parental cells, P2X7R and P2X7R-
V5-His stably transfected cells were seeded into a 6-well plate at 4 x 105 cells/well 
on sterile glass coverslips precoated with poly-L-lysine (100 µg/ml). Cells were 
grown in DMEM with 10% serum for 1 day. Cells were then washed with PBS, fixed 
with 2% PFA for 10 min at RT followed by extensive washing with PBS. To allow 
antibodies to bind to the intracellular C-terminus of P2X7R, cells were permeabilized 
with Triton-X-100 (0.1% in PBS) (Sigma) for 10 min. After washing, coverslips 
were blocked with 1% BSA (Cohn Fraction V, Fisher Scientific) in PBS for 30 min 
to prevent unspecific binding of antibodies. Coverslips were incubated for 2 h in a 
humidified chamber with specific rabbit anti-P2X7R (2 µg/ml, Santa Cruz), mouse 
anti-V5 (1 µg/ml, Invitrogen) antibodies reconstituited in PBS with 1% BSA or with 
a combination of both antibodies (details of antibodies used can be found in Table 
2.1 and 2.2). Coverslips were washed three times with PBS. Anti-rabbit Alexa Fluor 
488 or anti-mouse Alexa Fluor 594 secondary antibodies (both at 10 µg/ml in PBS 
with 1% BSA) were added separately or simultaneously to the corrsponding 
coverslips. Incubation was performed in a humidified chamber in the dark. Control 
coverslips were only stained with the secondary antibodies in the same manner. After 
washing three times with PBS, coverslips were mounted using Vectashield with 
DAPI stain (Vector Laboratories) to visuallize the nucleus. Images were taken using 
the Leica SP5 confocal microspope and 63x/1.4 NA oil objective (HCX PL Apo CS). 
Sequential scanning (xy scanning mode) was adopted to collect the fluorescence 
from each channel. Alexa Fluor 488 was excited at 458 nm using an argon-ion laser 
source and emission was captured from 494-535 nm. The helium-neon 543 nm laser 
source was used to excite Alexa Fluor 594 at 543 nm and the emission was read at 
555-620 nm. Nuclear staining was visualized by exciting the specimen at 405 nm 
using the 405nm diode laser and collecting the emmison between 430-512 nm. 
Pictures were analyzed and exported using the LAS AF Lite program. 
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2.19.2  Shedding of Amphiregulin-AP upon P2X7R activation 
The ADAM (a disintegrin and metalloprotease proteins) activation by P2X7R was 
studied using Shedding Assay. Two different approaches were performed to 
investigate Amphiregulin – alkaline phosphatase  (AR-AP) shedding upon P2X7R 
activation. 
2.19.2.1 Transfection of HEK293 cell lines overexpressing P2X7R with 
Amphiregulin-AP  
The HEK293 parental cells, P2X7R and P2X7R-V5-His stable cells were seeded into 
24-well plates at a density of 1.5 x 105 cells/well in 0.5 ml of DMEM medium 
supplemented with 10% FBS. For each cell type 4 replicates were prepared. The next 
day, growth medium was replaced with 1 ml antibiotic free medium containing 
serum. Cells were transiently transfected with 0.5 µg Amphiregulin-AP construct per 
well at a 3 µl FuGENE: 1 µg DNA ratio. Briefly, for 4 wells 6 µl of FuGENE 
Transfection reagent (Promega) was mixed with 450 µl serum free DMEM and 
incubated for 5 min at RT. Then 2 µg of the Amphiregulin-AP construct was added 
into the tube to allow transfection reagent:DNA complex formation during 30 min 
incubation at RT. 100 µl of FuGENE: DNA complex was added drop-wise into each 
well. The plate was gently swirled in order to evenly distribute the lipid DNA 
complexes.  
After 48h the growth medium was removed and cells were washed with 200 µl pre-
warmed PSS/well for 5 min in the incubator. Cells were stimulated with 250 µl of 
PSS  +/- 1 mM ATP or PSS  +/- 300 µM BzATP for 30 min at 37 °C in the 
incubator. Following stimulation, 200 µl of PSS was taken from each well and 
transferred into a fresh tube. The medium was centrifuged for 3 min at 10 000 x g to 
remove cell debris and 100 µl of the cell free supernatant was transferred into a 96 
well plate. The AP buffer containing the alkaline phosphatase substrate (4NPP) was 
prepared as following: 100 mM Tris/HCl pH 9.5, 5 mM 4-Nitrophenyl phosphate 
(Sigma), 100 mM NaCl and 20 mM MgCl2. 100 µl of freshly prepared AP buffer 
was added to each well. The increase in the absorbance of the 4NPP substrate was 
measured at 405 nm over time. The plate was incubated at 37 °C in between the 
measurements. OD values were plotted against time and analyzed by linear 
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regression to determine alkaline phosphatase activity, which is equivalent of the AR-
AP ectodomain released into the medium upon P2X7R activation.  
2.19.2.2 Co-transfection of HEK293 cells with P2X7R and Amphiregulin-AP  
For co-transfection experiments the HEK293 parental cells were seeded as above and 
simultaneously transfected with both, 1 µg of AR-AP construct and 2 µg of P2X7R 
construct (clone 6) or P2X7R-V5-His construct (clone 6). The DNA mixture was 
prepared first and then added into serum free medium containing FuGENE 6 as 
outlined above. Cells co-transfected with AR-AP construct and P2X7R or P2X7R-
V5-His constructs were washed and stimulated using pre-warmed and pre-gassed 
OptiMEM (Invitrogen) +/- 1 mM ATP or OptiMEM +/- 300 µM BzATP. Following 
stimulation, 200 µl of conditioned medium was taken from each well and transferred 
into a fresh tube and processed as previously. The alkaline phosphatase activity in 
the medium was determined as outlined above.  
 
2.19.3 Calcium measurements in agonist treated HEK293 cells using confocal 
microscopy 
HEK293 parental cells and HEK293 P2X7R cells were seeded at 7 x 104 cells/well in 
glass bottom dishes (MatTek Corporation) precoated with poly-L-lysine (100 µg/ml), 
washed once with PBS and air-dried before cell seeding. Fluo-4 AM (Invitrogen) 
calcium indicator was dissolved in DMSO containing 20% (w/v) Pluronic F-127 
(Invitrogen).48 hours after cell seeding, cells were loaded with 3 µM Fluo-4 AM in 
OptiMEM for 20 min at 37°C and medium was replaced with 200 µl fresh 
OptiMEM. Cells were monitored for 1 min under the confocal microscope and prior 
to stimulation with an equal volume of ATP or BzATP in OptiMEM, which was 
carefully added to the cells to obtain a final concentration of 1 mM ATP or 100 µM 
BzATP.  
For the experiments with the P2X7R inhibitor, HEK293 P2X7R cells were seeded at 
5 x 104 cells/compartment in glass bottom dishes (Greiner Bio-One), precoated with 
poly-L-lysine (100 µg/ml). Two days later, cells were washed and loaded with 3 µM 
Fluo-4 AM in OptiMEM containing 5 µM P2X7R inhibitor (A740003, Tocris). After 
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20 min preincubation, medium was replaced with 200 µl of OptiMEM containing the 
same concentration of the inhibitor. Cells were then stimulated with the 100 µM 
BzATP in the presence of 5 µM A740003 inhibitor.  
Cell stimulations were performed in the atmospheric control chamber kept at 37°C 
with 5% CO2 under confocal microscope (see section 3.2.3.5.1). 
2.19.3.1 Dynamic Ca2+ imaging  
Movies were recorded using the Leica SP5 confocal microscope and a 63x/1.4 NA 
oil objective (HCX PL Apo CS) for approx. 10 min. Sequential scanning (xyt 
scanning mode) was employed at a scanning rate of 2,62 s/frame. The argon laser 
was used to excite the Fluo-4 calcium indicator and the fluorescence emission was 
monitored using the FITC channel (excitation at 488 nm, emission 500-535 nm). 
Pictures were analyzed and exported using the LAS AF Lite program. 
2.19.3.2 Calcium measurements in agonist treated HEK293 cells using the plate 
reader 
HEK293 P2X7R cells were resuspended in DMEM medium containing 10% FBS 
lacking antibiotics. A black 96-well plate (Nunc) was precoated with 100 µg/ml 
poly-L-lysine (Sigma), washed once with PBS and air-dried. Cells were seeded at 3 x 
104 cells/well. The next day, growth medium was removed and cells were loaded for 
20 min with 3 µM Fluo-4 AM in OptiMEM at 37°C. After 20 min, cells were 
washed once with OptiMEM and medium was replaced with 90 µl fresh OptiMEM. 
The plate was transferred to the FLUOstar OMEGA plate reader (BMG Labtech). 
Measurements were performed using the plate reader equilibrated to 37 °C in the 
presence of 5% CO2. The Fluo-4 fluorescence was measured using the 485-12 nm 
excitation filter and the 520-10 nm emission filter (bottom optics, gain 2200). 
Fluorescence was measured in each well separately using a well-mode protocol. 
After measuring baseline fluorescence for 5 s (5 x 1 s interval), various volumes of 
BzATP stock solution in OptiMEM (1 – 10 µl) were automatically injected to yield 
for different concentrations of agonist and these spanned the 15 – 300 µM range. The 
change in Fluo-4 fluorescence was measured for 20 s after agonist addition (40 
cycles of 0.1 s and then 40 cycles of 0.4 s measurement intervals). Control wells 
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were injected with 10 µl of OptiMEM without agonist. The change of fluorescence 
from 8 wells per condition was measured for each experiment. The average 
fluorescence of control wells was subtracted from the curves derived with agonist 
treatment. Each curve was analyzed by fitting the data initially using first order 
kinetics to estimate the value for a shared constant baseline (C) using the equation: 
y=(Ymax-Ymax*exp(-k*x)+C 
whereby k is the association constant and C is the shared constant for the data set. 
Data were then analyzed by fitting the kinetic data for the first 10s using equation:  
y=(1-exp(-(A-Ymax)*k*x))/(1/Ymax-1/A*exp(-(A-Ymax)*k*x)+C,  
whereby k is the association constant, A is the function of agonist concentration and 
C is the constant for baseline correction previously determined. This fitting was used 
to estimate the maximal fluorescence value (Ymax). The value for association 
constant (k) obtained from data fitting was: 1.7730-6 .Subsequently, Ymax was plotted 
against the agonist concentration to derive a dose-response curve.   
Materials and methods in Chapter 6 
2.20 Detection of TG2 in cell free supernatant using Western blotting. 
Parental HEK293 cells and HEK293 cells stably expressing P2X7R were suspended 
in 0.5 ml of DMEM containing 10% FBS and lacking antibiotics. Cells were seeded 
in a 24-well plate at the density of 1.2 x 105 cells/well. For each condition 4 
replicates were prepared. After 1 day of culture, growth medium was replaced with 
0.5 ml of medium of the same composition as above. Cells were transiently 
transfected with 0.5 µg per well wild-type TG2 or TG2-GFP construct using 
FuGENE-6 transfection reagent (Promega) at a 3 µl Fugene: 1 µg DNA ratio. After 
48h the growth medium was removed and each well was washed with 200 µl pre-
warmed serum-free OptiMEM for 5 min in the humidified incubator. The washing 
step was extended up to 10 min when P2X7R inhibitor (A740003, Tocris) was 
present during washing. Cells were then stimulated with 250 µl of OptiMEM per 
well +/- 100 µM BzATP (Sigma) in the absence or presence of selected inhibitors. 
Cells were left at 37 °C in the humidified incubator. For each condition 800 µl of 
total amount of conditioned medium was collected. Briefly, 200 µl of pulse fraction 
was collected from each well of 4 replicates per condition and media from 2 wells 
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were combined in the tube. Meantime cells were washed with 200 µl of OptiMEM 
and then another 250 µl of OptiMEM without BzATP was added to the cells. At the 
indicated times, 800 µl of total amount of conditioned medium was collected. As 
previously, 200 µl of chase fraction was collected from each well of 4 replicates per 
condition and media from 2 wells were combined in the tube. Conditioned media 
was centrifuged for 10 min at 1500 x g at RT to remove any remaining cells. From 
each tube 250 µl of supernatant was transferred into a fresh tube resulting in 500 µl 
of cell free supernatant per condition. 1M Tris/HCl, pH 7.4, was added up to 5 mM 
final concentration before freezing at -20 °C. Frozen media was lyophilized and 
reconstituted in 50 µl of 8M urea and 2 x reducing SDS sample buffer (1:1). Samples 
were boiled 3 min at 97 °C and 15 µl loaded per lane of a 4-20% Tris/Glycine gel. 
Proteins were resolved by SDS electrophoresis followed by Western Blotting.  
To visualize potential changes in cell-associated protein levels, stimulated cells were 
washed with PBS and lysed with 60 µl per well of Cell Extraction Buffer (as 
described in Materials and Methods, Chapter 2, section). Harvested cell lysate was 
centrifuged for 10 min at 16000 x g (4 °C) and the supernatant was decanted and 
frozen. Protein concentration of the cell extracts was determined using the BCA 
assay (as described in General Materials and methods, section 2.3.2).  10 or 5 µg of 
cell lysate was mixed with 2x reducing sample buffer (1:1) and loaded per lane. 
Proteins were resolved by SDS electrophoresis followed by Western Blotting. 
2.21 Transfection of HEK293 P2X7R cells with TG2-GFP and GFP-TG2 
constructs. 
HEK293 P2X7R cells were seeded at 4 x 105 cells/well in 6-well plates on glass 
coverslips precoated with poly-L-lysine (100 µg/ml) (mol weight 150000-300000, 
P4832, Sigma). The next day, medium was changed and cells were transiently 
transfected with 2 µg/well TG2-GFP or GFP-TG2 constructs, respectively, using 
FuGENE -6 transfection reagent (Promega) at a 3 µl FuGENE: 1 µg DNA ratio. The 
laboratory has designed both TG2-GFP and GFP-TG2 constructs before my arrival. 
The coding sequences are inserted in the PrC plasmid under control of a CMV 
promoter (Invitrogen). After 24h, each well was washed with 200 µl pre-warmed (37 
°C) OptiMEM for 5 min in the humidified incubator. The glass coverslip was 
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transferred from the 6-well plate and attached to a plastic holder prior to applying 
experimental conditions. The holder consisted of a 35mm plastic dish with a circular 
hole drilled into the centre (resembling those commercially available from MatTek 
Corporation/Greiner. Coverslips were secured to the underside of the dish with high 
vacuum silicone grease (Sigma) and were placed onto the microscope stage and 200 
µl pre-warmed OptiMEM was added. Cells were monitored for 1 min under baseline 
conditions using a confocal microscope. Then a defined volume of ATP or BzATP in 
OptiMEM was manually added to the cells to obtain 1 mM ATP or 100 µM BzATP 
final concentration. Cells were stimulated in the atmospheric control chamber kept at 
37°C with 5% CO2. Movies were recorded using the Leica SP5 confocal microscope 
and a 63x/1.4 oil objective. Movies were recorded for approx. 10 min using 
sequential scanning (xyt scanning mode), taking a scan every 2,62 s/frame. The 
argon laser was used to excite the GFP and the fluorescence was monitored using the 
FITC settings (excitation at 488 nm, emission 500-535 nm). Pictures were analyzed 
and exported using the LAS AF Lite program (Leica Microsystems). 
2.22 Annexin V labeling of the exposed phosphatidyloserine. 
HEK293 P2X7R cells were seeded at 5 x 104 cells/compartment in glass bottom 
dishes (Greiner Bio-One), precoated with poly-L-lysine (100 µg/ml) (mol weight 
150000-300000, P4832, Sigma). Two days later, cells were washed with 200 µl pre-
warmed (37 °C) OptiMEM. To the cells 200 µl of OptiMEM containing 2 mM Ca2+ 
and FITC-conjugated Annexin V at concentration 1:100 (31490013, ImmunoTools). 
Cells were monitored for 1 min under baseline conditions using confocal 
microscopy. Movies were recorded for approx. 10 min using sequential Z-scanning 
(xyzt scanning mode), taking a scan every 2,62 s/frame. Then a defined volume of 
BzATP in OptiMEM was manually added to the cells to obtain 100 µM BzATP final 
concentration. Movies were recorded using the Leica SP5 confocal microscope with 
the atmospheric control chamber set to 37°C and 5% CO2. The 63x/1.4 oil objective 
was used to visualize the cells. The argon laser was used to excite the FITC-
conjugated Annexin V and the fluorescence was monitored in using the FITC 
channel (excitation at 488 nm, emission 500-535 nm). Pictures were analyzed and 
exported using the LAS AF Lite program (Leica Microsystems). 
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2.23 Densitometry analysis 
X-ray films of ECL probed Western blots were scanned and converted into grayscale 
tiff images. Densitometry was performed using Image Quant analysis software 
(Amersham). 
Materials and methods in Chapter 7 
2.24 Detection of TG2 in cell free supernatant in the presence of inhibitors and 
at various Ca2+ concentrations using Western blotting. 
HEK293 cells stably expressing P2X7R were seeded and transfected with wild-type 
TG2 or TG2 mutant C277S using the same transfection conditions as in Materials and 
Methods Chapter 6 (section 2.20). Briefly, 48h of transfection the growth medium 
was removed and each well was washed with serum-free OptiMEM for 5 min in the 
humidified incubator. The washing step was extended for up to 10 min when 
Calmidazolium chloride (Merck) was present during washing. Then cells were 
stimulated with 250 µl of OptiMEM per well +/- 100 µM BzATP in the absence or 
presence of Calmidazolium chloride or TG2 inhibitor (Boc-DON-QIVMeEs, Zedira). 
Where indicated, cell stimulation with BzATP was performed in standard OptiMEM 
(0.9 mM Ca2+) or OptiMEM containing 2.2 mM Ca2+ or 1 mM EDTA. The following 
steps were performed according to the protocol detailed in Materials and Methods 
Chapter 6 (section 2.20). 
2.25 Monitoring P2X7R-dependent pore formation by YO-PRO-1 uptake. 
Black optical bottom 96-well plates (Nunc) were coated with 100 µg/ml poly-L-
lysine, washed with PBS and air-dried. HEK293 P2X7R and parental HEK293 cells 
were re-suspended in DMEM containing 10 % FBS and no antibiotics. Cells were 
seeded at the density of 3 x 103 cells/well. When they reached 80% confluence, the 
cells were washed with pre-warmed PSS without Ca2+ (10 mM HEPES/NaOH, pH 
7.4, 147 mM NaCl, 12 mM glucose, 2 mM KCl, 1 mM MgCl2). Then, 99 µl of Ca2+ -
free PSS containing 1 µM YO-PRO-1 (Y3603, Invitrogen) was added to each well 
and the plate was transferred into the plate reader equilibrated to 37°C/ 5% CO2. YO-
PRO-1 fluorescence was measured using the FLUOstar Optima instrument (BMG 
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Labtech). The fluorescence was read from the bottom of the plate by scanning a 4 
mm orbital area in the center of the well. The probe was excited at 480 nm and the 
fluorescence emission was collected at 520 nm using a gain of 2200. The baseline 
fluorescence prior to stimulation was read every 40 s for 10 min. After cycle 14 the 
measurement was paused and 1 µl of BzATP at various concentrations was added to 
selected wells. To the control wells 1 µl of H2O was added. YO-PRO-1 uptake by the 
cells was monitored for 30-60 min.  The data were normalized for well-specific 
fluorescence and then the fluorescence of YO-PRO-1 without BzATP stimulation 
was subtracted form those obtained after BzATP-induced pore formation. 
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Chapter 3 Real-time fluorescence assay for monitoring of transglutaminase 
activity by determining isopeptidase activity 
3.1 Introduction 
In order to address the hypothesis that cells can actively externalize TG2 and that 
ATP stimulation (purinergic signaling) can potentiate TG2 externalization it was 
necessary to develop a novel method for quantifying extracellular enzyme. This will 
minimise cell handling or membrane perturbation caused by fixation or extensive 
washing and allow studying TG2 unconventional secretion and activation at the same 
time. Thus, in this chapter a real-time fluorescent TG2 isopeptidase assay was 
designed to track changes in TG2 activity. The advantage of this method is that once 
established as a cell-based assay, the activity of TG2 could be simultaneously 
measured on the outer leaflet of the cell membrane (cell associated), in the ECM or 
in conditioned medium. In contrast, this method should not detect intracellular TG2. 
As an interesting and unusual feature of TG2 is its large conformational change upon 
Ca2+ activation (Griffin et al. 2002; Pinkas et al. 2007), this transition may be an 
important factor regulating enzyme activity following release by the cells. Pinkas and 
colleagues suggest that secreted TG2 remains mainly in a closed conformation, 
despite low GTP and high calcium concentrations, implying that its activity is latent 
under normal physiological conditions (Pinkas et al. 2007). In the scratch wound 
assay performed on WI-38 fibroblast monolayers the activity of TG2 disappears at 
12 h post wounding, although TG2 is still detected by immunostaining (Siegel et al. 
2008). It was thus postulated that certain types of stress conditions lead to rapid and 
transient activation of extracellular TG2. On the other hand, it is well documented 
that physiological concentrations of Ca2+ in the ECM environment will keep the 
enzyme activated (Folk and Chung 1973; Bergamini 1988; R Király et al. 2011). 
Another factor that led me to design a real time assay are the recent findings about 
possible inactivation of TG2 through oxidation upon release (Stamnaes et al. 2010) 
or its fast endocytosis from the cell surface (Zemskov et al. 2007). A recent study 
describes a redox sensitive cysteine triad (C230, C370, C371) involved in regulation of 
the oxidation state of extracellular TG2 (Stamnaes et al. 2010). The existence of a 
redox sensitive cysteine bond was previously postulated by Chung and Folk (1970) 
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and the crystal structure of TG2 confirmed the existence of a C370-C371 disulfide 
bridge (Chung and Folk 1970; Pinkas et al. 2007). Investigation of Stamnaes and 
colleagues point at C230 to have a dominant role in oxidative inactivation of TG2 
activity as it promotes C370-C371 disulfide bond formation (Stamnaes et al. 2010). 
Interestingly, the loss of activity by oxidation is prevented in the presence of TG2 
substrates or Ca2+ ions (at approx. 1-3 mM concentration). Ca2+ abolishes disulfide 
bond formation probably due to occupying its putative binding site, which is situated 
in close proximity to C230. Still, once the disulfide bond is formed, addition of Ca2+ is 
unable to restore TG2 activity. Taken together this means that the level of active 
TG2 present in vivo can be influenced by the local oxidation state and is modulated 
by the presence of Ca2+ and substrate. On the other hand, modulation of local TG2 
activation was confirmed by in vitro studies where incubation of WI-38 fibroblasts 
with oxidized glutathione markedly reduced TG2 activity around the wounded area, 
however TG2 activity could be restored by addition reducing agent (Jin et al. 2011). 
Authors of that study show evidence that the oxidative state of TG2 can be altered by 
specific redox-active proteins rather than by environment per se. They show that 
human thioredoxin can be a specific substrate for oxidized TG2 thus restoring its 
activity. Although thioredoxin is a cytosolic protein, its presence in the extracellular 
matrix can occur upon tissue injury and potentially this specifically drives TG2 
activation. thioredoxin released from THP-1 cells primed with interferon-γ, as well 
as, recombinant thioredoxin were both able to induce TG2 activity on the surface of 
fibroblasts and on the cryosections of the mouse small intestinal biopsies. The data 
suggest that latent TG2 is present and can be activated.  
As the transition from inactive to active TG2, and vice versa, is potentially 
relatively fast, the designed assay needed to detect rapid changes due to release and 
activation in the ECM in response to addition of P2X7R agonist, ATP. This chapter 
details the experimental steps that were necessary to establish a reliable method to 
detect the TG2 enzymatic activity of TG2 and verifies its use for the investigation of 
TG2 release in live cells. 
 
The aims of the chapter: 
1. Establish a sensitive real-time method to detect enzymatic activity of TG2. 
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2. Determine what is the influence of ATP, an allosteric regulator, on TG2 
activity? 
3. Investigate if the assay can be applied to live cells? 
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3.2 Results 
3.2.1 Isopeptide substrate cleavage mediated by TG2 (assay principle) 
 
The assay is based on measuring fluorescence changes over time with the use of a 
quenched substrate, with cleavage indicating the presence of TG2 activity (Fig. 3.1). 
The substrate was designed according to the well-known protease assays and work 
on isopeptidase activity by Laszlo Lorand group (Parameswaran et al. 1997). 
Although the predominant reaction driven by TG2 is the formation of covalent Nε(γ-
glutamyl)lysine bonds between or within polypeptides in the extracellular matrix 
(Raghunath et al. 1996; Aeschlimann and Thomazy 2000). TG2 can catalyze 
isopeptide bond hydrolysis in the presence of excess of an already cross-linked 
substrate (Parameswaran et al. 1997).  To establish the isopeptidase activity assay, 
the Abz-APE(γ-cad-Dnp)QEA peptide, which is commercially available, was used as 
the substrate. This peptide is a quenched fluorescent probe derived from the 
osteonectin sequence (APQQEAL) that imitates an already cross-linked TG reaction 
product (Hohenadl et al. 1995). The backbone of the peptide is changed by 
attachment of the fluorophor (2-aminobenzoyl (Abz)), which is quenched by the 2,4-
dinitrophenyl-cadaverine (cad-Dnp) moiety (Fig. 3.1A). The cad-Dnp substituent on 
the first glutamine residue mimics the Lys side chain in Nε-(γ-glutamyl)lysine 
peptides cross-linked by TG2. TG2-catalysed hydrolysis of the isopeptide bond leads 
to the release of the cad-Dnp moiety from the peptide backbone resulting in a 
fluorescent signal from the Abz group. The isopeptidase reaction mediated by TG2 is 
a two-step process and ultimately results in the substrate hydrolysis or aminolysis 
(Fig. 3.1B). The first step is identical for both reactions and occurs when the 
isopeptide bonded residue in the Abz-APE(γ-cad-Dnp)QEA substrate transiently 
acetylates the thiol group in TG2 active site (step 1: intermediate). The thioester 
enzyme intermediate reacts then with the primary amine (e.g. glycine methylester 
provided in the buffer), which results in substrate aminolysis and release of a 
‘crosslinked’ polypeptide (step 2a). However, this step is reversible as a new 
isopeptide bond is generated. In the absence of amine, TG2 can catalyze the 
hydrolysis reaction resulting in glutamate replacing the original isopeptide-bonded 
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glutamine in the substrate (step 2b). Once the substrate is cleaved, the TG2 is 
regenerated and able to enter into another reaction cycle. 
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3.2.2 Fluorescence spectra of the Abz-APE(γ-cad-Dnp)QEA substrate 
In order to measure fluorescence of the reaction product at appropriate wavelengths, 
the excitation and emission spectra of the quenched Abz-APE(γ-cad-Dnp)QEA 
substrate as well as unquenched Abz-APQQEA peptide were determined (see 
Appendix 1 for structure of Abz-APQQEA). According to the literature, 320 and 420 
nm correspond to the excitation and emission peak maxima for the Abz group. As 
expected, after exciting samples at 320 nm, the fluorescence emission of the Abz-
APE(γ-cad-Dnp)QEA quenched substrate was weak due to Dnp group absorbing the 
energy of the Abz group (Fig. 3.2A and B). On the other hand, the unquenched Abz-
APQQEA peptide showed strong fluorescence emission even for 10-fold lower 
concentration than of the quenched. The maximum emission signal of Abz-
APQQEA peptide was detected at 418 nm (Fig. 3.2B). When the Abz-APE(γ-cad-
Dnp)QEA quenched substrate was incubated with 20 µg/ml TG2 in the presence of 2 
mM Ca2+ a time-dependent increase in fluorescence emission was observed as an 
effect of TG2-mediated cleavage (Fig. 3.2C). A 10-fold increase in fluorescence was 
detected after 827 min. The increase in fluorescence was fast for approx 240 min, but 
slowly reached a plateau value after more than 900 min (Fig. 3.2D). Less than 10 % 
of substrate was converted in the first 30 min of the reaction. The maximal 
fluorescence signal of the reaction product was observed at 418 nm resulting in the 
highest detection sensitivity. However, fluorescence yield at 440 nm was > 80 % that 
of 418 nm. Thus, fluorescence emission coming from Abz-APE(γ-cad-Dnp)QEA 
cleavage mediated by TG2 could be effectively collected with 440 nm filter available 
with the plate reader.  
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3.2.3 Optimization of the isopeptidase assay using an automated “high 
throughput” plate reader 
The TG2 isopeptidase assay was developed to measure enzyme activity using the 
plate reader format. The assay optimization was performed using a FLUOstar 
OPTIMA instrument, which is a filter-based reader that uses excitation and emission 
filters in order to achieve the high sensitivity. Initially, different filters combinations 
were explored as filters can have different bandwidths that allow for the light to pass 
the filter and therefore generate different amount of signal. The light transmission 
through 320ex and 320-10 excitation filters that have 60 and 10 nm band pass, 
respectively, was measured. Moreover the light transmission through 410-80, 440-20 
and 420-12 emission filters that have 80, 20 and 12 nm band pass, respectively, was 
measured as well. Obtained light transmission is presented in relation to the Abz-
APQQEA excitation and emission spectra, respectively (Fig. 3.3A and B). The 
320ex excitation and 410-80 emission filters had the best light transmission profile 
and were expected to give the best detection. Gain was adjusted for each filter pair to 
have comparable baseline conditions. The same filters were used on the FLUOstar 
OPTIMA instrument in order to select the best setting for the fluorescent product 
detection. The cleavage of Abz-APE(γ-cad-Dnp)QEA substrate with recombinant 
TG2 was performed in the 96-well plate format and initiated by addition of 2 mM 
Ca2+ and the reaction was captured for 1h with different combinations of filter pairs. 
The fluorescence value after 20 min of reaction were significantly higher when 
320ex excitation filter (60 nm band pass) rather than 320-10 filter (10 nm band pass) 
was used (Fig. 3. 3C). By combining the 320ex excitation filter with 440-20 or 410-
80 emission filters the amount of light collected with was not markedly different, 
when the gain values for each of pair was adjusted to give result within similar range 
of the scale on photomultiplier. Thus, 320ex excitation and 440-20 emission filter 
were chosen for the assay. 
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3.2.4 Isopeptidase activity of recombinant TG2 
In order to establish optimal reaction conditions with regard to sensitivity and 
reproducibility to measure TG2 isopeptidase activity, a number of FLUOstar 
OPTIMA instrument settings were tested. This included choosing the plate reading 
mode, top or bottom optics, number of light flashes for each measurement, number 
of cycles and cycle time, sample mixing before and after injection, injection volume, 
temperature and type of 96-well plates. The detailed protocol parameters and 
optimized conditions that were adjusted during the assay establishment can be found 
in the Appendix 2. Recombinant TG2 was initially used to optimize conditions for 
Abz-APE(γ-cad-Dnp)QEA substrate cleavage before applying this method to assay 
surface TG2 activity in live cells. Here, I will discuss initially the properties of the 
assay. The Fig. 3.4A with the raw data represent a typical result of the isopeptidase 
cleavage obtained for different TG2 concentrations, where the fluorescence is 
proportional to the amount of TG2 used. The protocol was designed to read baseline 
fluorescence for 10 cycles, to account for small well-to-well differences, prior to 
TG2 activation with 2 mM CaCl2 injection. No activity was detected in control wells, 
where water was injected (Fig. 3.4A). As the change in substrate concentration is 
small within 1h reaction time, TG2-mediated substrate conversion is linear at > 30 
min and after control subtraction the fluorescence can be analyzed by linear 
regression (Fig. 3.4B). To verify that reaction rates are truly linear, the linear 
regression fit were calculated at different time intervals post Ca2+ injection and 
compared in the table (Fig. 3.4C). Table compares the reaction rates (ΔF/s), when the 
data were analyzed including the initial time-points of the reaction (first 5 min) or 
were excluded from the calculations. The data show a small log phase at the 
beginning of the reaction but otherwise very small differences were observed 
between different time intervals. This confirms linearity of the data and that a 5-35 
min analysis interval provides an accurate representation of the reaction.  
 90 
 
 91 
3.2.5 TG2 activation by Ca2+ 
As calcium binding is necessary for TG2 catalytic activity, the isopeptidase cleavage 
under different Ca2+ concentration was investigated. Under physiological 
concentrations of Ca2+ (2 mM), TG2 is highly active whereas no activity could be 
detected in the presence of 2 mM Mg2+ (Fig. 3.5A). By adding high, non-
physiological concentrations of Ca2+ (10 mM and 50 mM) the isopeptidase cleavage 
was further increased (Fig. 3.5B). However, 2 mM Ca2+ was always used for enzyme 
activation in the assays, as the interest was to measure TG2 activity at physiological 
Ca2+ concentrations. 
3.2.6 Buffer composition for the isopeptidase measurements 
The isopeptidase assay was used to determine the influence of buffer composition on 
TG2 activity measurements in order to understand how the activity can be modulated 
and how to achieve the best assay sensitivity. TG2 is known to undergo reversible 
oxidative inactivation and carrying out isopeptidase cleavage in the presence of 
different concentrations of the reducing agent DTT confirmed a dose-dependent 
increase in activity. Addition of DTT up to a 10 mM concentration significantly 
enhanced the reaction rate and improved assay reproducibility between independent 
experiments (Fig. 3.6A). It was also important to determine to what extend ionic 
strength and pH affect the reaction. In order to do so, the isopeptidase cleavage was 
performed at pH 7.5 in Tris buffer containing different concentration of NaCl in the 
absence of glycine methylester. TG2 activity was similar in the presence of 0 – 85 
mM NaCl concentration but the reaction rates started to decrease with increasing salt 
concentrations above 85 mM (Fig. 3.6B). In order to measure isopeptidase cleavage 
at various pH, MOPS and Tris buffering compounds were used and buffers prepared 
with or without 10 mM glycine methylester. It was expected that in the presence of 
an excess amine the aminolysis was the predominant reaction. However, there were 
no significant differences between reaction rates of hydrolysis and aminolysis at any 
pH (Fig. 3.6C). This was unexpected as the concentration of the reactive form of the 
amine (unprotonated) is clearly pH-dependent over the pH range examined, given 
that glycine methylester has a pKa of ∼ 7.6. In both cases, the reaction was strongly 
pH dependent and fastest when buffer pH reached 6.5. 
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3.2.7 Analysis of product of TG2-mediated isopeptidase cleavage 
In the next step, it was necessary to confirm the balance between deamidated and 
transamidated product that is formed during the reaction, under selected conditions. 
Thus, the cleavage of Abz-APE(γ-cad-Dnp)QEA substrate mediated by TG2 was 
performed with or without amine donor. Glycine methylester was present in the 
buffer as previously or other donor Nα-acetyllysine methylester was used instead. 
HPLC analysis of the reaction products revealed the presence of specific peaks 
corresponding to the deamidated (Abz-APEQEA) or transamidated (Abz-APE(γ-
NαMeEster)QEA and Abz-APE(γ-NαAcLysMeEster)QEA) products (Fig. 3.7). The 
Abz-APE(γ-cad-Dnp)QEA substrate was always detected at 17.5 min. The 
deamidated product was detectable in the absence of amine present (Fig. 3.7B) or at 
its low concentrations after approx. 11.5 min (Fig. 3.7C). Depending on the amine 
used, the deamidated products were eluted at slightly different positions in relation to 
the Abz-APE(γ-cad-Dnp)QEA substrate (Fig. 3.7C,D and E). Relative increase in the 
fluorescence of the deamidated vs transamidated products were similar (Fig. 3.8A 
and B) suggesting that differences in product formation were largely guided by 
amine concentration. To estimate the amine concentration required for the transition 
from the reaction of hydrolysis to aminolysis reaction mediated by TG2 for different 
amine substrates, the formation of deamidated versus transamidated product at 
different glycine methylester and Nα-acetyllysine methylester concentrations was 
analyzed (Fig. 3.8C). There is a big difference in the concentration of each amine 
necessary to yield a transamidated product (approx. 14-fold higher concentration of 
Nα-acetyllysine methylester than glycine methylester is needed) (Fig. 3.8C). Those 
data suggest that while the nature and concentration of the amine donor substrate has 
a pronounced influence on product formation. 
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3.2.8 Standard reaction conditions 
After evaluating a number of parameters relevant to the study of the isopeptidase 
activity, the standard conditions for the reaction were established. As an internal 
standard, the activity of 20 µg/ml TG2 in Tris/HCl at physiological pH (7.5) and in 
the presence of 100 mM NaCl was determined in all experiments. Enzyme activity 
was analyzed at 2 mM Ca2+ in the presence of 5 mM DTT to reverse oxidation. To 
avoid measuring both, the deamidated and transamidated fluorescent product, the 
glycine methylester concentration was kept at 10 mM to favor the reaction of 
aminolysis (showed on Fig. 3.8C as dashed line). Therefore, all subsequent 
experiments were performed under those conditions. 
3.2.9 The isopeptidase assay sensitivity 
The aim of developing the isopeptidase assay was to measure small changes in TG2 
activity at cell surface therefore it was important to determine the detection limit of 
the assay. The isopeptidase cleavage was performed using standard conditions and 
different TG2 concentrations (1.25 – 20 µg/ml). The assay sensitivity was compared 
between the FLUOstar OPTIMA and FLUOstar OMEGA plate reader whereby the 
OMEGA instrument is supplied with a more sensitive photomultiplier (Fig. 3.9A and 
B). Fluorescence emission of the standard peptide Abz-APQQEA showed linear 
relationship when concentrations of 0.13-2.0 µM substrate were used on OPTIMA 
(gain 2450) and 0.016-0.5 µM (gain 2450) or 0.03-2.0 µM (gain 1883) on OMEGA 
instrument, respectively (Fig. 3.9C and D). The detection limit for enzymatic 
conversion of Abz-APE(γ-cad-Dnp)QEA was 1 µg/ml (~13 nM) TG2 on both 
instruments (Fig. 3.9E). This could not be enhanced by longer reaction times. 
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3.2.10 TG2 activity in the presence of nucleotides 
Using the outlined reaction conditions, 20 µg/ml TG2 and different concentrations of 
nucleotides, the allosteric regulation of TG2 activity by nucleotides was investigated. 
This was important, as both ATP and BzATP will be later used as P2X7R agonists. 
Whereas GTP binds to TG2 structure, promotes it closed conformation and therefore 
acts as a high affinity regulator of TG2 activity (Achyuthan and Greenberg 1987), 
the data concerning ATP effect on TG2 is more debatable. The reaction was 
performed in the presence of Ca2+ and various concentrations of GTP, GTPγS, ATP 
and BzATP (Fig. 3.10). GTP and GTPγS (its nonhydrolyzable form) were strongly 
inhibiting TG2 activity, with an apparent binding affinity of 2.9 and 3.6 µM, 
respectively, whereas ATP and BzATP had an approx. 1000 fold lower affinity. GTP 
inhibition of enzyme activity was not influenced at high ionic strength (200 mM 
NaCl). However, it was approx. 500-fold weaker at saturating, non-physiological 
Ca2+ concentrations (50 mM Ca2+).  
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3.2.11 TG2 activity in live cells  
After optimizing conditions for the isopeptidase assay with recombinant TG2, 
preliminary measurements of enzyme activity in live cells were performed to 
validate the use of this method for cell-based studies. The method should allow 
measuring activity of released TG2 in real time (Fig. 3.11). Experiments were 
performed in the same plate reader format but the reaction was measured in the PSS 
buffer (physiological salt solution). The PSS buffer is a salt solution that is 
mimicking the physiological extracellular conditions and is widely used to stimulate 
P2X7R in live cells when supplemented with ATP or BzATP (Mackenzie et al. 
2005). Before performing experiments with cells the activity of recombinant TG2 in 
both standard Assay buffer and PSS was compared and the rate of the reaction was 
similar in both buffers (only approx. 1.25 x higher reaction rate in PSS than in 
standard assay buffer based on two independent measurements, data not shown). 
Two different cell lines were used: MDA-MB-231 breast cancer cells that express 
high levels of intracellular TG2 (see Chapter 4) and HEK293 human kidney cells 
stably transfected with P2X7R that are negative for TG2 (see Chapter 5 and 6). In the 
presence of 2 mM Ca2+, the reaction rates were similar when the activity of the 
recombinant TG2 (10 µg/ml) was measured alone or in the presence of either cell 
line (Fig. 3.12). Data show that the presence of cells or cellular products does not 
influence the assay. In wells containing HEK293 P2X7R cells and no Ca2+, there was 
also a small increase in fluorescence in the absence of added TG2. This likely was a 
non-specific event as those cells do not express TG2. Similarly, activity of TG2 was 
detected in MDA-MB-231 cells but only when recombinant TG2 was added 
indicating that the assay is not sensitive enough to detect extracellular TG2 activity 
in MDA-MB-231 cells or its activity is latent on the surface of cells (Fig. 3.12A and 
B).  
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It was not clear whether insufficient sensitivity of the assay or the absence of active 
TG2 in the extracellular environment was responsible for the lack of signal. 
Therefore, Abz-APE(γ-cad-Dnp)QEA substrate cleavage was assessed after lysing 
the cells with Triton-X-100. The assay was performed as previously in the presence 
of HEK293 P2X7R and MDA-MB-231 cells and recombinant TG2 was added to one 
group of samples to detect potential interference with the assay. When the cell 
membrane of either cell types was permeabilized with Triton-X-100, the fluorescent 
signal increased rapidly but this process was calcium independent (Fig. 3.13A). The 
apparent substrate cleavage was greater in the wells where lysed MDA-MB-231 cells 
were present. Given that hydrolysis was Ca2+ independent, the reaction likely was the 
result of non-specific proteolytic processing of the fluorescent peptide. However, it 
may also possible that sufficient Ca2+ was released from intracellular stores to 
activate TG2. Therefore, the specific TG2 blocking inhibitory peptide Boc-DON-
QIVMeEs (B003 inhibitor) that alkylates the active site cysteine was chosen to block 
TG2 activity, which was potentially released from MDA-MB-231 cells. The inhibitor 
concentration that can fully block recombinant TG2 activity was assessed. The 
addition of 1 µM of the B003 inhibitor completely prevented the cleavage of Abz-
APE(γ-cad-Dnp)QEA substrate by 10 µg/ml TG2 (Fig. 3.13B). The B003 inhibitor 
was then used to determine to what extend intracellular TG2 released upon MDA-
MB-231 permeabilization participates in the cleavage of the fluorescent substrate. 
Thus, 5 µM or 25 µM TG2 inhibitor was added to permeabilized MDA-MB-231 
cells and only a small change in reaction rates was observed, indicating that 
proteolysis and not isopeptidase activity is principally responsible for the signal. 
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3.3 Discussion  
There are not many sensitive tools available to measure extracellular TG2 activity in 
situ. Different research groups are trying to develop an assay to assess TG2 activity 
in an intact biological system that will not disrupt cells leading to activation of 
possibly mostly latent TG2. Established and most widely used methods to study 
transglutaminase activity are based on the transamidation reaction. They are based on 
modified amine donor substrates such as radiolabelled putrescine incorporation into 
N,N-dimethylcaseine (Lorand et al. 1976; Dadabay and Pike 1987) or incorporation 
of dansylated cadaverine into casein (Murtaugh et al. 1984) or fibronectin 
(Aeschlimann and Paulsson 1991). However, those techniques require protein 
precipitation from cells or incubation of cells with the substrate followed by cell 
fixation for visualization. A number of novel techniques have recently been 
developed based on conformational changes of TG2 and its allosteric regulation in 
situ, trying to visualize these changes as a proxy for activity. One of the interesting 
examples are the “clickable” inhibitors for TG2 that can only bind the active, open 
conformation of the enzyme and this have been successfully used in mammalian 
cells and tissue experiments (Dafik and Khosla 2011). Another interesting technique 
is the lately described FLIM-FRET biosensor, which has mCerulean and eYFP pair 
attached to the N- and C- terminus of TG2. This biosensor allows to quantify 
changes in TG2 conformation in live cells (Caron et al. 2012). Clearly, there is a 
need for novel approaches to investigate TG2 activation in intact cells. The aim of 
this study was to evaluate whether the fluorescent substrate Abz-APE(γ-cad-
Dnp)QEA was able to detect TG2 activity in real time in the absence of sample 
processing, in order to potentially visualize local fluctuations in activity in live cells.  
It was essential to use a TG2 substrate that closely mimics the naturally 
occurring peptides in cartilage in order to further investigate TG2 catalytic activity. 
The substrate that was used to establish the assay is derived from the natural 
substrate for TG2, osteonectin (BM-40, SPARC). Osteonectin is a protein expressed 
during chondrocyte maturation and is one of the substrates for TG2 in cartilage 
(Aeschlimann et al. 1995). The N-terminal domain I of osteonectin was identified as 
a major glutamine donor substrate for TG2-mediated reactions in vivo. TG2 is able 
to modify both Q3 and Q4 glutamine residues in the APQQEAL sequence of 
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osteonectin. Q3 and Q4 glutamine residues are conserved in higher vertebrates, which 
suggests that there is a specific function of those amine acceptor sites in the 
cartilaginous tissue (Hohenadl et al. 1995). TG2 can catalyze isopeptide bond 
hydrolysis in the presence of excess of a cross-linked substrate (Parameswaran et al. 
1997). In agreement with that, the established assay measures hydrolysis rate of the 
Abz-APE(γ-cad-Dnp)QEA substrate as an effect of acyl-enzyme intermediate 
formation and separation of fluorescent Abz from quenching Dnp moiety. Addition 
of the Abz-APE(γ-cad-Dnp)QEA to the buffer containing TG2 and Ca2+ results in the 
time-dependent increase of the fluorescence emission coming from the Abz group 
thus confirming that the substrate is actively converted by TG2. 
A number of parameters were established to improve assay sensitivity and 
mimic the reaction conditions likely to occur in a physiological context. TG2 
enzymatic activity is dependent on the presence of Ca2+ ions that can promote the 
open structure and allows the active site of the enzyme to react with available amine 
acceptor substrate (Aeschlimann and Thomazy 2000; Pinkas et al. 2007; Róbert 
Király et al. 2011).  Similarly, TG2 isopeptidase cleavage of the Abz-APE(γ-cad-
Dnp)QEA substrate is only initiated when sufficient Ca2+ is available but enzyme is 
inactive in the presence of Mg2+, which is in agreement with the literature (Folk and 
Chung 1973; Róbert Király et al. 2011). TG2 is highly active at physiological Ca2+ 
concentrations (∼2 mM) however increasing the concentrations of Ca2+ to 10 mM or 
even 50 mM enhance the isopeptidase cleavage rate, presumably due to saturation of 
Ca2+ binding sites. As those conditions do not represent the physiological situation 
and because it was previously reported that activation of TG2 occurs at > 200 µM 
Ca2+ (Pinkas et al. 2007; Kurta et al. 2009; Schaertl et al. 2010) increasing Ca2+ 
levels were not considered as a relevant option to improve assay sensitivity. 
Automated injection of Ca2+ for enzyme activation, combined with the ability to 
continuously measure linear increase of fluorescence intensity over a considerable 
time period enables the acquisition of kinetic data. The isopeptidase assay was 
proven to be a sensitive and highly specific method for measuring recombinant TG2 
activity with approx. 1 µg/ml detection limit. The addition of 1 µM Boc-DON-
QIVMeEs inhibitor to the reaction mixture produced complete inhibition of TG2 
activity at 10 µg/ml. This inhibitor has been reported to block TG2 activity with high 
potency (Schaertl et al. 2010) and was successfully inhibiting TG2-dependent 
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substrate conversion even when activity of recombinant TG2 was measured in the 
presence of intact cells.  
The isopeptidase assay with recombinant TG2 was useful to measure 
different factors that can influence TG2 activity such as oxidation, ionic strength or 
pH before conducting experiments in cell systems. Oxidative inactivation is an 
independent mechanism that does not affect C277 in the active site but it sterically co-
strains the enzyme and thereby prevents its activation (Stamnaes et al. 2010). Recent 
evidence provided by Stamnaes and colleagues indicates that handling of TG2 in an 
oxidizing enviroment or treatment with oxidizing agents results in disulfide bond 
formation and consequently leads to enzyme deactivation but treatment with 
reducing agents such as DTT, can restore its activity. This was observed for the 
established isopeptidase cleavage reaction, which was significantly improved in the 
presence of reducing agent. The existence of redox sensitive cysteine bonds is 
thought to regulate the conformation of TG2 and ultimately controls TG2 activity in 
the extracellular environment. Hence, adding DTT to the reaction allows for 
maximal enzyme activity and improved assay reproducibility. TG2 was most active 
in low ionic strength buffer and higher concentrations of salt impaired its activity, 
suggesting that ionic interactions are relevant to catalysis. The hydrolysis of the 
substrate was strongly pH-dependent and optimal at pH 6.5. This is in agreement 
with the result obtained for cleavage of a similar Dns-labelled quenched substrate 
hydrolysed by human TG2 purified from blood cells (Parameswaran et al. 1997). 
There were no significant differences between reaction rates at different pH in the 
presence or absence of glycine methylester, which suggested that both aminolysis 
and hydrolysis are similarly fast. This is in agreement with the data collected by Folk 
and Cole where they show that pH is affecting both deamidated and transamidated 
product formation and that catalysis reaches a peak at pH 6 (Folk and Cole 1966). 
The pH will affect reactive residues involved in catalysis and change the protonation 
state of the amine substrate (Gross et al. 1977; Leblanc et al. 2001). HPLC analysis 
showed that transamidation did indeed take place and that ratio of transamidated to 
deamidated product depends on the nature of the amine structure and its 
concentration used but not the acid dissociation constant (pKa) of the amino group as 
such (Leblanc et al. 2001). Taken together these data show that the measurements are 
highly pH-dependent and therefore the tight control of reaction pH is paramount.  
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The plate format is ideal for investigating the effect of potential regulators or 
inhibitors on TG2 catalysis. Beside some of them being ligands for purinergic 
receptors, GTP and other nucleotides are well-characterized allosteric regulators of 
TG2 (Liu et al. 2002; Han et al. 2010). The IC50 concentrations of 2.9 µM, 3.6 µM, 
and ~1 mM obtained for GTP, GTPγS and ATP are in good agreement with data in 
the literature (Parameswaran et al. 1997). As expected, the inhibitory effect of GTP 
on TG2 activity was strongly dependent on the amount of Ca2+ present 
(Parameswaran et al. 1997; Mhaouty-Kodja 2004; Schaertl et al. 2010). Therefore, 
the IC50 concentration is the binding constant for GTP as this was derived in the 
presence of Ca2+. This method was successfully used to study the allosteric 
regulation of a novel member of TG family – TG6 – by nucleotides (Thomas et al. 
2013) (publication in Appendix 3). For this project it was important to compare TG2 
activity in the presence of nucleotides in order to assess at what concentration of 
ATP and BzATP in the presence of 2 mM Ca2+ affect its activity. High ATP 
concentration (>1 mM) is crucial for P2X7R activation on the cell surface (Di 
Virgilio et al. 2001; Coddou et al. 2011). However, at 1 mM ATP half-maximal 
inhibition of TG2 activity was observed. As BzATP is a more potent P2X7R agonist, 
the concentration needed for P2X7R activation is lower (>50 µM) (North 2002; 
Mackenzie et al. 2005). Therefore, 100 µM BzATP can be used in experiments in 
order to fully activate the P2X7R receptor without blocking surface TG2 activity.  
To summarize, in this chapter I have presented the experimental conditions 
for determination of TG2 isopeptidase activity using the fluorescent model substrate 
Abz-APE(γ-cad-Dnp)QEA and plate reader format (see also Appendix 2 for the 
Application Note for BMG LABTECH). The assay is rapid, direct and sensitive 
when purified TG2 is used. Small sample size and plate format make the assay cost-
effective and adaptable to high-throughput analysis. The usage of the isopeptidase 
activity assay for cell-based studies is promising. The kinetics of the reaction was not 
changed when cells were present and no cell autofluorescence that would alter the 
baseline fluorescence was observed. However, a number of substrate modifications 
need to be introduced for applications beyond in vitro studies. Firstly, the backbone 
of the peptide should be further modified to avoid spontaneous Abz-APE(γ-cad-
Dnp)QEA substrate cleavage by proteases when the cell membrane becomes 
permeable. Addition of a TG2 specific inhibitor only partially reduced substrate 
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conversion, and the majority of the reaction was Ca2+ independent. Future analysis of 
the cleavage products that are formed upon cell lysis are necessary in order to 
determine whether the products are formed due to TG2 activity. Secondly, the 
detection limit for measuring small changes in TG2 activity on the cell surface/in 
conditioned medium upon stimulation with P2X7R agonists lacked detectable 
activity. Replacing the Abz group on the substrate backbone for a more powerful 
fluorophore would likely improve sensitivity. Once the specificity and sensitivity of 
the assay has been addressed, the isopeptidase assay potentially could serve as a 
powerful tool for investigating changes in TG2 activity in live cells.  
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Chapter 4 TG2 upregulation and release in different cell types 
4.1. Introduction 
The overarching aim of the project was to investigate whether increased expression 
and aberrant release and activation of TG2 leads to protein modifications not 
normally present in extracellular matrix components. Their formation may be an 
indicator of compromised tissue integrity, occurring as a consequence of abnormal 
joint loading or in association with the inflammatory processes. In order to identify 
potential novel modifications formed in a physiological context, there was a need to 
identify a cell system that allows for induction of TG2 externalization in a defined 
way, which is amenable to manipulation. TG2 release can be linked with cell damage 
(Upchurch et al. 1987). However, there is substantial evidence to suggest that TG2 
can be actively exported by cells is a context dependent manner (Aeschlimann et al. 
1995; Raghunath et al. 1999). This pathway and its regulation remain enigmatic. 
Given the well established link to inflammation (Kim 2006), we decided to test 
whether secretion of TG2 is regulated by P2X7R in analogy to interleukin-1β (IL-
1β)/interleukin-18 processing and release from activated monocytes/macrophages.  
 IL-1β belongs to a group of soluble signaling proteins that lack a signal peptide 
and are secreted from the cells through a non-conventional pathway (Ferrari et al. 
2006; Dubyak 2012). There is some overlap between IL-1β and TG2 release from 
cells with regards to biological context. Therefore, it serves as a good model 
molecule to study alternative secretion of proteins as TG2 externalization might 
occur after applying similar external signals. IL-1β is an important proinflammatory 
cytokine released mainly by blood monocytes and tissue macrophages (Hogquist et 
al. 1991; Wewers et al. 1997; Mehta et al. 2001; C Andrei et al. 2004; Qu et al. 
2007), dendritic cells (Pizzirani et al. 2007) or microglia (Bianco et al. 2005). During 
inflammation IL-1β plays a major role in regulation of important mediators: it 
induces synthesis of cyclooxygenase type 2, phospholipase A, nitiric oxide and 
adhesion molecules which can lead to systemic fever, pain and promote infiltration 
of inflammatory cells into the affected tissue (Dinarello 2009). There are two splice 
variants of IL-1 described: IL-1α and IL-1β (Singer et al. 1988). IL-1β can be found 
in the cytosol (Stevenson et al. 1992), where it is synthesized on free ribosomes 
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(Thornberry et al. 1992) and translated into a ~31-kDa pro-protein that is 
proteolytically cleaved by caspase-1  to give the 17 kDa active form (Mosley et al. 
1987). Proteolytic processing of pro-IL-1β by caspase-1 occurs upon assembly of the 
multiprotein scaffold called the “inflammasome” (Rathinam et al. 2012). This 
complex has been suggested to be a crucial element in autoimmune and rheumatic 
diseases (Martinon et al. 2009). Proteolytic cleavage is necessary for IL-1β to 
express biological activity and effectively bind to the IL-1 receptor (Dinarello 2009). 
Caspase-1 is a serine protease that is able to proteolytically cleave also other 
cytokine precursors of the same family: IL-1α, Il-18, Il-33 and Il-1F7. In order to 
induce IL-1β release from cells, two distinct stimuli need to be provided: 1) an 
inflammatory signal such as lipopolysaccharide (LPS) (activates Toll-like receptor 
signaling) that leads to pro-IL-1β and pro-caspase-1 synthesis and their accumulation 
in the cytosol; 2) exogenous ATP that triggers ion channel-mediated K+ efflux 
followed by release of mature active IL-1β. While passive IL-1β release can occur, 
the phenomenon of ATP-induced IL-1β release is an active and rapid process critical 
to inflammatory responses (Rathinam et al. 2012). Non-classical secretion of IL-1β 
is mediated by activation of the purinergic receptor (P2X7R) with high 
concentrations of extracellular ATP (Ferrari et al. 2006). Once ATP is released from 
injured tissue/cells it can act as a danger signal amplification system and spread the 
alarm within the local milieu through paracrine signaling (Grol et al. 2013). 
Therefore, P2X7R was considered as a potential upstream signaling receptor 
involved in TG2 secretion.  
As TG2 may be externalized by various cell types in different ways, or its 
localization upon release depends on the cell type (Iismaa et al. 2009), there was a 
need to explore cell systems, other than connective tissue cells, in which TG2 release 
is likely to depend on ECM deposition. In order to study actively controlled TG2 
release by cells, three different cell models were chosen for investigation. This was 
based on the evidence supporting TG2 release by cells and expression of P2X7R. 
First, the monocytic leukemia cells (THP-1) that mimic the behaviour of 
monocytes/macrophages (Tsuchiya et al. 1980) and second, the human breast cancer 
cells MDA-MB-231 that constitutively secrete TG2 into the medium and to some 
extend reflect the epithelial cell responses (Antonyak et al. 2011). The third model 
was fibroblast cell line, HCA2 cells, to represent connective tissue cells (Stephens et 
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al. 2004) but this was subsequently abandoned as those cells did not revealed P2X7R 
expression/activation. 
The aims of the chapter: 
1. Investigate if THP-1 cells differentiated into macrophages are able to release 
IL-1β upon ATP stimulation? 
2. Verify whether TG2 can be detected in the conditioned medium of MDA-
MB-231 breast cancer cells? 
3. Identify whether TG2 release in MDA-MB-231 cells relate to constitutive 
P2X7R signaling? 
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4.2 Results 
4.2.1 TG2 upregulation during THP-1 monocyte differentiation into 
macrophage-like cells 
A monocyte/macrophage cell model was chosen in order to establish an assay for IL-
1β release in response to P2X7R activation, in which potential TG2 secretion in a 
similar way could be monitored. The human leukemia cells THP-1 express distinct 
monocytic markers (Tsuchiya et al. 1980) and are fully competent in P2X7R-
mediated IL-1β secretion after LPS priming (Mackenzie et al. 2001). However, in 
those cells TG2 is not detectable but it is possible to substantially increase TG2 
levels and activity by inducing monocyte to macrophage differentiation (Mehta and 
Lopez-Berestein 1986). Therefore, three different differentiation factors were applied 
in order to upregulate TG2 expression: interleukin-6 (IL-6), 12-O-
tetradecanoylphorbol-13-acetate (TPA) and all-trans retinoic acid (ATRA). The pro-
inflammatory cytokine IL-6 was chosen as IL-6 induced differentiation was shown to 
effectively increase TG2 activity upon its transcription in human hepatoblastoma 
HepG2 cells in a time- and dose- dependent manner (Suto et al. 1993). Also, ATRA- 
and TPA- dependent differentiation in THP-1 cells has been proven to be 
accompanied by elevated TG2 expression (Mehta and Lopez-Berestein 1986). These 
three mediators are known to act through distinct signaling pathways. 
The aim of the experiment was to optimize the conditions, such that 
upregulation of TG2 and pro-IL-1β synthesis in cells is simultaneously observed. 
THP-1 cells were grown with 10% FBS in the presence of IL-6 (0.8 nM), TPA (50 
ng/ml) or ATRA (1 µM). Where indicated, cells were simultaneously incubated with 
LPS for 48 or 72 hours to upregulate pro-IL-1β expression, the processing and 
release could be monitored by ATP stimulation. Changes in cell morphology were 
examined during the differentiation process (Fig. 4.1A). THP-1 monocytes are 
rounded cells with a smooth surface that grow in suspension (see also Fig. 4.2). 
Upon differentiation they become adherent, have a more granular appearance and 
spread/migrate on the plastic surface. Simultaneous priming of cells with LPS (0.1 
µg/ml) seemed to promote the process of differentiation even further as cells 
appeared to be more spread and activated. Among the three differentiation factors, 
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TPA had the fasted effect and strongest capacity to differentiate THP-1 cells into 
adherent macrophage-like cells (Fig. 4.1A). Cells that were treated with TPA 
significantly increased their size and changed morphology when compared to control 
or cells treated with other differentiation factors. In the case of differentiation with 
ATRA, some of the treated cells remained rounded but most of them started to attach 
and spread, which indicated monocyte to macrophage transition (Fig. 4.1A). 
Combination of IL-6 and LPS altered cell morphology only to some extend and IL-6 
stimulation alone had little effect on THP-1 cell differentiation over the 72h time 
period (Fig. 4.1A).  
Cell extracts from differentiated THP-1 cells were prepared in order to 
investigate the expression of TG2 by Western blotting. Consistent with the previous 
findings by Mehta and Lopez-Berestein (1986), the TG2 was not detectable in 
undifferentiated THP-1 cells (Fig. 4.1B). However, in my experiment after 
differentiation into macrophage-like cells, TG2 expression was significantly 
upregulated with selected agents as was anticipated (Fig. 4.1B). The calculated 
molecular mass of TG2 is ~77 kDa but the migration of the band in SDS-PAGE is 
approx. corresponding to 80-85 kDa when compared with the protein marker, which 
is consistent with the literature (Hadjivassiliou et al. 2008). TPA and ATRA alone 
were able to markedly upregulate TG2 expression and this was visible after both, 48h 
and 72h of differentiation (Fig. 4.1B). TG2 expression was even more potentiated in 
the presence of simultaneous priming with LPS. Note, the absence of the TG2 band 
after 48h simultaneous stimulation of cells with ATRA and LPS occurred only in this 
particular experiment. An increase in TG2 expression was only observed in IL-6 
differentiated cells after 48h in the presence of LPS but TG2 could not be detected 
any more at 72h, which was consistent between replicate experiments (Fig. 4.1B). 
For further experiments, ATRA was selected for THP-1 differentiation as it 
effectively upregulated TG2 expression without causing enhanced release of IL-1β in 
the absence of ATP stimulation from LPS-primed cells as was the case with TPA 
(data not shown). ATRA was also more effective than IL-6 to induce the anticipated 
changes in cell morphology associated with cell differentiation. 
 116 
 117 
4.2.2 Establishing the assay for analysis of ATP-induced IL-1β release from 
LPS-primed THP-1 cells 
4.2.2.1 Optimization of THP-1 cell differentiation with ATRA 
In order to optimize conditions for cell handling such as cell washing and buffer 
exchange necessary for ATP stimulation, THP-1 cells were grown on different 
substrates for 3 days to determine which surface effectively immobilized THP-1 cells 
without causing changes in their morphology associated with cell activation. Cells 
were seeded on tissue culture plastic, the glass or surface pre-coated with collagen 
type I or fibronectin or poly-L-lysine (Fig. 4.2A). Culture of THP-1 cells on glass, 
collagen type I and fibronectin induced cell spreading and activation. The plastic and 
poly-L-lysine coated surfaces were the best substrates for THP-1 cell growth as they 
did not induce cell activation (Fig. 4.2A). After culture for 3 days on the different 
surfaces, the cells were washed and the PSS buffer required for subsequent 
experimental steps was added in order to see how well the cells attached to each 
substrate (Fig. 4.2B). As poly-L-lysine was the only substratum that did not induce 
cell activation while at the same preventing cells from being lost during cell washing, 
this substratum was selected for future experiments (Fig. 4.2B).  
To verify that the best conditions for ATP stimulation of differentiated THP-
1 cells had been selected, two different experimental protocols for cell priming were 
performed in order to induce TG2 and pro-IL-1β synthesis and compared: 1) 48h 
differentiation of cells with ATRA in the presence of LPS performed on cells 
attached to poly-L-lysine and 2) 48h differentiation with ATRA followed by 24h 
LPS priming on cells grown on plastic. This direct comparison is the result of a 
series of optimization experiments that were conducted. 
4.2.2.2 ATRA-mediated THP-1 cell differentiation simultaneous with LPS 
priming  
 
THP-1 cells were grown on glass coverslips coated with poly-L-lysine and were 
stimulated for 48h in the absence or presence of ATRA (1 µM) and LPS (0.1 µg/ml) 
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simultaneously. After 48h, conditioned medium was gently harvested and the 
concentration of IL-1β was measured by capture ELISA (Fig. 4.2C). Surprisingly, 
THP-1 monocytes (DMSO control) and macrophage-like cells (ATRA treated) were 
able to spontaneously release a low amount of IL-1β into the medium upon LPS 
treatment. This markedly upregulated extracellular IL-1β levels to approx. 20 pg/ml 
released within an hour (Fig. 4.2C). It is likely that this represents a passive release 
of non-processed pro-IL-1β as the antibodies used for ELISA can recognize both the 
pro-and mature form (data not shown). This unstimulated release of IL-1β seemed to 
be slightly upregulated in cells differentiated into macrophage-like cells (Fig. 4.2C). 
The same cells were now used to perform P2X7R stimulation with ATP. After gentle 
washing with PBS, PSS buffer -/+ 1 mM ATP was added to each well. Cells were 
stimulated in the incubator for 30 min or 1 hour and the conditioned medium was 
used for quantification of the cytokine. The result showed that the cells even without 
ATP stimulation can spontaneously release a substantial amount of cytokine under 
this conditions (Fig. 4.2D). ATP treatment of cells resulted in differences in the 
kinetics of IL-1β release from ATRA differentiated cells as compared to DMSO 
control cells (Fig. 4.2D). Whereas the addition of ATP to non-differentiated cells 
increased IL-1β secretion approx. 2-fold after 30 and 60 min, the differentiated cells 
showed more variable and lower secretion of IL-1β. It appeared that prolonged 
treatment of cells with LPS might lead to spontaneous IL-1β secretion and that this 
effect was enhanced in ATRA differentiated cells. 
 119  
 120 
4.2.2.3 THP-1 cell differentiation with ATRA followed by LPS priming 
 
In the second approach, THP-1 cells were grown for 48h on the plastic surface in the 
absence or presence of ATRA (1 µM) and then primed for another 24h with or 
without LPS (0.1 µg/ml). After 48 and 72h, the cell supernatant was used to measure 
IL-1β concentration by ELISA. Cells were lysed in order to confirm TG2 and IL-1β 
upregulation at different stages of cell differentiation. Detection of immunoreactive 
species of the cell extract showed that ATRA can effectively upregulate TG2 
expression after 48 and 72h and when acting alone, does not stimulate synthesis of 
pro-IL-1β (Fig. 4.3A). ELISA analysis of conditioned medium showed that ATRA-
mediated differentiation elevated IL-1β secretion from LPS treated monocytes (20 
pg/ml per hour) compared with the DMSO control (8 pg/ml per hour) (Fig. 4.3B).  
The rate of IL-1β release at baseline was similar to that observed in the previous 
experiment (Fig. 4.2C). After 72h, the cells were transferred gently from the 24-well 
plate into tubes and collected by centrifugation. For P2X7R stimulation, cells were 
washed with PBS prior to re-suspending in PSS buffer -/+ 1 mM ATP and after 
transferring to a 24-well plate, incubated for 30 min or 1 hour at 37 ˚C/5% CO2. At 
the end of the experiment, cell supernatant was used for IL-1β quantification by 
ELISA and the cells were lysed to analyse TG2 levels by Western blotting. It was 
predicted that the ATP stimulation might lead to TG2 secretion but that this is 
unlikely to substantially decrease its intracellular concentration in such a short 
treatment time. Furthermore, even if TG2 was externalized efficiently it may largely 
remain cell associated as has previously been reported for macrophages (Hodrea et 
al. 2010) and therefore invisible to this analysis. As expected, the ATP stimulation 
had no overt effect on cellular TG2 levels as indicated by the fact that the TG2 band 
remained of the same intensity (Fig. 4.3C). On the other hand, there was a slight 
reduction in the amount of the intracellular pull of pro-IL-1β after ATP addition in 
both DMSO treated control cells and ATRA differentiated cells primed with LPS 
thus suggesting that P2X7R activation lead to pro-IL-1β processing and release in 
mature form (Fig. 4.3C). In fact, quantification of IL-1β in the conditioned medium 
confirmed that addition of ATP lead to an increase in the amount of IL-1β being 
secreted by the cells (Fig. 4.3D). ATRA differentiated cells released more IL-1β 
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compared to the DMSO control when stimulated with ATP (Fig. 4.3D). However, 
spontaneous release of IL-1β by ATRA differentiated cells into the PSS was also 
increased. The difference in cytokine concentration in the supernatant in response to 
P2X7R receptor activation was more significant after 1 hour of stimulation and this 
is in agreement with the results from Western blotting on the cell extracts (Fig. 4.3C 
and D). Examination of cell morphology at the end of the experiment revealed that 
ATRA differentiated and LPS primed cells were already clustered, spread and 
activated prior to ATP stimulation, unlike the control ones (Fig. 4.3E). This may 
explain the high rate of baseline IL-1β secretion and might suggest some endogenous 
P2X7R activation. The ATP treatment lead to gross morphological changes and 
potentially some cell death. The original intend was to quantify TG2 activity in real 
time during ATP stimulation using the isopeptidase assay developed in Chapter 3. 
However, sensitivity of the substrate to proteolysis prevented this approach.
 122 
 
 123 
4.2.3 Constitutive TG2 release into the medium by serum starved MDA-MB-231 
breast cancer cells 
At this point of the study another research group interested in non-conventional 
release of TG2 published a manuscript showing that serum starved MDA-MB-231 
breast cancer cells can constitutively secrete TG2 into the medium via microvesicle 
shedding (Antonyak et al. 2011). Therefore, I decided to test whether this could be 
confirmed in our hands and whether a protocol for TG2 analysis in medium could be 
optimized based on the same cell model (MDA-MB-231 cells). Additionally, this 
would allow me to examine if ATP or BzATP elevate the levels of TG2 in the 
medium as some of the reports suggested that these cells express purinergic receptors 
(Kawai et al. 2008). This could give me the scope to obtain the answers and than 
later return to the THP-1 cell model and investigate if TG2 is secreted into the 
conditioned medium in parallel with IL-1β processing and release. 
4.2.3.1 TG2 expression by MDA-MB-231 cells and its localization upon ATP 
and BzATP treatment 
The aim was to use the MDA-MB-231 cells to trigger TG2 externalization by 
P2X7R activation. However, before performing this experiment, cell lysate from 
MDA-MB-231 cells was prepared to investigate the expression levels of TG2 and 
P2X7R by Western blotting (Fig. 4.4A). The cell lysate of MDA-MB-231 cells was 
compared with THP-1 cell extract as those monocyte-like cells express P2X7R at 
detectable amounts. As expected, undifferentiated THP-1 cells were lacking TG2 
whereas in MDA-MB-231 cells anti-TG2 antibodies recognized a strong band for 
TG2 of approx. 80 kDa. THP-1 and MDA-MB-231 cells expressed P2X7R at 
comparable levels, and the anti-P2X7R antibodies recognized the glycosylated wild-
type receptor of approx. 77 kDa in size, which is consistent with the literature (Nicke 
2009). This indicated that the MDA-MB-231 cells could be used to test P2X7R 
involvement in triggering TG2 secretion as those cells express both components 
necessary for the study. In next step, the TG2 expression in serum starved MDA-
MB-231 cells was examined by immunolocalization (Fig. 4.4B). Permeabilization of 
cells with Triton-X-100 was performed in order to investigate total TG2 distribution 
and possible association with intracellular organelles. Staining of the cells with anti-
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TG2 antibodies revealed a ubiquitous cytoplasmic distribution of TG2 within the 
cytosol and lack of specific compartments enriched with TG2. Cells were then 
incubated in the presence or absence of 1 mM ATP or 300 µM BzATP and at the end 
of the experiment fixed and stained with anti-TG2 antibodies. The staining of cells 
was performed without cell permeabilization to see if changes in TG2 on the cell 
surface on in the ECM can be seen. The MDA-MB-231 cells revealed an interesting 
pattern of surface TG2 expression (Fig. 4.4C). TG2 seemed to be localizing to 
specific focal areas of the cell membrane (Fig. 4.4C, 60 min control). When the cells 
were stimulated for 60 min with the P2X7R agonist ATP or BzATP, the 
immunolabelling of TG2 revealed its accumulation at specific membrane 
subdomains that might be the sites of newly forming microvesicles (Fig. 4.4B, 60 
min ATP and BzATP, respectively). 
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4.2.3.2 Enhanced secretion of TG2 in MDA-MB-231 cells stimulated with ATP  
The change in TG2 surface staining upon ATP and BzATP stimulation indicated its 
potential association with shedding microvesicles (MVs) (Fig. 4.4). Therefore, to 
quantify any potentially secreted TG2 the analysis of conditioned medium from 
serum starved MDA-MB-231 cells with and without P2X7R stimulation was 
performed (Fig. 4.5). Antonyak and colleagues (2011) reported that treatment of 
HeLa cells with epidermal growth factor (EGF) enhanced formation of MVs on their 
surface. Thus, MDA-MB-231 cells were serum starved for 18h and then stimulated 
for 60 min in serum free OptiMEM with or without EGF, BzATP and ATP. 
Moreover, recombinant TG2 was added to the cells to check if it can be retrieved 
from the medium and detected by Western blotting after the duration of the 
experiment. The same amount of conditioned medium were harvested, lyophilized 
and analyzed by Western blotting (Fig. 4.5A). A serial dilution of recombinant TG2 
in OptiMEM was lyophilized as well and separated next to the conditioned medium 
to estimate the concentration of TG2 released by the cells. Analysis of the 
nitrocellulose membrane with anti-TG2 antibodies confirmed that serum starved 
MDA-MB-231 cells are able to spontaneously secrete TG2 into the conditioned 
medium to a concentration of approx. 10 ng/ml in 1 hour (Fig. 4.5A). ATP 
stimulation increased its release into the medium (Fig. 4.5A, see also Fig. 4.5B) 
whereas BzATP and EGF were not able to increase its extracellular levels. As it was 
previously reported that microvesicles and exosomes contain specific proteins of the 
cytoskeletal network including actin (Théry et al. 2002; Burnier et al. 2009; 
Antonyak et al. 2011), the membrane was re-probed for the presence of actin. Both, 
ATP and BzATP stimulation noticeably induced actin release into the conditioned 
medium. Actin was running at the expected size of approx. 42-45 kDa (Fig. 4.5A, 
see also Fig. 4.5B). This indicated that both agonists are likely to have caused 
microvesicles shedding and therefore were effective in activating P2X7R. The 
membrane was negative for β-tubulin (~55 kDa in size), which was included as a 
control of nonspecific release of cellular proteins due to possible cell damage (Fig. 
4.5A). Similarly, the membrane was probed for GAPDH that should be running at 
approx. 37 kDa and was found to be absent in the conditioned medium of MDA-MB-
231 cells (Fig. 4.5B) thus suggesting that TG2 and actin increase upon ATP 
stimulation is not related to non-specific loss in membrane integrity. 
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To better understand the kinetics of agonist-mediated TG2 release, medium 
was collected after 15, 60 or 120 min from cells that were left unstimulated or were 
stimulated with 1 mM ATP (Fig. 4.5C). The analysis confirmed that TG2 and actin 
are constitutively secreted into the medium and accumulate over time. Treatment of 
cells with 1 mM ATP lead to faster TG2 and actin accumulation in the medium (Fig. 
4.5C). This might indicate that there is constitutive upregulation of the process of 
MVs shedding from serum-starved cells and that stimulation with ATP accelerates 
the kinetics of their accumulation. This therefor further suggested that TG2 secretion 
into the extracellular space triggered by stimulation with ATP was mediated by 
purinergic receptor activation on the surface of MDA-MB-231 cells. However, the 
finding that BzATP was unable to trigger TG2 release was not consistent with a 
P2X7R dependent process.
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4.2.3.3 Changes in intracellular calcium induced by ATP and BzATP 
stimulation 
In order to further confirm purinergic receptor activation in MDA-MB-231 cells, 
changes in intracellular Ca2+ concentrations were measured using Fluo-4 calcium 
indicator. The aim of the experiment was to check if stimulation with both 1 mM 
ATP and 100 µM BzATP lead the expected increase in intracellular calcium levels. 
The comparison of the two agonists was important as ATP can not only act on 
receptors of the P2X family but also on P2Y receptors, which evoke G-protein 
coupled responses (Grol et al. 2013), whereas BzATP is a potent agonist for P2X7R 
but can potentially also activate other members of the P2X family (Jarvis and Khakh 
2009). MDA-MB-231 cells were loaded with Fluo-4 calcium indicator and then 
stimulated with either agonist in order to monitor potential changes in fluorescence 
intensity using confocal microscopy (Fig. 4.6). Stimulation of MDAMB231 cells 
with 1 mM ATP induced a rapid transient increase in intracellular Ca2+ that returned 
to baseline levels after approx 2 minutes (Fig. 4.6 left panel and graph). Treatment of 
cells with 100 µM BzATP lead to a substantially smaller increase in fluorescence and 
showed a different biphasic desensitization kinetics. Agonist treatment failed to 
produce sustained high calcium levels nor induce “cell blebbing”, which are the 
characteristic cell responses observed upon P2X7R activation. This may suggest that 
MDA-MB-231 cells do not express functional P2X7R or express it at low level and 
that Ca2+ spikes are predominantly driven by activation of different surface receptors.
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4.2.3.4 Attempt to inhibit TG2 secretion with P2X7R and P2X4R inhibitor 
To identify if P2X7R was involved in the process of rapid TG2 release upon ATP 
stimulation of MDA-MB-231 cells, a potent P2X7R inhibitor was used (A740003) 
(Honore et al. 2006). It was further predicted that the addition of inhibitor might 
decrease the levels of constitutively released TG2. Detection of immunoreactive 
species analysis of TG2 in the conditioned medium confirmed previous findings that 
ATP was able to upregulate its release (Fig. 4.7A). Flotillin-2 is a scaffolding protein 
that is involved in formation of lipid-raft microdomains (Otto and Nichols 2011) but 
was also describe to be localizing in exosomes (Trajkovic et al. 2008) and 
microvesicles (Antonyak et al. 2011) and was used as a marker of shedding 
membrane-bound vesicles. However, the addition of the P2X7R inhibitor failed to 
block TG2 as well as flotillin-2 secretion into the conditioned medium of cells 
stimulated with either ATP or BzATP (Fig. 4.7A). Surprisingly, the addition of 
inhibitor seemed to induce TG2 translocation in both non treated control and ATP 
stimulated cells (Fig. 4.7A). A similar trend was observed in the next experiment 
where the concentration of the P2X7R inhibitor was increased from 5 to 100 µM to 
be confident that the lack of an effect was not due to insufficient inhibitor 
concentration (Fig. 4.7B). Cells stimulated with 1 mM ATP in the presence of 
inhibitor were still able to secrete TG2 at a similar level to control and P2X7R 
inhibition did also not seem to affect release of actin (Fig. 4.7B). Therefore, it was 
predicted that another member of the P2X family might be involved in regulating 
ATP-dependent signaling in those cells. P2X4 receptor was the assumed candidate. 
Thus, the stimulation of MDA-MB-231 cells was repeated using ATP and BzATP as 
agonists but this time in the presence of P2X7 inhibitor (A740003), P2X4 inhibitor 
(5-BDBD) or a combination of both inhibitors (Fig. 4.7C). The concentration of 
P2X7R inhibitor was reduced back to 5 µM. Western blotting analysis of conditioned 
medium was not fully conclusive, as both inhibitors seemed to promote its secretion 
rather than inhibiting TG2 translocation when applied individually. However, partial 
reduction in released TG2 levels was observed in ATP treated cells in the presence of 
both inhibitors. Though, it was not clear why release was increased in unstimulated 
cells in the presence of the inhibitors as compared to vehicle control (Fig. 4.7C). 
Therefore, the studies with the P2X7R inhibitor did not clearly answer the question if 
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TG2 release can be P2X dependent but rather suggested that it maybe caused at least 
in part by P2Y-dependent responses in MDA-MB-231 cells. 
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4.3 Discussion 
In this chapter, P2X7R-mediated IL-1β processing and release was studied in the 
monocytic THP-1 cells using ELISA and Western blotting techniques. Moreover, the 
induction of TG2 expression during differentiation of monocyte into macrophage-
like cells was investigated to enable the investigation of TG2 upregulation in the 
context of a physiologically relevant model. This gave interesting insights into 
regulation of TG2 expression by various modulators that are involved in the process 
of inflammation or terminal cell differentiation. At the beginning of this study, it was 
important to select a relevant cell model to investigate P2X7R-dependent TG2 
externalization. A monocyte/macrophage cell model was chosen in order to establish 
an assay for IL-1β release and to later study non-conventional TG2 release. It is well 
supported by experimental evidence that synovial macrophages are key players in 
driving destructive inflammatory responses in rheumatoid arthritis (Brennan and 
McInnes 2008) as well as in osteoarthritis (Bondeson et al. 2010). Furthermore, 
macrophages were found to express catalytically active TG2 on the cell surface 
(Murtaugh et al. 1984; Hodrea et al. 2010) and also P2X7R (Qu et al. 2007), which 
makes this cell type a good candidate to investigate the consequence of ATP 
treatment on TG2 externalization. THP-1 cells are able to secrete active IL-1β 
(Mackenzie et al. 2001), express P2X7R in the plasma membrane (Humphreys and 
Dubyak 1996) and upregulate P2X7R expression after stimulation with inflammatory 
mediators such as LPS (Falzoni et al. 1995). Regulation of TG2 expression was 
explored in the context of THP-1 differentiation into macrophage-like cells using 
three different differentiation agents: IL-6, TPA and ATRA. Both, IL-6 and ATRA 
mediate effector binding to the their respective response elements in the TMG2 
promoter and therefore directly regulate TG2 expression (Aeschlimann and Thomazy 
2000). However, regulation of TG2 by proinflammatory IL-6 is dependent on NFκB 
signaling (Suto et al. 1993; Kuncio et al. 1998), whereas retinoids regulate TG2 
expression through activating RAR and RXR binding enhancer element upstream of 
the TMG2 gene (Nagy et al. 1996; Aeschlimann and Thomazy 2000). Retinoids are 
being a differentiation signal mostly associated with developmental process. On the 
other hand, TPA, which is a derivate of the phorbol ester is indirectly acting on TG2 
expression levels by activating the protein kinase C α (PKCα) signaling cascade and 
ultimately FAK phosphorylation (Stephens et al. 2004; Iismaa et al. 2009). PKCα 
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outside-in signaling promotes cell spreading and motolity (Verderio et al. 2003; Telci 
et al. 2008). Enhanced transcription of TGM2 can be regulated by other molecules 
such as EGF, TNF-α, TGFβ1 or IL-1β itself, depending on the cell type and 
biological context (Mehta and Eckert 2005; Mehta and Han 2011b; Nurminskaya and 
Belkin 2012). However, the selected mediators were chosen because of their role in 
macrophage differentiation. In my experiments, THP-1 cell differentiation with 
ATRA proved to be effective in inducing TG2 expression during differentiation into 
macrophage-like cells (Mehta and Lopez-Berestein 1986). Thus, this model was 
chosen for optimizing the assay for ATP-dependent IL-1β release.  
ATP stimulation and measurement of secreted IL-1β from differentiated 
monocytes was investigated using two different conditions 1) when TG2 and pro-IL-
1β expression was simultaneously upregulated; 2) when TG2 induction was followed 
by pro-IL-1β upregulation with LPS. In both cases, the capture ELISA showed that 
ATP enhanced IL-1β release from LPS-primed macrophage-like cells which is in 
agreement with the literature (Mackenzie et al. 2001; Mehta et al. 2001; Qu et al. 
2007). It was not possible to fully confirm that ATP caused release of the processed 
17 kDa form of IL-1β as I did not manage to detect mature IL-1β in the conditioned 
buffer by Western blotting. However, the fact that in LPS-primed cells a decreased 
level of intracellular pro-IL-1β was detected after 1 hour of ATP stimulation suggests 
that pro-IL-1β is processed and released. LPS treatment of THP-1 cells lead to a low 
level of IL-1β release in the absence of ATP stimulation. Differentiation with ATRA 
enhanced baseline IL-1β release. ATRA can have both stimulatory and inhibitory 
influence on IL-1β as well as IL-6 release by LPS-challenged monocytes, depending 
on the length of the stimulation (Gross et al 1993). This is in line with my results, 
which showed that the differentiation protocol affected the susceptibility of the cells 
to ATP stimulation. The differentiation status of the cell could determine the 
response to ATP. P2X7 receptors were shown to be upregulated on the mRNA levels 
during THP-1 stimulation with LPS and interferon-γ and this increased the formation 
of membrane pores (Humphreys and Dubyak 1998). Oppositely, Gudipaty and 
colleagues (2001) showed that there are no differences in P2X7R mRNA levels 
between freshly isolated monocytes and those differentiated into macrophages. 
However, the function of P2X7R was greatly enhanced in macrophages. This 
response is cell type specific as ATRA downregulates P2X7R expression in human 
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neuroblastoma cells and inhibits both P2X7R expression and function in mouse 
Neuro2A cells (Bilbao et al. 2012). The second model in which monocyte 
differentiation was followed by LPS treatment would be preferably chosen as under 
those conditions THP-1 cells showed greater potency for ATP-dependent IL-1β 
secretion. In pathology of arthritis, the monocytes are attracted to the affected joint 
where they undergo differentiation into macrophages and start to secrete 
proinflammatory IL-1β (Pope 2002). Our model of cell differentiation could then 
reflect the in vivo process of monocyte recruitment and activation. However, to fully 
understand whether the experimental conditions are relevant to the in vivo situation, 
further experiments would need to be performed. 
In this chapter, the conditions for TG2 release and its detection in the 
supernatant of serum starved MDA-MB-231 cells were also established. This 
enabled me to show for the first time that purinergic signaling might be linked to 
non-conventional secretion of TG2. Specifically, Western blotting analysis revealed 
that serum starved breast cancer cells secrete TG2 into the conditioned medium in a 
time-dependent manner and that ATP stimulation markedly potentiated TG2 
externalization. Some recent reports seem to be indicating that P2X7R activation can 
promote growth and survival of cancer cells by tonic regulation of Ca2+ fluxes 
(Francesco Di Virgilio et al. 2009; Di Virgilio 2012). Increased expression of P2X7R 
might promote cell survival in severe stress conditions such as serum deprivation. 
ATP driven growth is mediated by an autocrine-paracrine loop, and removal of 
extracellular ATP by apyrase that degrades it, leads to the arrest of cancer cell 
growth. It has been postulated that this activity of P2X7R is unrelated to the “pore 
formation” phenomenon but relates to P2X7R constant channel activity. However, it 
is still unclear how very low concentrations of ATP mediate P2X7R activation 
despite the low ATP affinity of P2X7R (North 2002). There is substancial evidence 
that TG2 is upregulated during metastatic cell transformation is the number of 
different cell types (Mehta and Eckert 2005; Iismaa et al. 2009). For example, TG2 is 
involved in the invasive phenotype of pancreatic cancer cells (Mehta and Han 
2011b). TG2 was also found to be secreted into the ascites fluid surrounding ovarian 
tumour cells (Yakubov et al. 2013). Also TG2 is upregulated during epithelial to 
mesenchymal transition following persistent activation of NFκB signaling (Kumar 
and Mehta 2012). Interestingly, the screening of various cancer cells showed that 
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upregulation of TG2 correlates with increased IL-6 production (Keunhee Oh et al. 
2011). Moreover, knocking-down the TG2 expression with shRNA significantly 
reduced IL-6 secretion into the medium in MDA-MB-231 cells and reduced 
anchorage-independent cell growth. Taken together, this indicates that cytokine 
production and TG2 expression may be linked and may form an important feedback 
loop not only for cells of immune origin. Antonyak and colleagues (2011) showed 
that MDA-MB-231 breast cancer cells are able to secrete TG2 that localizes on the 
surface of budding microvesicles (MVs). Yet, not all cell types known to secrete 
TG2 were able to produce those structures. Serum starved HeLa cervical carcinoma 
cells required EGF treatment to produce such MVs and NIH3T3 fibroblasts were 
incapable to form MVs even upon serum starvation or EGF stimulation (Antonyak et 
al. 2011). Therefore, the authors of that study speculated that this type of TG2 
release might be the dominant pathway of TG2 secretion in highly metastatic cancer 
cells. In my experiments I could not find clear evidence that would estabilished a 
link between MV’s and TG2 release as differential ultracentifugation (results not 
shown) suggest it localization in the soluble, non vesicular fraction even though TG2 
showed a localized surface topology in non-permeabilized cells. 
In my experiments, ATP was able to trigger rapid TG2 secretion into the 
conditioned medium of serum starved MDA-MB-231 cells. Interestingly, actin was 
found to be co-released with TG2, which is in agreement with data shown by 
Antonyak and colleagues (2011). Actin belongs to the proteins, which are found in 
released MVs (Burnier et al. 2009) and exosomes (Théry et al. 2002). Other 
intracellular proteins such as β-tubulin or GAPDH could not be detected in the same 
medium fractions where TG2 and actin were accumulating. This suggests that release 
of TG2 and actin is not simply due to cell damage but is triggered by purinergic 
signaling. The P2X7R was a candidate receptor driving the active TG2 release into 
the medium. Western blotting analysis confirmed P2X7R expression in these cells. 
However, the studies with the selective P2X7R inhibitor were unable to block TG2 
externalization and in some instances even seemed to promote its release. The more 
prominent intracellular Ca2+ fluxes evoked by ATP stimulation compared to BzATP 
as well as the higher sensitivity of cells to ATP versus BzATP suggested a P2X4R 
response rather than a P2X7R response. However, a P2X4R inhibitor was also 
unable to clearly block TG2 accumulation in medium in response to ATP treatment. 
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The partial inhibition observed upon ATP stimulation when both P2X7R and P2X4R 
inhibitors were present might indicate the presence of P2X7R/P2X4R hetero-
oligomers in the membrane of MDA-MB-231 cells. Although P2X7R was believed 
not to form hetero-oligomeric assemblies with any of the P2X family members 
(Torres et al. 1999; North 2002), recent functional data indicate that those hetero-
oligomers can exist in the cell membrane of HEK293 when co-expressed and 
primary murine bone marrow derived macrophages (Guo et al. 2007). It was further 
shown that P2X7R stabilized the surface expression of P2X4R and those complexes 
remained sensitive to BzATP stimulation but were less active than P2X7R on its 
own. Another explanation of our finding might be that MDA-MB-231 cells do not 
express a fully functional P2X7R or express a distinct splice variant that has aberrant 
activity. Cervical cancer cells express the truncated P2X7R(j) isoform lacking part of 
the extracellular domain and the entire second transmembrane domain as well as C-
terminus (Feng et al. 2006). When expressed in HEK293 cells, this naturally 
occurring splice variant, shows reduced channel function and fails to mediate dye 
uptake, which is characteristic feature of P2X7R-dependent ‘pore formation”.  
The fact that cells were more sensitive to ATP than BzATP stimulation, 
which consequently triggered TG2 release, could also suggest activation of 
metabotrophic purinergic receptors of the P2Y receptor family (Baroja-Mazo et al. 
2012; Grol et al. 2013). This is further supported by the fact that BzATP is an 
approx. 10-fold stronger agonist than ATP for P2X7R (Rassendren et al. 1997) but 
not for P2Y receptors (Burnstock 2007). The reduced intracellular Ca2+ signaling in 
response to BzATP was observed and this is not consistent with a P2X7R activation 
profile. P2Y receptors are likely to be activated by lower concentrations of ATP and 
this may lead to release of Ca2+ from intracellular stores (Grol et al. 2013). Thus, the 
TG2 release in those cells may be mediated by P2YR. This should be further 
investigated to determine if P2X or P2Y-dependent signaling is responsible for TG2 
secretion.  
P2X7R was shown to be present in both THP-1 and MDA-MB-231 cells and 
some encouraging results were obtained in those cell models. However, it was 
difficult to clearly establish a link between P2X7R function and TG2 release given 
the experimental conditions and possibly expression of different types of receptors. 
Therefore, there was a need to produce a stable cell line with P2X7R expression, 
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channel function and “pore” forming” capacity to have a model, in which our 
questions could be addressed more directly. Stably transfected HEK293 cells 
expressing wild-type P2X7R were considered to be a useful tool to study the 
intracellular events upon P2X7R activation and a possible link to TG2 
externalization. This is outlined in the next chapter. 
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Chapter 5 Establishing cell model expressing functional P2X7R 
5.1 Introduction 
Understanding the pathway leading to TG2 externalization that could be both linked 
with P2X7R activation and be common for different cell types was important at the 
stage of this study. Stably transfected HEK293 cells are a widely used model to 
investigate P2X7R biology, as this cell type lacks other P2X receptor family 
members (Wilson et al. 2002; Mackenzie et al. 2005). In fact, HEK293 cells 
overexpressing rat P2X7R or human P2X7R were used to analyze electrophysiology, 
receptor gating, the kinetics of dye uptake and served as a good model to describe the 
distinct features of P2X7R (Surprenant et al. 1996; Rassendren et al. 1997; Virginio 
et al. 1999; MacKenzie et al. 2001; Mackenzie et al. 2005). The aim of this part of 
the study was to establish cell lines stably expressing functional P2X7R, untagged 
wild-type and V5 tagged receptor, that could be later used for investigating TG2 
release upon P2X7R stimulation.  
In HEK293 cells overexpressing P2X7R, ATP triggers remarkable 
morphological changes called “cell blebbing” and the presence of cell membrane 
ruffling indicates P2X7R activation (A Morelli et al. 2003; Adinolfi et al. 2010). 
Therefore the term “blebbing” is commonly used to describe large membrane 
reorganization events such as rapid formation of protrusions or plasma membrane 
projections that follow P2X7R stimulation (MacKenzie et al. 2001). These are 
thought to occur due to cytoskeletal rearrangements. It was observed that cell 
blebbing is a secondary response to the cation permeation through the P2X7R pore. 
This indicates that changes in cell morphology are occurring after P2X7R channel 
opening or subsequent large membrane pore formation (A Morelli et al. 2003; 
Mackenzie et al. 2005). However those authors also showed that cell blebbing is 
reversible and no longer visible after agonist removal. The cell blebbing is usually 
characterized by initial formation of numerous microvesicles (<0.5 µm) that precede 
development of the large blebs (>1 µm) (Solle et al. 2001; Mackenzie et al. 2005). 
Mackenzie and colleagues describe that microvesicles are actively shed from the cell 
surface and consequently lead to loss in membrane area (Mackenzie et al. 2005). On 
the other hand, large but organellum free membrane blebs stay attached to the cell 
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surface and remain intact even during prolonged agonist application. However, they 
also can be retracted from the plasma membrane. They called this type of cell 
activation the “zeotic” membrane movement to indicate that such changes may also 
be associated with an apoptotic response. However, they have shown that only 
prolonged stimulation of P2X7R with a potent agonist like BzATP (≥ 30 min) can 
induce cell death as measured by lactate dehydrogenase (LDH) release (MacKenzie 
et al. 2001). Also, it has been suggested that very high agonist concentrations might 
cause cell leakage and LDH release from P2X7R overexpressing cells (Ferrari et al. 
1997). Therefore, careful selection of the optimal conditions for P2X7R stimulation 
is necessary in order to investigate the physiological cell response. This chapter 
details the experimental steps that were used to establish and characterize two stable 
HEK293 cell lines expressing P2X7R that were subsequently used as a cell model to 
investigate TG2 externalization. 
The aims for the chapter: 
1. Establish cell lines stably expressing wild-type or V5-His tagged P2X7R 
2. Confirm that P2X7R is expressed and functional in the stably transfected cell 
lines  
3. Establish optimal conditions for P2X7R activation and optimize 
concentrations of agonists, ATP and BzATP 
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5.2 Results 
5.2.1 Cloning of the P2X7R coding sequence into mammalian cell expression 
vector 
 
The purpose of the experiment was to design two DNA vectors containing the 
P2X7R coding sequence: one to be translated into wild-type P2X7R with its natural 
stop codon (P2X7R) and the other with a V5-His tag attached to the C-terminus 
(P2X7R-V5-His). Fig. 5.1A shows the experimental steps that were necessary to 
clone the P2X7R sequence into pcDNA/FRT/V5-His plasmid. Five and four positive 
bacterial clones were obtained for pcDNA5/FRT/V5-His with subcloned P2X7Rstop 
and P2X7R, respectively (data not shown). The complete coding sequence from 2 
positive clones of P2X7Rstop and P2X7R was sent for Sanger dideoxy sequencing, 
which confirmed that no mutations were present in the selected clones according to 
the NCBI GenBank reference P2X7R sequence (BC011913; gi_33877741). The 
complete sequencing results are shown in Appendix 4. The sequencing also 
confirmed the presence of the stop codon downstream of the P2X7R coding 
sequence in P2X7Rstop and its lack in the second construct that should be translated 
into protein with V5-His epitope (Fig. 5.1B). 
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5.2.2 Stable transfection of HEK293 cells with P2X7R and P2X7R-V5-His 
expression constructs 
 
Given that both P2X7R and P2X7R-V5-His constructs were successfully obtained, 
they were used for stable transfection of HEK293 Flp-In cells as they contain an 
integrated FRT site (Fig. 5.2A). The principle of the stable cell line generation using 
this cell line is detailed in the Materials and Methods (section 2.18). HEK293 Flp-In 
host cells were co-transfected with pOG44 vector encoding the Flp recombinase and 
the P2X7R or P2X7R-V5-His constructs and after 24h subjected to selection with 
100 µg/ml Hygromycin B. Selection was carried out for four weeks until cell 
colonies were big enough to be transferred to a new culture dish. As integration is 
site-specific there is no difference to be expected between individual cell clones. At 
the end of stable cell line generation, there were no evident differences in cell 
morphology between established cell lines and parental cells (Fig. 5.2B). Cell 
colonies that were formed after transfection with different DNA preparation (E.coli, 
clones 3 and 6) of P2X7R construct were gently trypsinized and combined. 
Similarly, cell colonies formed for P2X7R-V5-His construct were also combined and 
transferred to another dish. The resulting cell lines will be referred to as HEK293 
P2X7R and HEK293 P2X7R-V5-His. 
After establishing HEK293 P2X7R and P2X7R-V5-His cell lines, cell 
extracts were obtained and P2X7 expression was analyzed by Western blotting to 
confirm expression of the receptor. As a negative control cell extract from parental 
HEK293 cells was used. Proteins were separated by SDS polyacrylamide gel 
electrophoresis and subsequently transferred to a nitrocellulose membrane. 
Membranes were stained with anti-V5 or anti-P2X7R antibodies to investigate 
protein expression levels and antibodies specificity (Fig. 5.2C). Expression of P2X7 
was confirmed in both stable cell lines using the P2X7R antibodies and no signal was 
detected in the lane where protein extract from parental cells was separated. The anti-
P2X7R antibodies recognized a protein band of approximately 77 kDa calculated 
from the relative migration of the protein marker. This is in agreement with previous 
reports and corresponds to the glycosylated wild-type receptor (Nicke et al. 2009). 
The P2X7R-V5-His version of the receptor was running with a slightly higher 
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apparent MW which is due to the V5-His tag that adds approx 3.5 kDa in molecular 
mass. It seems that the P2X7R-V5-His variant is expressed at a slightly higher level 
than wild-type receptor. The increased signal intensity for P2X7R-V5-His was not 
due to loading differences as β-tubulin levels were equivalent in lysates from P2X7R 
or P2X7R-V5-His expressing cells (Fig. 5.2C, P2X7R staining, left membrane). 
Staining with anti-V5 antibodies was only positive for P2X7R-V5-His cells and 
recognized a protein band of the same band as the anti-P2X7R antibodies (Fig. 5.2C, 
V5 staining, right membrane).
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5.2.3 Accessing functionality of transgene in HEK293 cells 
5.2.3.1 P2X7R immunolocalization 
The Western blotting experiment confirmed that P2X7R is expressed in both 
established cell lines. However, it was now important to confirm that the P2X7R is 
trafficked to the cell surface. Therefore, cells were analyzed by immunolocalization 
to study P2X7R expression pattern. HEK293 parental and P2X7R overexpressing 
cells were permeabilized and stained with anti-P2X7R and whereas P2X7R-V5-His 
cells were stained with anti-V5 antibodies to investigate P2X7R localization. 
Fluorescent labelling with secondary antibodies confirmed that in both P2X7R and 
P2X7R-V5-His cell types P2X7R was detectable in the plasma membrane and absent 
from the parental cells (Fig. 5.3A). Detection of a fluorescent signal in the nucleus 
with anti-P2X7R antibodies was not considered specific as it was also detected in 
parental cells, which do not express P2X7R and which were negative for the P2X7R 
membrane staining (Fig. 5.3A, top panel). Wild-type and V5- tagged receptor levels 
in the cell membrane were comparable suggesting that the tag does not interfere with 
receptor trafficking. Then P2X7R and P2X7R-V5-His cells were analyzed by 
immunolocalization to examine if P2X7R and the V5-tag co-localize in P2X7R-V5-
His cells. When anti-P2X7R and anti-V5 antibodies were used simultaneously the 
co-localization of the staining could be detected in cells expressing P2X7R-V5-His 
but not in those expressing P2X7R as expected (Fig. 5.3B). 
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5.2.3.2 ADAM activation by P2X7R 
Once cell surface P2X7R expression was confirmed it was important to investigate 
functionality of the receptor in the cell membrane. For this purpose, a shedding assay 
was selected based on the knowledge that stimulation of P2X7R activates ADAM-10 
metalloproteinases in the cell membrane (Le Gall et al. 2009). The release of 
functional EGFR ligands from the precursor proteins by ADAM10 can be easily 
monitored. Amphiregulin tagged with alkaline phosphatase (AR-AP) was used as an 
ADAM substrate to monitor ADAM activity. The presence of AP activity in the 
conditioned medium will indicate that ADAM-dependent cleavage occurred. 
Therefore, the stimulation of P2X7R with agonists should result in enhanced release 
of AP and its activity in the conditioned medium (Fig. 5.4A). Parental cells, P2X7R 
and P2X7R-V5-His were transiently transfected with an AR-AP construct and after 
48h, stimulated with 1 mM ATP or 300 µM BzATP for 30 min in physiological salt 
solution (PSS). BzATP is an ATP analogue that shows a high degree of selectivity 
for P2X7R and is not a ligand for P2Y receptors (Coddou et al. 2011). Cells from 
both established cell lines (P2X7R and P2X7R-V5-His) showed increased levels of 
AP activity present in the conditioned medium after agonist treatment, suggesting 
that P2X7R activation is able to induces ADAM-mediated cleavage of AR-AP (Fig. 
5.4B and C). Parental cells were unable to respond to 300 µM BzATP and only a 
negligible increase in the AP activity was detectable after challenge with 1 mM ATP 
(Fig. 5.4B and C). Throughout the experiments a similar trend of relative AR-AP 
shedding activity after agonist addition was observed. However, the absolute AP 
activity was greatly variable between transfections of the stable cell lines between 
different experiments, which was possibly due to differences in transfection 
efficiency and made it difficult to clearly compare the P2X7R and P2X7R-V5-His 
response (Fig. 5.4B and C). Moreover, the cell stimulation was performed in the PSS 
buffer that contains 2 mM Ca2+ and consequently the P2X7R activation might not be 
maximal. Therefore, a second approach was used to investigate AR-AP shedding. To 
have more equal concentration of P2X7R and AR-AP reporter a co-transfection of 
parental HEK293 cells with P2X7R or P2X7R-V5-His constructs together with AR-
AP was performed. Additionally, cell stimulation was performed in OptiMEM that 
contains 0.9 mM Ca2+, which should enhance P2X7R response to agonists. The co-
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transfection experiments were reproducible and clearly confirmed that wild-type 
P2X7R and P2X7R-V5-His are functional. In both cases the addition of 300 µM 
BzATP for 30 min lead to a dramatic, approximately 20-fold for P2X7R and 17-fold 
for P2X7R-V5-His increase in AR-AP shedding over the unstimulated control (Fig. 5 
4D and E). Stimulation of cells with 1 mM ATP was also able to significantly induce 
AR-AP shedding in cells expressing wild-type receptor (approx. 13-fold). In this 
case, the activation of cells expressing P2X7R-V5-His was 5 fold different to control 
but the difference did not reached statistical significance (Fig. 5.4D and E).  These 
data confirm that trends observed in the stable cell lines and indicate that ADAM 
activation is increased in P2X7R cells when compared to P2X7R-V5-His although 
both support ADAM activation to a degree.
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5.2.3.3 Changes in intracellular calcium  
In order to assess if P2X7R activation leads to Ca2+ influx in the established P2X7R 
cell line, changes in intracellular Ca2+ concentrations upon ATP and BzATP 
application were investigated. Fluo-4 calcium indicator was used to monitor the 
intracellular free [Ca2+] concentrations. Parental cells and cells stably expressing 
wild-type P2X7R were loaded with Fluo-4 indicator and then stimulated with the 
agonists to observe fluorescence transients using confocal microscopy. An increase 
in fluorescence, representing a rise in intracellular [Ca2+] was observed within 
seconds of agonist application and was much more pronounced in cells expressing 
the P2X7R receptor (Fig. 5.5 and 6). Moreover, in cells overexpressing P2X7R, the 
increase in intracellular Ca2+ concentration upon 1 mM ATP (Fig. 5.5 and 7A) or 100 
µM BzATP application (Fig. 5.6 and 7C) was followed by fast and extensive cell 
blebbing (within 30 s). The P2X7R overexpressing cells were able to respond to both 
agonists in a similar way but the response to 100 µM BzATP was stronger and lead 
to sustained calcium influx that was maintained even up to 10 min as long as agonist 
was present. High intracellular Ca2+ levels only returned to baseline when BzATP 
was washed away. 10 µM BzATP application was tested as well but failed to induce 
sustained Ca2+ influx or cell blebbing (data not shown). Stimulation of parental cells 
with 1 mM ATP induced smaller and transient oscillations in intracellular Ca2+ that 
returned to baseline levels after a few minutes (Fig. 5.5 and 7A). It was speculated 
that this response reflects activation of P2Y receptors in HEK293 cells. In agreement 
with this, treatment with 100 µM BzATP was unable to cause a similar response 
(Fig. 5.6 and 7B).  
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In order to further confirm that changes in [Ca2+] and cell blebbing were 
induced by P2X7R and not other changes in transfected cells, a potent and 
competitive inhibitor of P2X7R (A740003) was used. This inhibitor was shown to be 
highly selective as it blocks intracellular Ca2+ signaling, pore formation and IL-1β 
release (in monocytes differentiated into macrophages) (Honore et al. 2006). Cells 
were loaded with Fluo-4 indicator in the presence of P2X7R inhibitor and stimulated 
with BzATP as described previously. Preincubation of cells with 5 µM inhibitor 
followed by stimulation in its presence completely blocked intracellular Ca2+ spikes 
after addition of BzATP agonist (Fig. 5.8). Furthermore, P2X7R inhibitor treatment 
also inhibited cell membrane blebbing. The sensitivity to BzATP was partially 
restored after removing the inhibitor from the cells demonstrating reversibility but 
the response was markedly reduced (Fig. 5.8 A and C). Collectively, this 
demonstrates that BzATP induces a rise in [Ca2+] and membrane reorganization via 
P2X7R activation in HEK293 P2X7R cells.
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5.2.3.4 BzATP dose response measured by changes in intracellular Ca2+ 
A BzATP dose response of in HEK293 P2X7R cells was determined by measuring 
intracellular [Ca2+] signaling as readout for P2X7R activation using a plate reader 
format (Fig. 5.9). Cells were loaded with Fluo-4 Ca2+ indicator as described 
previously and the change in fluorescence was measured after automated injection of 
different concentrations of BzATP (9 - 300 µM range). At concentrations lower than 
13 µM, intracellular [Ca2+] increase was not detected. When the BzATP 
concentration was close to the apparent Kd (< 50 µM), the cell response was quite 
variable between individual wells probably due to the fact that a specific threshold 
needs to be reached for membrane depolarization and allowing Ca2+ entry. This is 
illustrated in Fig. 5.9A, which shows the response obtained from 8 replicate wells in 
a single experiment that were treated with either 200 or 40 µM BzATP 
concentration. The variable response between each well can be caused by a small 
difference in cells responding, the delay in response of some cells or unequal cell 
loading with the Fluo-4 indicator. Nevertheless, there was a clear dose-dependence 
in the response, both in terms of the number of wells that responded and the 
magnitude of the signal. Given the variability, a larger number of repeats was 
performed in each experiment to obtain acceptable results (n=8 wells). The data 
analysis were performed without excluding any repeat. Therefore no response was 
also considered as valid result. As intracellular [Ca2+] increase is only an indirect 
measure for P2X7R activation and is regulated through many different pathways 
within the cell, only the first 10s of the Ca2+ influx were considered. Those data 
should most accurately represent ligand binding to the receptor that directly triggers 
a rapid increase in Ca2+ influx without interference from subsequent cell response. 
Each curve was analyzed by fitting the data initially with first order kinetics to 
estimate the value for a shared constant C. This analysis was done to perform the 
baseline correction of data set obtained in each experiment. Then the data were fitted 
with a second order kinetics equation in order to determine the Ymax (maximal 
fluorescence) for specific BzATP concentrations (Fig. 5.9B). The obtained Ymax was 
then plotted against the BzATP concentrations to estimate the minimal effective 
BzATP dose required for P2X7R activation as measured by Ca2+ influx. The 100 µM 
BzATP concentration, which was used in the previous experiments was able to 
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induce an intracellular [Ca2+] spike that was close to maximal P2X7R activation 
(Fig. 5.9C, dashed green line). Thus, this BzATP concentration was used in Chapter 
6 and 7, where TG2 release was investigated. Additionally, the Kd for BzATP 
binding to P2X7R was estimated at approx. 80 µM. This is in line with literature 
data, which report EC50 from 40 to 100 µM BzATP concentration measured as the 
peak current using P2X7R expressed in HEK293 cells in the presence of 0.3 and 2 
mM extracellular Ca2+, respectively (Rassendren et al. 1997).  
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5.3 Discussion 
Two HEK293 cell lines stably expressing human P2X7R were established: cells that 
express wild-type P2X7R and cells with P2X7R containing a V5-His tag carboxy 
terminal. Western blotting using anti-V5 antibodies and anti-P2X7R antibodies 
confirmed the expression of P2X7R in both established cell lines. Moreover, staining 
the V5 tag on P2X7R with anti-V5 antibodies was helpful to confirm the specificity 
of anti-P2X7R antibodies. Thus, the anti-P2X7R antibodies were subsequently used 
to investigate P2X7R expression by immunocytochemistry. Both, wild-type and V5 
tagged receptor were expressed in the cell membrane as demonstrated by 
colocalization studies using confocal microscopy. This indicates that the wild-type 
P2X7R and V5 variant are properly trafficked to the cell surface. The observed 
P2X7R expression pattern is in agreement with data in the literature where cells 
transfected with rat P2X7R expressed it in the lipid bilayer, with some staining for 
P2X7R also detected in the cytosolic compartment (Smart et al. 2002; Wilson et al. 
2002).  
Functionality of the P2X7R in the membrane of HEK293 cells was initially 
confirmed using the shedding assay. Cells which co-express AR-AP and P2X7R or 
the V5-tagged version of P2X7R showed a significant increase of alkaline 
phosphatase activity in the conditioned medium following agonist stimulation. The 
cleavage of AR-AP ectodomain is likely mediated by members of ADAMs family (a 
disintegrin and metalloprotease proteins), which are membrane proteineses 
responsible for cleaving the ectodomains of growth factors, cytokines or receptors 
(Blobel 2005; Murphy 2008). ADAM-10 and ADAM-17 are metalloproteinases 
expressed in HEK293 cells (Ali and Knaüper 2007) and the literature suggests that 
ADAM-17 is the main one responsible for releasing the AR-AP domain because it 
regulates shedding of a number of EGFR ligands including AR (Murphy 2008). On 
the other hand, it has previously been shown that cleavage of Betacellulin from the 
surface of CHO cells endogenously expressing P2X7R is potentiated upon 300 µM 
BzATP addition and that this is due to ADAM-10 activation (Le Gall et al. 2009). It 
is more likely that ADAM-10 regulates AR-AP shedding in my experiments as it is 
activated by Ca2+ influx (Horiuchi et al. 2007), which is one of the consequences of 
P2X7R channel function (North 2002). Further experiments would be required to 
determine the relative contribution of different ADAMs to shedding as this was 
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outside the main focus of the PhD the involvement of ADAMs sheddases was not 
further investigated. The higher increase in shedding induced by BzATP in 
comparison to ATP likely relates to the fact that BzATP is an approx 10-fold better 
agonist than ATP to activate P2X7R (Rassendren et al. 1997). The reduced response 
of P2X7R-V5-His cells to ATP when compared with cells expressing wild-type 
receptor may result from reduced activity of the receptor due to the attachment of the 
V5-His tag. This is possible even when the surface expression between established 
cell lines was comparable. The approach to introduce a tag on the C-terminus was 
successfully used in the past and P2X7R with FLAG or HA epitope showed 
comparable functional properties as the wild-type receptor (Torres et al. 1999). On 
the other hand, it was also reported that an EGFP tag on the C- but not on the N-
terminus of P2X7 required higher concentrations of the ATP-dose response as C-
terminal EGFP alters ion transduction through the channel (Smart et al. 2002; A 
Morelli et al. 2003).  In order to exclude a possible effect of the V5-His-tag on 
receptor function, the cells expressing wild-type receptor were used for further 
experiments.  
P2X7R activity in the membrane of HEK293 was additionally investigated 
using calcium imaging. In the established HEK293 P2X7R cell model, application of 
1 mM ATP or 100 µM BzATP caused sustained high intracellular Ca2+ levels that 
were followed by cell blebbing characteristic for P2X7R mediated cell responses. 
These results are in agreement with previous reports, which show that stimulation of 
HEK293 cells expressing homomeric rat P2X7R with 30 µM BzATP causes massive 
membrane blebbing after appox. 1 min of agonist addition (Virginio et al. 1999) and 
that addition of BzATP at a concentration of 100 µM causes sustained increase in 
intracellular calcium (Wilson et al. 2002). Elevation of intracellular Ca2+ 
concentration is an effect of Ca2+ influx through the open channel. However, the 
release of Ca2+ from intracellular stores as a part of the response cannot be ruled out 
and might contribute to the overall fluorescence signal measured. P2X7R activation 
is known to also cause intramitochondrial Ca2+ increase and swelling (Mackenzie et 
al. 2005). The spike in intracellular Ca2+ observed in parental cells upon 1 mM ATP 
application is likely due to activation of P2YR as P2Y1 and P2Y2 receptors are 
constitutively expressed in HEK293 cells and their maximal activation can occur at 
100 µM ATP concentration (Schachter et al. 1997). The P2YR response is however 
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distinct from P2X7R activation and does not involve sustained Ca2+ influx but is 
caused by release of Ca2+ from intracellular stores and therefore displays rather fast 
desensitization kinetics, that do not correlate with cell blebbing (Smart et al. 2002; 
Wilson et al. 2002; Stokes et al. 2006). Application of 100 µM BzATP was not able 
to evoke the same intracellular Ca2+ spike in parental cells, which is consistent with 
the literature (Stokes et al. 2006). Therefore, with BzATP as an agonist, a significant 
P2Y response can be excluded (Jacobson et al. 2002; Coddou et al. 2011). According 
to the literature, the EC50 value for ATP and BzATP varies from 100-720 and 20-55 
µM, respectively, depending on the levels of Ca2+ present in the external solution, 
using human P2X7R expressed in HEK293 cells (Stokes et al. 2006; Jarvis and 
Khakh 2009). In our system, the cells were stimulated in the presence of OptiMEM 
that contains 0.9 mM Ca2+ and therefore 1 mM ATP and 100 µM BzATP induced a 
response close to maximal receptor activation. Those concentrations of agonists were 
used throughout further experiments.  
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Chapter 6 TG2 externalization upon P2X7R activation  
6.1 Introduction 
In the previous chapter the conditions for optimal P2X7R activation in the HEK293 
cell model were determined. Cells overexpressing P2X7R were able to open a 
membrane channel that allows Ca2+ influx and were forming plasma membrane 
vesicles in the presence of P2X7R agonists, hence showed the classical response to 
P2X7R activation. I was therefore now in a position to investigate whether P2X7R-
activation has an effect on TG2 externalization. Thus, the purpose of this chapter was 
to examine the mechanism of TG2 secretion in analogy to P2X7R-dependent IL-1β 
release, although IL-1β secretion requires inflammasome assembly (Dinarello 2009; 
Dubyak 2012). If a functional inflammasome is required for TG2 release, then 
further components such as CARD domain proteins would need to be introduced into 
P2X7R HEK293 cells, as previously shown for human fibroblasts lacking CARD 
domain of Nlrp1 inflammasome complex (Liao and Mogridge 2009). Soluble IL-1β 
was shown to be directly secreted into conditioned medium by various cell types 
(Brough and Rothwell 2007; Dinarello 2009). Several alternative pathways for its 
secretion have been proposed that might participate in generating extracellular active 
cytokine. The first model proposes that IL-1β secretion is due to shedding of 
microvesicles filled with pro- and mature IL-1β from a specific site of the plasma 
membrane (MacKenzie et al. 2001). The second hypothesis suggests exosomes as the 
main pathway for rapid IL-1β release (Qu et al. 2007). The third model suggests IL-
1β processing in the lysosomal compartment from which it is secreted by membrane 
fusion and exocytosis (Cristina Andrei et al. 2004; Bianco et al. 2005). Also, some 
recent reports are indicating participation of autophagy-dependent release as another 
way for IL-1β secretion (Deretic et al. 2012). Recent hypothesis on non-conventional 
TG2 export from the cells involves its association with microvesicles (Antonyak et 
al. 2011) or microparticles (van den Akker et al. 2011). Therefore, it was important 
to test whether P2X7R-mediated vesicle shedding leads to TG2 externalization in 
established HEK293 P2X7R cells.  
The field of microvesicles and exosomes is growing fast. For a long time as 
these cell structures were considered an artifact, cell debris or necrotic cell bodies but 
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they are now thought to have specific roles in various biological processes (Al-
nedawi et al. 2009; Cocucci et al. 2009). Small cytoplasmic protrusions eventually 
shed as small vesicles can carry receptors, signaling molecules, cytoskeletal proteins 
and consequently they are involved in surface-membrane trafficking, transfer of 
proteins and mRNA, coagulation cascade mediators released by platelets, release of 
cytokines during inflammation or tumor metastasis and cell transformation. The 
nomenclature is not yet well established in the literature and there are many terms to 
describe those small membrane-bound particles (Burnier et al. 2009; Al-nedawi et al. 
2009). The term “shedding vesicles”, “microvesicles” (MVs) or “microparticles” 
(MPs) is used to describe 100-1000 nm diameter vesicles that directly bleb from the 
membrane of viable cells (Al-nedawi et al. 2009; Cocucci et al. 2009). The term 
“microparticle” (MPs) is generally a more cell type specific term as it defines the 
particles shed from activated blood cells or vascular endothelial cells that can be 
found circulating in blood (Piccin et al. 2007). Clearly, this process is actively 
controlled by cells and occurs in response to specific signals. MVs and MPs originate 
from specific cells and consequently carry certain antigens on their surface (Burnier 
et al. 2009). They usually contain lipid raft proteins (flotillin-1, tissue factors, lineage 
markers or receptors e.g. EGFR) (Al-nedawi et al. 2009). They are usually formed 
due to phospholipid bi-layer re-arrangements. In this process enzymes such as 
calpain, flippase, floppase, aminophospholipid translocase and acidic 
sphingomyelinase are taking an active part. Their activation leads to flipping of 
phospholipids and cytoskeletal changes that allow blebbing of newly formed MVs. 
In contrast, the term “exosomes” relates to a smaller type of membrane vesicles, 
these are 40-100 nm in size and are retained inside the multivesicular bodies of the 
endosomal system (MVBs) (Al-nedawi et al. 2009; Cocucci et al. 2009). They are 
transported via the endosomal sorting complexes as early endosomes and might be 
released from MVBs to the extracellular space upon cell stimulation. Those small 
vesicles are considered to be more specialized and carry slightly different cargo than 
MVs or MPs (HSP70, CD63, mRNA). Both, microvesicles and exosomes have been 
suggested to be involved in the non-conventional release of specific proteins that 
lack a signal sequence for ER import and hence are candidate mechanisms for TG2 
externalization.  
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The aims of the chapter: 
1. Investigate if P2X7R by itself is sufficient to enable agonist-mediated TG2 
externalization? 
2. Investigate if P2X7R activation leads to re-distribution of intracellular TG2?  
3. Examine if TG2 is externalized via microvesicle shedding? 
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6.2 Results 
6.2.1 Time-dependent release of TG2 into the medium upon P2X7R activation 
The purpose of this study was to investigate if HEK293 cells stably expressing 
functional P2X7R are able to secrete TG2 into the conditioned medium during or 
after P2X7R activation. As HEK293 lack endogenous TG2 expression, cells were 
transiently transfected with wild-type TG2 and then stimulated in the presence or 
absence of the potent and selective P2X7R agonist BzATP. As 100 µM BzATP was 
sufficient to fully activate P2X7R activation as demonstrated by Ca2+ influx (see 
Chapter 5, section 5.2.3.3, Fig. 5.6), this concentration was used to study TG2 
release. In order to determine the stimulation time necessary to detect changes in 
extracellular TG2 levels, but at the same time minimize cellular damage caused by 
prolonged P2X7R activation, the initial experiment was designed to collect 
conditioned medium at different time-points of P2X7R stimulation (Fig. 6.1A). 
Medium was collected at the end of BzATP stimulation (pulse fraction) and also 
harvested 30 min after agonist removal (chase fraction) to see if there is potentially a 
delay in TG2 release. Analysis of the conditioned medium collected from HEK293 
P2X7R cells expressing TG2 by Western blotting showed that low levels of TG2 can 
be detected in cell supernatant under baseline conditions. BzATP treatment markedly 
(~ 10-fold) increased TG2 levels in the medium (Fig. 6.1B and C). Time course 
analysis of the pulse fractions indicated gradual accumulation of TG2 in the medium 
caused by P2X7R activation. 5 min pulse was not sufficient to detect TG2 
externalization, however, after 10 min BzATP treatment TG2 export into the 
medium was triggered and TG2 accumulated further in the supernatant when BzATP 
was present for 30 min. Interestingly, after removal of the agonist, elevated levels of 
TG2 in the chase fractions were still observed, even in cells that were initially only 
challenged for 5 min. This indicates that there is a delay upon which TG2 is recruited 
for externalization. It seems that the initial P2X7R activation, even a pulse as short as 
5 min, might be sufficient to trigger active release of TG2, and the presence of the 
agonist at later stages might not be required. However, cells that were challenged 
with BzATP for 10 or 30 min were able to release marginally more TG2 than those 
stimulated for 5 min only, which can be seen in the chase fractions that are of equal 
 169 
duration (Fig. 6.1B and C). The increased TG2 levels detected in the medium were 
not caused by intracellular TG2 depletion, as the total TG2 levels were similar 
between the control and BzATP treated cells at the end of the experiment (Fig. 6.1D; 
see also Fig. 6.4B). Moreover, the BzATP evoked signaling did not apparently 
change total P2X7R levels associated with the cells nor was receptor degradation 
evident, even after 30 min of stimulation (Fig. 6.1D).  
Shedding of TG2 and flotillin-2 containing MVs was previously reported by 
Antonyak and colleagues (2010). Hence, the presence of the lipid raft protein, 
flotillin-2, in the cell-free supernatant was monitored in my experiments (Fig. 6.1B). 
As expected and consistent with results obtained for TG2, elevated levels of flotillin-
2 were only detected upon P2X7R activation, suggesting that MVs release correlates 
with receptor activation (Fig. 6.1B). However, it seems that the timing of flotillin-2 
release is different to that of TG2. After 30 min of P2X7R stimulation, in medium 
collected during 30 min of chase, the TG2 levels are still maximally upregulated 
whereas flotillin-2 could not be detected (Fig. 6.1B, see also Fig. 6.2A).
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6.2.2 Inhibition of TG2 release with P2X7R inhibitor 
In order to further confirm that P2X7R activation is responsible for TG2 
translocation, HEK293 P2X7R cells were stimulated for 30 min with BzATP in the 
presence of 5 µM P2X7R inhibitor (A740003). This inhibitor concentration has 
previously been shown to be sufficient for blocking BzATP-evoked calcium 
signaling in respective cells (see Chapter 5, section 5.2.3.3, Fig. 5.8). Cells that were 
pre-treated with P2X7R inhibitor and later stimulated with BzATP in its presence 
were no longer able to accumulate TG2 as well as flotillin-2 in the medium (Fig. 
6.2A and B). Inhibition of P2X7R abolished TG2 externalization during stimulation 
as well as subsequent release in the chase fraction. This demonstrates that the agonist 
BzATP by itself has no unspecific effect on TG2 externalization and thereby 
confirms it to be a P2X receptor-dependent process (Fig. 6.2, see also Fig. 6.4A and 
C). In addition, similar to results shown in Fig. 6.2B, flotillin-2 could not be detected 
in the 30 min chase fraction that still contain TG2 at high concentration, thus further 
indicating that the mechanism of TG2 export from the cells might be distinct to 
flotillin-2 release. 
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6.2.3 Effect of BzATP treatment on cell viability 
It is known that prolonged stimulation of cells expressing P2X7R with high 
concentrations of BzATP or ATP may lead to cell death (Surprenant et al. 1996; Di 
Virgilio et al. 2001). However, previous reports also indicate that stimulation with 
100 µM BzATP for up to 10 min is not associated with increased cell necrosis, 
apoptosis or non-controlled lysis (Mackenzie et al. 2001). It was therefore important 
to investigate whether short BzATP stimulation affects viability of P2X7R 
expressing and non-expressing cells. Hence, the parental HEK293 cells and HEK293 
cells overexpressing P2X7R were challenged with 100 µM BzATP in OptiMEM for 
5, 10 and 30 min, then washed and left for 24h in DMEM containing 10% FBS. At 
the end of each time-point of stimulation and after 24h phase contrast images of cells 
were taken to observe gross changes in cell morphology and estimate cell numbers 
(Fig. 6.3). As expected, BzATP addition induced cell rounding and extensive 
blebbing in cells expressing P2X7R but not in the parental cells, as I have previously 
shown in Chapter 5 (section 5.2.3.3, Fig. 5.6). After 24h, significant cell loss was 
observed only in P2X7R cells that were stimulated with BzATP for 30 min (Fig. 6.3, 
bottom panel). The 30 min BzATP treatment did not affected the cell number in the 
parental cells. One of the reasons for the observed cell loss of P2X7R expressing 
cells is that BzATP treatment induces remarkable changes in cytoskeleton 
organization (Mackenzie et al. 2005) that lead to loss of cell attachment to the plate 
surface. Therefore, some cell loss occurs from cell handling during medium 
replacement. On the other hand, the observed cell loss might come from the fact that 
30 min BzATP treatment induced some cell death and this cannot be ruled out at this 
stage. As 10 min BzATP treatment did not cause detectable cell loss and because this 
stimulation time is sufficient to detect TG2 in the cell supernatant, those conditions 
were chosen for all following experiments.  
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6.2.4 P2X7R-mediated secretion of TG2 from HEK293 cells is not linked to loss 
of cell membrane integrity 
The experiment with the P2X7R inhibitor confirmed that active TG2 release was 
dependent on P2X7R function in cells overexpressing P2X7R. However, I also had 
to exclude that the same is possible in parental cells treated with BzATP. Thus, 
parental and P2X7R cells were transiently transfected with wild-type TG2 and 
stimulated with 100 µM BzATP as previously. The response to stimulation was 
observed only in P2X7R cells where an initial increase of TG2 and flotillin-2 in the 
pulse fraction was followed by rapid accumulation of both proteins in the chase 
fraction (Fig. 6.4A and C). Parental cells were unable to secrete TG2 or flotillin-2 in 
a similar manner during BzATP treatment or after agonist removal and TG2 clearly 
remained at the baseline level. Lysis of cells at the end of the experiment confirmed 
that both parental and P2X7R cells were expressing TG2 and flotillin-2 at similar 
levels and hence a lack of release was not due to a lack of protein expression (Fig. 
6.4B). This result clearly shows that in HEK293 cells, active TG2 secretion requires 
P2X7R activation.  
To eliminate the possibility that TG2 release might occur as an effect of cell 
lysis, membrane damage or unspecific release of their cytoplasmic content, a 
membrane containing both medium fractions and total cell extracts from a single 
experiment (separated in parallel on the same gel) was probed for the presence of 
IκBα (Fig. 6.4A and B). The same approach was previously used by Antonyak and 
colleagues (2011) where IκBα staining was used to distinguish between microvesicle 
and cytosolic protein fractions. As shown in Fig. 6.4 A, B and D, IκBα was only 
present in the cell lysate but was absent in the conditioned medium. This indicates 
that TG2 release is occurring in a selective manner and is not related to cell damage 
or transient loss of plasma membrane integrity. 
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6.2.5 TG2 localization upon P2X7R-stimulation 
To further investigate whether shedding of TG2-containing microvesicles could be 
observed in real-time upon P2X7R activation, GFP labeled TG2 was used to track its 
localization during cytoskeleton rearrangements and plasma membrane blebbing. 
Transfection of P2X7R cells with TG2-GFP (GFP on C- terminus) showed a clear 
ubiquitous TG2 cytoplasmic distribution (Fig. 6.5A). Most of the transfected cells 
did not reveal any specific localization of TG2-GFP within particular intracellular 
compartments. However, in occasional cells where the expression was quite low, 
small fluorescent spots were visible suggesting that TG2-GFP might associate with 
specific organelles. As the presence of the bulky GFP tag was considered to 
potentially affect TG2 secretion, the P2X7R cells were transiently transfected with 
wild-type and TG2-GFP constructs and the cell supernatant analyzed for TG2 release 
after stimulation with BzATP as previously. Analysis of the conditioned medium by 
Western blotting revealed that P2X7R activation is also triggering secretion of TG2-
GFP as evident by the accumulation of approx. 110 kDa protein that was detected 
with anti-TG2 antibodies in the 30 min chase fraction (Fig. 6.5B and C).  
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As TG2-GFP was externalized form the cells, presumably in the same 
manner as the wild-type TG2, it served as a model to investigate changes in TG2 
localization upon P2X7R activation. Thus, in the next step cells overexpressing 
P2X7R were transfected with TG2-GFP (C-term) and stimulated with 1 mM ATP or 
100 µM of BzATP to study the dynamics of membrane changes and possibly 
associated TG2 re-distribution by time-lapse microscopy (Fig. 6.6). Monitoring of 
cells revealed that they remained responsive to application of the agonist 
(comparable with Chapter 5). Moreover, even high levels of TG2 expression did not 
seem to have an effect on morphological changes and cell blebbing. Redistribution of 
TG2-GFP within cells was fastest at the initial timepoints when the Ca2+ influx is 
observed (Fig. 6.6; see Chapter 5, Fig. 5.6 and 5.7). However, this appeared to relate 
to changes in cell morphology rather than specifically alter the localization of TG2 
per se. On the other hand, there was a noticeable reduction in fluorescence levels 
over time suggesting that TG2 was released although this could not be visualized. At 
later time points, the cytoplasmic TG2 localization remained largely unchanged. 
Detailed analysis showed that upon stimulation, TG2-GFP was also localizing in 
membrane blebs and was freely translocating to sites where new membrane blebs 
formed (Fig. 6.7).  It was difficult to clearly confirm shedding of vesicles with 
fluorescent TG2. Careful inspection revealed that despite abundant “cell blebbing” in 
most cases the membrane protrusions remained continuous with the plasma 
membrane and some blebs were eventually retracted by the cells. It appears therefore 
that the big vesicles that are formed post P2X7R activation are still a part of the 
cellular membrane and that TG2-GFP can diffuse between the cytosol and the lumen 
of newly formed blebs. This was further confirmed by a set of bleaching approaches 
where a small area inside the “bleb” was bleached and the redistribution of 
fluorescence was investigated (data not shown). 
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The same set of experiments were also performed with or GFP-TG2 to 
investigate if the GFP attachment to the N-terminus of TG2 would alter its 
localization and to exclude any tag related artefacts. The stimulation of HEK293 
P2X7R cells expressing GFP-TG2 with 1 mM ATP or 100 µM of BzATP gave the 
same pattern of cell behaviour as previously revealed with the C-terminally tagged 
TG2 (Fig. 6.8). Similarly, GFP-TG2 was uniformly distributed within the cytosol 
and was freely translocated between cell body and protruding membrane upon cell 
challenge with both ATP and BzATP. 
Taken together, the data suggest that TG2 tagged with GFP is externalized as 
indicated by a loss of fluorescence over time and by its presence in the conditioned 
medium confirmed by Western blotting. However, either vesicles containing TG2 are 
very small, beyond available resolution or that TG2-GFP is directly translocated 
across the membrane and not vesicle bound. 
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6.2.6 Exposure of phosphatidyloserine evoked by BzATP stimulation 
P2X7R activation can lead to transient pseudoapoptosis that manifests by the 
phosphatidyloserine (PS) flipping to the outer leaflet of the cell membrane 
(MacKenzie et al. 2001). This can be visualized by adding fluorescently labelled 
annexin V, which binds to exposed PS. The aim of the experiment was to test if upon 
selected conditions i.e. 100 µM BzATP stimulation, the spontaneous flip of PS in the 
membrane bilayer can be observed. Hence, P2X7R cells were stimulated in the 
presence of FITC labelled annexin V and the process was monitored under the 
confocal microscope in real time. Images of activated cells were collected using Z-
stack analysis and revealed the presence of Annexin V positive clusters of cell 
membrane that are developing following P2X7R activation (Fig. 6.9). This is 
reminiscent of the localization of extracellular TG2 immunostaining in MDA-MB-
231 cells presented in Chapter 4. However, it remains to be experimentally shown 
that these membrane subdomains where PS is exposed are the sites of TG2 
translocation. 
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6.3 Discussion 
The most important finding of this part of the study is that P2X7R stimulation 
induces rapid release of TG2 from HEK293 cells stably expressing functional 
receptor. This mechanism identifies a novel pathway of active TG2 release that is 
relevant in the context of tissue damage. As TG2 externalization occurs in the 
HEK293 P2X7R cells that are devoid of the inflammasome components (Bryan et al. 
2010; Lu et al. 2012), this might represent a general mechanism that regulates 
presence of biologically active TG2 outside of the cells also in absence of 
inflammation. Beside cell injury, ATP can be released by cells in response to 
different stimuli such as mechanical stress, which activates purinergic signaling 
(Garcia and Knight 2010; Rumney et al. 2012). BzATP-evoked TG2 release was 
abolished by P2X7R inhibitor clearly indicating that P2X7R is an important player in 
the process of non-classical secretion of proteins other than IL-1β. The absence of 
the cytosolic marker IκBα in the cell supernatant of stimulated cells suggests, that 
rapid TG2 translocation is independent of cell damage and represents a specific 
mechanism for active TG2 delivery to the extracellular space.  
Our current understanding of TG2 function suggests its close association with 
the cell surface and quick deposition into ECM upon release (Nurminskaya and 
Belkin 2012).  These observations come from many studies that look at cross-linking 
and transamidation activity of TG2 in the presence of high extracellular Ca2+ and its 
interaction with the numerous ECM proteins such as fibronectin, collagen, syndecan-
4 or heparin (Aeschlimann and Thomazy 2000; Telci et al. 2008; Scarpellini et al. 
2009; Belkin 2011). However, those extracellular/membrane interactions 
demonstrate how TG2 may be retained on the cell surface or ECM but does not 
explain the trafficking mechanism through the membrane (Nurminskaya and Belkin 
2012). There are already a number of studies showing that TG2 can be collected 
from cell medium; however, the common pathway of this type of secretion remains 
elusive (Balklava et al. 2002; van den Akker et al. 2011; Antonyak et al. 2011; Chou 
et al. 2011). Additionally, enzymatically active TG2 was found in the ascites of the 
ovarian cancer and potentially plays a role in cancer cell growth (Satpathy et al. 
2007; Yakubov et al. 2013). 
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Zemskov and colleagues recently proposed a model of TG2 unconventional 
export, which says that the recycling endosomes are the intracellular machinery 
required for TG2 release (2011). They state a hypothesis that TG2 is recruited to the 
endosomes prior its externalization and captured inside vesicles on its way to the cell 
surface. Therefore the deposited TG2 and endocytosed TG2 remains in the state of 
equilibrium. In order to investigate TG2 surface trafficking, authors of the study used 
embryonic mouse fibroblasts (NIH3T3) with an inducible TG2 expression system 
and compared the externalization pathway with human endothelial cells (HUVEC) 
endogenously expressing TG2. They observed that in fibroblasts de novo synthesized 
TG2 was accumulating in perinuclear vesicles after approx. 4h and after reaching the 
cell surface TG2 was deposited into the ECM (after approx. 8h). The same timing of 
release was observed for HUVEC cells, however only NIH3T3 fibroblast were able 
to release TG2 into the growth medium after approx. 24h post induction of 
expression. They have also looked more closely at the non-canonical secretory 
pathway of TG2 from the cells by using various inhibitors of protein trafficking. 
Agents that block the ER/Golgi pathway or secretion of other non-classically 
released proteins, such as FGF2 and IL-1β unable to inhibit TG2 release from 
NIH3T3 fibroblasts. However, they showed that inhibition of N-ethylmaleimide-
sensitive factor (NSF), which is an ATPase involved in intracellular membrane 
fusion between synaptosomal-associated protein (SNAP) and SNARE, reduces total 
levels of cell surface TG2. Thus, authors concluded that association of TG2 with the 
membrane of intracellular organelles is necessary event for its proper externalization. 
By blocking the VAMP3 and SNAP23 SNAREs proteins, with which NSF can 
interact they showed that TG2 failed to reach the cell membrane. The model 
suggested by Zemskov and colleagues explains how TG2 could be secreted from the 
cells in a constitutive manner, however does not answer the question if TG2 
secretion can be triggered by any specific external signal. It also does not give a hint 
on how TG2 can cross the lipid membrane barrier of perinuclear endosomes. 
However their work suggests that unconventional export of TG2 is a tightly 
controlled process that involves membranous organelles inside fibroblasts and 
endothelial cells.  
Evidence collected in this chapter suggests that TG2 release might occur 
together with microvesicles shedding from activated cells. The analysis of 
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microvesicles is challenging due to the lack of standardized methods for their 
isolation that does not affect release of their content and break down (Burnier et al. 
2009). Because of their small size, there are many limitations on how to visualize 
and analyse the specific fraction of microvesicles that contain specific biological 
information. In order to determine the presence of TG2 in the supernatant of 
HEK293 P2X7R cells a similar approach to the medium collection from MDA-MB-
231 was used (as described in Chapter 4). Cell-free medium analysis by Western 
blotting using specific markers is not ideal to distinguish between soluble protein, 
microvesicles or exosome populations. However, it gave a handle to sensitively and 
reproducibly show that P2X7R activation leads to downstream signaling necessary 
for TG2 and flotillin-2 accumulation in the cell supernatant.  
Antonyak and colleagues proposed a model of TG2 release that involves its 
association with cell-derived microvesicles (MVs), which represents a pathway of 
TG2 transfer between cells (Antonyak et al, 2010). They observed that MVs 
containing TG2 of approx. 0.2-2 µm in diameter are actively shed from a subset of 
serum starved MDA-MB-231 breast cancer cells and U87 human glioma cells (from 
35 and 25% of cells, respectively). However their model does not address the 
question of TG2 translocation from cytosol to the outer leaflet of budding membrane 
vesicle. Nevertheless, they draw an interesting possible function of MVs shed from 
highly progressive tumours. They show that MVs have a transforming effect on 
normal recipient cells and this mechanism might be important for cancer metastasis 
(REF). 
A similar approach to study TG2 secretion was used by van der Akker and 
colleagues (2011), where they report the secretion of TG2/eGFP-containing 
microparticles (MPs) from human embryonic kidney cells (HEK293) and from 
mouse vascular smooth muscle cells (MOVAS). In order to capture TG2 release, 
they have transiently transfected cells with TG2 tagged with eGFP and used confocal 
microscopy and growth medium collection to assess for released MPs. They have 
observed that in HEK293 cells, TG2/eGFP containing MPs accumulate in the 
medium post transfection and show an example of fluorescent MPs being detached 
from the surface of a smooth muscle cell. Surprisingly, smooth muscle cells required 
the addition of FBS for 24h or 2h treatment with Ca2+ ionophore was necessary for 
the MPs to be observed and collected in the growth medium. The secretion of wild-
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type TG2/eGFP was positively correlating with the presence of Annexin V positive 
staining on the cell surface measured by flow cytometry thus confirming that MPs 
might be released during spontaneous PS flips. 
At this point it is uncertain whether TG2 release is linked to microvesicles 
formation in the HEK293 cells overexpressing P2X7R. Studies with GFP tagged 
TG2 confirmed that in the presence of P2X7R activation, the cytosolic form of TG2 
can freely translocate within the cell and localize at sites of extensive blebbing. I was 
however unable to clearly observe shedding of fluorescently labelled vesicles packed 
with TG2. Furthermore, the dynamics of flotillin-2 release differed from those of 
TG2 secretion, which suggests that TG2 may not be associated with microvesicles. 
On the other hand, those experiments confirmed that cells expressing both TG2 and 
P2X7R at high levels are still able to respond to BzATP treatment in a similar 
manner to those non-expressing TG2. Hence, TG2 does not apparently affect P2X7R 
activation.  
It has been reported that intracellular TG2 is not only present in the cytosol 
but also can be found associated with nuclear and mitochondrial membranes in some 
types of cells (Lorand and Graham 2003; Nurminskaya and Belkin 2012). Yet, the 
transfection with GFP labelled TG2 seemed to upregulate mainly the cytosolic form 
of the protein. Similar results were obtained by van den Akker and colleagues (2011) 
when they transfected HEK293 cells with TG2 C-terminally tagged with eGFP and 
showed a comparable distribution of TG2 within the cytosol. Localization of TG2 to 
subcellular compartments may be cell-type specific (Thomazy and Fesus 1989) or 
modulated by the cell cycle (Mian et al. 1995). It would be interesting to see if 
different forms of TG2 could undergo different surface trafficking and recycling 
within the cell. At the moment, it appears that the cytosolic fraction of TG2 is the 
main source of secreted TG2 in response to P2X7R activation. However, this needs 
to be further confirmed.  
In conclusion, my work reveals that the presence of TG2 in the cell 
supernatant might relate to an excess of TG2 being released and be an important 
novel mechanism for fast TG2 delivery to the extracellular space, which happens 
under certain conditions i.e. the activation of danger-sensing P2X7R. 
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Chapter 7 The role of Ca2+ signaling in TG2 secretion 
7.1 Introduction 
P2X7R are ligand–gated ion channels that after millisecond of ATP stimulation 
dilate and allow Ca2+, Na+ entry and K+ efflux, leading to membrane depolarization 
(North 2002). However, the receptor activation is also linked with the formation of 
large membrane pores upon prolonged stimulation with ATP or high agonist 
concentrations. This complex mechanism is not fully understood (Ferrari et al. 2006; 
Pelegrín 2011). As HEK293 cells expressing functional P2X7R are able to actively 
release TG2 upon BzATP stimulation, it was important to investigate which activity 
of P2X7R is required to induce TG2 externalization. 
The P2X7R is highly polymorphic, and it becomes increasingly clear that 
some amino acid substitutions predispose to disease. SNP linkage analysis in an 
rheumatoid arthritis (RA) cohort revealed the presence of P2X7R gene mutations 
that impair receptor function, which correlate with the presence of rheumatoid factor 
or C-reactive protein in patients carrying those alleles (Al-Shukaili et al. 2011). 
Interestingly, mutations in P2X7R that disable membrane pore formation have also 
been associated with reduced chronic pain in osteoarthritis (OA) patients (Sorge et 
al. 2012). This suggests that sustained P2X7R activation could also contribute to 
arthritis pathogenesis, and inhibiting P2X7R-mediated pore formation but not 
channel activity may therefore have therapeutic potential. 
Opening of the P2X7R membrane pore is usually manifested by entry of 
large cations such as N-methyl-D-glucamine (MW 195) or dyes such as ethidium 
bromide (MW 394) or YO-PRO-1 (MW 629) through the membrane of viable cells 
(Virginio et al. 1999; Pelegrín 2011; Browne et al. 2013). Currently, there are two 
hypothesis trying to explain the phenomenon of P2X7R-dependent increase in 
membrane permeability commonly called “pore formation” (Costa-Junior et al. 2011; 
Pelegrín 2011; L. H. Jiang et al. 2013). The first one suggests that prolonged 
application of ATP induces further conformational changes within P2X7R subunits 
leading to dilation of the channel itself. The channel dilates to the stage where 
ultimately a pore is formed that is large enough so that dyes can permeate the 
channel. Gradual occupation of all ATP binding sites on the trimeric P2X7R receptor 
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may be involved in a transition from activated receptor toward pore formation (Jiang 
et al. 2013). The second model suggests that proteins such as pannexins and 
connexins are coupling with activated P2X7R and are responsible for dye 
translocation across the membrane.   
The first hypothesis is supported by findings that activation of P2X7R evokes 
a large inward cation current that has a “double” nature (Roger et al. 2010; Browne 
et al. 2013). The initial fast rise in the current is followed by a slower rise in 
“current”, which suggests further channel dilation to the point when dye uptake is 
possible (Yan et al. 2011). Gradual opening of the P2X7R channel rather than a one-
step switch mechanism implies that further agonist binding is essential for the 
channel expanding leading to possible pore formation (Virginio et al. 1999). This is 
also consistent with high agonist concentrations promoting high current facilitation 
and pore formation i.e potential saturation of ligand binding sites. Electropysiology 
data on the P2X7R show that repeated application of ATP is needed to reach the full 
capacity for ion flux and only sustained application of agonist is necessary to reach 
the steady-state current and cell blebbing (Roger et al. 2010). Recently, Browne and 
colleagues (2013) suggested that dyes permeate the P2X7R channel in the same 
manner as passing ions. When the YO-PRO-1 entry was simultaneously measured 
with the changes in membrane current, dye uptake was greatest at -60 mV membrane 
potential, which produced the largest inward cation current. By changing the 
membrane potential to +60 mV and inducing an outward ionic current, they reported 
reduced dye uptake, which confirms that YO-PRO-1 translocation is also voltage 
dependent. Moreover, they have observed that introduction of a positive charge 
inside the channel decreases the entry of positively charged ethidium bromide and 
increases translocation of negatively charged FITC. The opposite was observed when 
the respective residue was exchanged for a negatively charged amino acid. 
Therefore, the authors speculated that dyes (up to 1.4 nm in diameter) can permeate 
directly through the P2X7R pore in the same way as ions do. However, they do not 
fully exclude the possibility that other proteins might be involved. 
The second model proposes an interaction of P2X7R with the membrane 
hemichannel, Pannexin-1 as a possible pathway explaining “pore formation” 
(Pelegrin and Surprenant 2006). Pannexin-1 is a transmembrane protein closely 
related to family of gap-junction proteins, the connexins, however it is not acting in 
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the same manner as gap-junction that are quickly delivered and internalized from the 
cell surface and therefore seems to mediate different types of cell-cell 
communication (Penuela et al. 2007). Pannexin-1 was suggested to mediate the 
observed dye uptake upon P2X7R activation. It was shown that the initial dye uptake 
is abolished after blocking Pannexin-1 with antagonistic peptides or reducing its 
expression with siRNA in HEK293, which did not affect ionic currents due to 
P2X7R activation. Similarly, inhibition of Pannexin-1 also successfully blocked 
initial rapid dye uptake after ATP stimulation of J774 macrophages endogenously 
expressing P2X7R (Pelegrin and Surprenant 2007). Moreover when overexpressed, 
Pannexin-1 was shown to co-immunopecipitate with P2X7R (Pelegrin and 
Surprenant 2006). The addition of colchicine had similar effects and prevented pore 
formation without altering membrane currents through P2X7R clearly suggesting the 
presence of distinct molecular events regulating those two states (Marques-da-Silva 
et al. 2011). However, there are also some data that argue against pannexin-1 
involvement (Jiang et al. 2013). Macrophages from Pannexin-1 KO mice are still 
able to take up dye and therefore, there must be a different mechanism allowing for 
the pore to be formed (Qu et al. 2011; Baroja-Mazo and Pelegrín 2012). Also, the 
presence of some differences between HEK293 cells and macrophages in the dye 
uptake process suggest, that separate permeation pathways might be involved 
depending on the cell type (Schachter et al. 2008; Cankurtaran-sayar et al. 2009). 
Despite the fact that there are conflicting data about the role of Pannexin-1 in pore 
formation, it is possible that both receptor channel dilation and hemichannel 
interaction contribute to the phenomenon and that different hemichannels are 
involved in the passage of anionic or cationic dyes through the membrane, depending 
on cell type (Pelegrín 2011). As P2X7R displays this interesting dual function in the 
cell membrane it was important to further investigate whether the initial ion current 
through the P2X7R channel itself or the subsequent pore formation is the necessary 
element for TG2 release in the HEK2393 cell model. 
The aims for the chapter: 
1. Investigate if TG2 release is dependent on extracellular Ca2+ entry upon 
P2X7R activation? 
2. Investigate if TG2 externalization is dependent on P2X7R pore formation? 
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7.2 Results 
7.2.1 Possible mechanisms of P2X7R-evoked signaling mediating TG2 
externalization 
At this point of study it was essential to consider which component of P2X7R-
evoked signaling may be involved in TG2 externalization (Fig. 7.1). One possible 
hypothesis was, that the initial P2X7R channel opening resulting in a fast Ca2+ 
influx, is the important element driving TG2 secretion (see Chapter 5, Fig. 5.5-5.7) 
(Ca2+ signaling). As this step results in membrane depolarization and is accompanied 
with Na+ entry and K+ depletion, those changes in ion concentrations might influence 
non-conventional TG2 release. A third possible mechanism for TG2 release might 
involve formation of large membrane pores by P2X7R itself that is known to develop 
upon prolonged BzATP stimulation. In addition, we predicted that ATP-evoked 
signaling could lead to P2Y activation, which is associated with subsequent release 
of Ca2+ from intracellular ER stores and this downstream step could contribute to 
TG2 externalization in addition to extracellular Ca2+ influx. The possible 
mechanisms of non-classical TG2 secretion involves its translocation across the 
membrane with the help of specific transporters or microvesicle shedding from the 
cell surface. As extracellular enzymatic activity of TG2 is regulated by Ca2+ ions and 
associated with substantial changes in enzyme conformation, it seemed possible that 
external Ca2+ plays an important role in the process of rapid TG2 translocation 
through the plasma membrane. Thus, the effect of extracellular Ca2+ on TG2 
secretion and activation was first studied. 
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7.2.2 Regulation of TG2 externalization by extracellular Ca2+  
The first hypothesis was that entry of extracellular Ca2+ through the P2X7R channel 
or membrane pore is regulating availability of TG2 in the extracellular space. The 
fact that TG2 was found to be present in the growth medium of HEK293 P2X7R 
cells was an interesting observation itself (see Chapter 6, Fig. 6.1-6.4), as most of the 
cells that externalize TG2 will express it only on the cell surface or deposit it directly 
into the ECM (Lorand and Graham 2003). Upon P2X7R stimulation, TG2 secretion 
was observed in medium (OptiMEM) that contained a Ca2+ concentration of 0.9 mM, 
which is slightly below the estimated free ionised extracellular Ca2+ is 1.1-1.3 mM 
(Riccardi and Kemp 2012). Therefore, the first question was whether TG2 release is 
still observed when extracellular Ca2+ concentrations are altered. Consequently, 
stimulation of HEK293 P2X7R cells with 100 µM BzATP was performed in 
OptiMEM supplemented with varying extracellular Ca2+ concentrations (0, 0.9 and 
2.2 mM Ca2+) (Fig. 7.2A and B). As shown in Chapter 6, BzATP stimulation under 
standard conditions (0.9 mM Ca2+) led to an increase of TG2 secretion into the 
culture supernatant in both pulse and chase fractions. Surprisingly, stimulation of 
cells at 2.2 mM Ca2+ completely abolished TG2 externalization to the growth 
medium. The amount of TG2 released was highest in the pulse fraction when cells 
were stimulated in the absence of Ca2+ (OptiMEM with 1 mM EDTA). However, 
TG2 levels dropped back to baseline levels in the chase fraction. This suggests that 
TG2 release was fastest but not sustained at lower Ca2+ concentrations. To further 
elucidate whether TG2 release into the medium might be associated with 
microvesicle shedding, the nitrocellulose membrane was probed for the presence of 
flotillin-2. The amount of flotillin-2 released was greatest at 0.9 mM Ca2+ and greatly 
reduced in cells stimulated with BzATP at 0 or 2.2 mM Ca2+ (Fig. 7.2A). This 
further confirms that TG2 and flotillin-2 secretory pathway may be distinct and 
hence differentially affected by extracellular Ca2+. 
Interestingly, HEK293 P2X7R cells transiently expressing TG2 that were 
challenged with BzATP at different extracellular Ca2+ concentrations revealed 
distinct morphological changes upon P2X7R activation (Fig. 7.2C). In standard 
conditions (0.9 mM Ca2+), cells stimulated with 100 uM BzATP became strongly 
activated and started to extensively bleb, whereas the same treatment at 2.2 mM Ca2+ 
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had a much less pronounced effect on cell morphology. Cells remained more spread 
and did not form visible membrane blebs seen in cells at 0.9 mM Ca2+. On the other 
hand, cells that were stimulated in OptiMEM containing 1 mM EDTA started to 
detach from the plate and become rounded even without BzATP stimulation, thus 
suggesting that cation chelation has effects besides those related to P2X7R 
activation. 
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7.2.3 Investigation of the role of Ca2+-mediated TG2 activation on its 
externalization  
There were several possibilities of how extracellular Ca2+ levels may influence TG2 
release into medium upon P2X7R activation. One of the hypothesis being that 
secreted TG2 was activated to a varying extent in the presence of different Ca2+ 
concentrations and may be crosslinked and therefore retained at the cell surface 
(pericellular ECM) at high but not low Ca2+ concentrations. Therefore, at high Ca2+ 
TG2 may no longer be detectable in the culture supernatant despite being 
translocated across the membrane. Thus, the aim of the experiment was to examine if 
addition of a potent TG2 inhibitor can restore its release into the medium at 2.2 mM 
Ca2+ by blocking its activity and therefore possible interaction/crosslinking to cell 
surface or ECM upon release. HEK293 P2X7R cells transiently expressing TG2 
were stimulated with BzATP in 0.9 and 2.2 mM Ca2+ in the presence of a carrier 
(DMSO control) or 25 µM TG2 inhibitor (Boc-DON-QIVMeEs) (Fig. 7.3A). This 
concentration was previously found to be effective in blocking in situ TG2 activity in 
culture models (see Chapter 3, section 3.2.11, Fig. 3.13B and C). However, the 
presence of TG2 inhibitor during BzATP stimulation had no effect on TG2 amounts 
in medium. This indicated that the expected TG2 activation at 2.2 mM Ca2+ might 
not be the reason for why it is not present in the cell free supernatant at high Ca2+ 
concentration. Nonetheless, it is possible that crosslinking occurred in a compartment 
inaccessible to inhibitor. Therefore, another approach was used to exclude that TG2 
enzymatic activity is an important factor influencing its release from the cells. This 
time externalization of wild-type TG2 was compared with secretion of TG2 that 
contains a mutation in the cysteine of the active site (C277S) (Fig. 7.3B). Release of 
mutant lacking transamidation activity should occur independent of extracellular 
Ca2+ concentrations if the role of Ca2+ in externalization relates to regulation of 
enzyme itself. The secretion was compared at both, 0.9 and 2.2 mM of extracellular 
Ca2+. BzATP stimulation induced both TG2 as well as TG2 C277S mutant 
translocation into the medium at 0.9 mM Ca2+ but not at 2.2 mM Ca2+ (Fig. 7.3B). 
This indicates that the observed differences in TG2 release at specific Ca2+ 
concentrations are not associated with altered TG2 activity, but might be related with 
differences in P2X7R activation or possibly pore formation. 
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7.2.4 TG2 release after blocking the P2X7R ion channel  
Previous experiments using A740003 P2X7R inhibitor confirmed that TG2 secretion 
could be specifically blocked in HEK293 overexpressing P2X7R cells (see chapter 5, 
section 5.2.3.3, Fig. 5.8). This competitive P2X7R inhibitor abolishes both P2X7R-
dependent current and pore formation at the same time (Honore et al. 2006). 
However, it was interesting to further distinguish which of those two intrinsic 
functions of P2X7R are necessary for mediating TG2 secretion. To assess the 
contribution of the initial ion flux on TG2 secretion calmidazolium chloride was 
chosen. Calmidazolium is a non-specific inhibitor of Ca2+ and Na+ membrane 
channels that is able to inhibit the initial ATP-evoked current through P2X7R 
without affecting the dye uptake by the cells (Virginio et al. 1997). The release of 
wild-type TG2 was assessed in standard conditions (OptiMEM  with 0.9 mM Ca2+ ) 
in the presence and absence of 1 µM calmidazolium chloride (Fig. 7.4A). The 
collection point of the chase fraction was reduced from 30 min to 10 min to be able 
to see if the presence of calmidazolium might delay TG2 release and be more 
apparent during the initial burst of TG2 release. Treatment of cells with BzATP in 
the presence of calmidazolium had no effect on TG2 release. However, 
calmidazolium was effective in blocking flotillin-2 secretion. This might indicate 
that the secretion of TG2 is dependent on the P2X7R-dependent pore formation, but 
not the initial ion flux and associated currents. 
7.2.5 Analyzing the role of Ca2+ in regulation of P2X7R pore formation 
Given that the observed TG2 release could be linked with the formation of the large 
P2X7R pore it was important to investigate if HEK293 P2X7R cells are able to 
undergo membrane pore formation when stimulated with 100 µM BzATP. 
Additionally, it was important to investigate whether the kinetics of this process 
correlated with TG2 release. Measurement of YO-PRO-1 uptake is one of the 
common methods used to study pore formation evoked by P2X7R activation. YO-
PRO-1 fluorescence assay was adapted to measure pore formation in HEK293 
P2X7R cells in real-time to test various conditions. Uptake was examined in PSS 
buffer containing 0 mM Ca2+ in order to evoke maximal P2X7R activation. The pore 
formation abilities were first compared between parental HEK293 cells and P2X7R 
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stable transfectants.  A fluorescence increase indicative dye entry into the cells was 
visible only in P2X7R cells and developed within 30 seconds of BzATP addition 
(Fig. 7.4B). Hence, pore formation occurred surprisingly fast and closely followed 
by Ca2+ signaling in these cells. Parental cells were unable to form the membrane 
pores and consequently failed to uptake YO-PRO-1 even at high BzATP 
concentrations (300 µM) as expected. In P2X7R positive cells the YO-PRO-1 uptake 
was clearly dose-dependent and the response potentiated at higher (300 µM) BzATP 
concentrations (Fig. 7.4B). We therefore decided to examine dose dependence in 
more detail (Fig. 7.4C and D). Dye uptake showed a bi-phasic concentration-
dependence profile. Unexpectedly, fast uptake followed by a much slower reaction 
but only when high BzATP concentrations were administered (>300 µM) (Fig. 
7.4D).  It seems that above a certain threshold of agonist concentration, P2X7R can 
further dilate or change conformation, which allows increased YO-PRO-1 uptake. 
However, this later change seems not to be required for TG2 release, as 100 µM 
BzATP is sufficient to trigger enzyme export. 
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In the next stage, it was important to understand if the presence of various 
concentrations of external Ca2+ will influence the process of pore formation. It has 
previously been shown that the removal of Ca2+ from the external solution can slow 
the increase of pore dilation (Virginio et al. 1999). As TG2 externalization was 
dependent on the levels of extracellular Ca2+ but not related with its catalytic activity, 
differences in P2X7R pore formation at various external Ca2+ concentrations could 
offer a potential explanation. The P2X7R response was therefore compared after 
addition of 500 µM BzATP in the presence of 0 or 2 mM Ca2+. Surprisingly, 
treatment of cells at 2 mM Ca2+ evoked a transient unexpected spike of fluorescence, 
that was not observed at 0 mM Ca2+  (Fig. 7.5A). However, this transient spike was 
not observed at lower Ca2+ concentrations (Fig. 7.5B). Furthermore, this spike was 
not related with P2X7R as this initial spike in fluorescence at 2 mM Ca2+ was also 
observed in parental HEK293 stimulated with 100 µM BzATP (Fig. 7.5D). It is 
unclear what causes the fluorescence change but it is unlikely related to dye uptake 
by cells. YO-PRO-1 accumulation over time was observed only in P2X7R 
overexpressing cells, even when stimulation at 2 mM Ca2+ (Fig. 7.5A and D). After 
reducing the BzATP concentration to 300 µM, the changes in YO-PRO-1 uptake at 
different Ca2+ concentrations was analyzed and indicated that the presence of Ca2+ is 
directly modulating the rate of dye uptake in those cells (Fig. 7.5C). When the initial 
reaction rates were compared the data indicated that dye uptake is inversely 
proportional to the Ca2+ concentration (Fig. 7.5D).   
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7.3 Discussion 
The main focus of this chapter was to study the role of extracellular Ca2+ on rapid 
TG2 externalization triggered by P2X7R activation. The aim of this part of study was 
to investigate if TG2 enzymatic activity is required for secretion. Moreover it was 
investigated whether increase in extracellular TG2 levels are occurring due to the 
initial BzATP-evoked Ca2+ influx through P2X7R open channel or happen as a 
consequence of membrane pore formation. Collected evidence is suggesting that 
intracellular sustained rise in intracellular Ca2+, mediated by membrane pore, might 
be a possible mechanism leading to TG2 delivery into extracellular space.  
Extracellular activity of TG2 is dependent on Ca2+ ions that facilitate the 
transition of TG2 into an active, open conformation that exposes the catalytic core 
(Bergamini 1988; Pinkas et al. 2007). It has been previously proposed that TG2 
unconventional secretion might be linked with Ca2+ signaling (Zemskov et al. 2011). 
It was shown that intracellular Ca2+ chelator (BAPTA) reduces the level of surface 
TG2, whereas Ca2+ ionophore (Ionomycin) upregulates its presence at the surface of 
HUVEC endothelium cells and WI-38 fibroblast endogenously expressing TG2. 
However, the detailed mechanism that connected intracellular [Ca2+] changes with 
non-classical TG2 secretion has not been proposed. In this part of study, the 
stimulation of cells with BzATP at different concentrations of Ca2+ suggested that 
extracellular Ca2+ levels are important for TG2 externalization process and regulate 
its availability in the growth medium. During P2X7R stimulation, the amounts of 
released TG2 were decreasing with increasing concentrations of extracellular Ca2+. 
Therefore, it was hypothesized that at 2.2 mM Ca2+, a condition when TG2 should be 
fully active (Király et al. 2011), it might immediately bind to ECM and be no longer 
detected in the growth medium. However, the experiment with active site mutant 
(C277S) revealed that the C277S mutant was also secreted in the same manner as wilt-
type protein. Thus, the increased enzymatic activity of TG2 is not the reason why its 
no longer present in the medium at 2.2 mM Ca2+. Moreover, it showed that the 
catalytic activity of TG2 is not a requirement for its rapid release. Similar results 
were previously reported by van den Akker and colleagues (2011), which showed 
gradual accumulation of TG2-conatinaing microvesicles in the growth medium of 
transiently transfected HEK293 cells. They also showed that C277S inactive mutant 
 206 
was localizing in the conditioned medium similarly to wild-type TG2. Alike, 
Antonyak and collagues (2011) reported that TG2 enzymatic activity was not 
essential for its release from MDA-MB-231 cells. Blocking TG2 surface activity by 
monodansylcadaverine or T101 inhibitor did not interfere with microvesicle 
formation. Different approach to detect TG2 in the medium was used by Balklava 
and colleagues (2002) where the conditioned medium from serum-starved 3T3 
fibroblasts was pre-cleared by centrifugation and protein precipitated or lyophilized 
in order to assess wild-type TG2 and C277S mutant levels by ELISA (Balklava et al. 
2002). However, they have observed that only wild-type TG2 could be deposited in 
the ECM and localize in conditioned medium, whereas C277S was retained on the 
surface of fibroblasts (Balklava et al. 2002). It is therefore likely that enzymatic 
activity of TG2 might be important factor controlling TG2 availability outside the 
cells and vary between different cell types. 
The experiment with variable concentrations of extracellular Ca2+ also 
suggested that the sustained increase of intracellular Ca2+ might be necessary 
element of the pathway recruiting TG2 for release. Increased levels of TG2 were 
detected in cells in OptiMEM with 0.9 mM Ca2+ even after removal of the BzATP 
but this was not the case at 0 mM Ca2+. One of the explanations why further TG2 
accumulation is not seen is that lack of external Ca2+ might induce complete 
depletion of Ca2+ from intracellular stores during first 10 min of BzATP stimulation. 
On the other hand, it was previously shown that BzATP stimulation induced 
intracellular [Ca2+] rise in HL-60 promyleocytes but only when cells were kept at 2.2 
mM Ca2+ (Suh et al. 2001). BzATP treatment at 0 mM external Ca2+ was not 
sufficient to induce rise in intracellular Ca2+ which indicate that P2X7R stimulation 
does not lead to IP3 generation and PLC-dependent signaling in those cells. 
However, they showed that BzATP addtition was still able to evoke membrane 
depolarization even without external Ca2+, which indicates that P2X7R activation is 
still prominent at this state. Thus, to fully understand involvement of intracellular 
[Ca2+] rise on TG2 externalization the experiments with PLC and IP3 inhibitors 
should be perform to investigate if only influx through P2X7R channel rather that 
[Ca2+] mobilization from intracellular stores is playing an important role in observed 
prolonged TG2 release not seen without external Ca2+.  
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Ca2+ signaling is a known inducer of MV shedding and activator of 
cytoskeletal rearrangements. The release of [Ca2+] from intracellular stores can 
activate plasma membrane enzymes such as flippase, floppase and scrambalase, 
which in stady-state are regulating phospholipid membrane asymmetry (Burnier et 
al. 2009). Changes in enzymes distribution lead to loss of aminosphingolipids 
anchorage to the cytosleleton and it dissociation. Therefore local [Ca2+] increase 
takes an active part in the process of membrane blebbing. Interstingly, the levels of 
extracellular Ca2+ were also regulating the release of flotillin-2, which were optimal 
at 0.9 mM Ca2+. Decreased levels of in flotillin-2 in EDTA treated medium might be 
explained by the reduced shedding of membrane vesicles upon removal of 
extracellular Ca2+. Mackenzie and colleagues (2001) observed that in the lack of 
external Ca2+ cell blebbing is reduced but no loss of membrane area is seen in both 
HEK293 expressing rat P2X7R cells and THP-1 monocytes. Moreover in a Ca2+ free 
medium, the release of IL-1β from LPS primed THP-1 cells was abolished after 
challenge with BzATP and no longer detected at early time points when IL-1β is 
postulated to be secreted via microvesicle pathway. Similarly microvesicles shedding 
is reduced in dendritic cells in the lack of external Ca2+ (Pizzirani et al. 2007). 
Morelli and colleagues (2003) showed that in the presence of EGTA the cells are not 
undergoing extensive blebbing but become more swollen and rounded. They 
speculate that this might be an effect of large Na+ influx that permeates the channel 
in the shortage of Ca2+. Therefore Ca2+ signaling through P2X7R is an important 
component of the microvesicles shedding (Morelli et al. 2003) and presence of Ca2+ 
seems to be required to induce their rapid formation. 
As the Ca2+ seems to be necessary element for microvesicles release and cell 
blebbing it was important to understand why TG2 and Flotillin-2 secretion was 
abolished at physiological Ca2+ concentrations (2.2 mM) when sustained Ca2+ entry 
should be expected. It was hypothesized that lack of TG2 and Flotillin-2 secretion 
might be due to insufficient P2X7R activation. It was previously shown that presence 
of divalent cations in the extracellular solution is reducing P2X7R channel opening 
and pore formation and speculated that cations are influencing the availability of free 
acidic form of ATP4- to activate P2X7R (Virginio et al. 1997; Coddou et al. 2011). 
The acidic form of ATP is the true ligand to activate P2X7R but not the cation bound 
ATP (North 2002; Yan et al. 2011). In the presence of Ca2+ there is a rightwards shift 
 208 
in agonist concentration dependence indicating that presence of Ca2+ decrease the 
potency of the agonist acting on P2X7R (Yan et al. 2008; Yan et al. 2011). However 
authors of that study show that Ca2+ is allosterically affecting P2X7R gating rather 
than only reducing the availability of BzATP4- (Yan et al. 2011). The same pattern of 
current facilitation response is observed when Ca2+ is present thus suggesting that 
extracellular Ca2+ itself does not affect transition from open to dilated receptor state. 
But the presence of Ca2+ significantly affected the P2X7R deactivation by altering 
the rate. Repeated stimulation of cells with 100 µM BzATP followed by washing 
periods showed that the deactivation of P2X7R is much slower in cells that were kept 
without extracellular Ca2+. Therefore, it is possible that due to reduced P2X7R 
activation at high external Ca2+ TG2 release is not visible any more whereas at lower 
Ca2+ the effect is prolonged due to slower P2X7R deactivation. It will be interesting 
to further investigate differences in [Ca2+] signaling upon different extracellular Ca2+ 
concentrations to understand how TG2 secretion is linked with rapid Ca2+ influx.  
The large C-terminus of P2X7R is involved in the process of pore formation 
possibly through interaction with hemichannels and proteins of cytoskeleton 
(Mackenzie et al. 2005; Costa-Junior et al. 2011; Baroja-Mazo et al. 2012). Thus, the 
observed changes in TG2 secretion might be as well linked with the changes in pore 
formation upon different Ca2+ concentrations but not initial Ca2+ influx. The 
preliminary experiments with YO-PRO-1 uptake seem to support this hypothesis as 
the initial rate of dye uptake was much lower at high Ca2+. However, it seems that 
there might be a formation of transient fluorescent product at 2 mM Ca2+ and in the 
presence of BzATP that is not related to the P2X7R pore formation that should be 
further investigated. But if this peak is ignored, the kinetics of dye uptake differs 
between zero extracellular Ca2+ and when some Ca2+ is present in the bath solution. 
In the lack of Ca2+ the YO-PRO-1 uptake was quick and seemed to reach a plateau 
faster, but in the presence of Ca2+ the uptake was gradually increasing. At the 
moment there is not enough data to explain how pore formation might influence TG2 
release at different extracellular Ca2+ levels. The experiment with calmidazolium 
suggest that the initial Ca2+ and Na+ entry might not be needed for TG2 releases but 
only pore formation is the key element. It is however not known what is the exact 
mechanism of calmidazolium chloride acting on P2X7R. This agent was previously 
used to block channel of cyclic-nucleotide-gated receptors and shows to inhibit the 
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initial current of rat P2X7R channel without affecting the pore formation (Virginio et 
al. 1997). Therefore, ATP is possibly able to bind to P2X7R and induce changes 
necessary for the pore to be formed even in the presence of calmidazolium. It is 
possible that its inhibition is similar to the action of another inhibitor, Invermectin. It 
was suggested that Ivermectin, which is an allosteric regulator of P2X4 receptor, 
might bind inside the open channel when the transmembrane domains slightly shift 
away from each other during receptor activation (Hattori and Gouaux 2012).The 
Invermectin could then bind to the lipid molecules of the membrane bilayer that fill 
the gap between the TM domains and modulate the function of the pore. In analogy, 
it is possible that binding of calmidazolium to P2X7R changes ions permeation 
pathway or delays their translocation but at the same time allow for the pore to be 
formed. As flotillin-2 but not TG2 release was affected by calmidazolium this further 
confirms that their release pathways are not the same. 
In summary, literature and collected evidence suggest that extracellular Ca2+ 
is an important regulator of TG2 membrane translocation and this might be due to 
Ca2+ ions regulating the degree of P2X7R activation rather than enzymatic activity of 
TG2. Further studies are necessary to fully answer whether TG2 externalization is 
linked with P2X7R-dependnent pore formation or transient Ca2+ influx and 
membrane depolarization.  
 210 
Chapter 8 General discussion 
 
The aim of this disscussion is to briefly summarise the different hypothesis regarding 
TG2 export and contrast them to my findings. I am proposing a novel mechanistic 
link between P2X7R activation and TG2 release. P2X7R activation triggers the 
delivery of TG2 after cell injury, when ATP levels are elevated and act through 
paracrine signaling. The results presented in this thesis show for the first time that 
introduction of functional P2X7R alone is sufficient to reconstitute rapid non-
conventional TG2 export in a cell model. The evidence presented here suggests that 
TG2 externalization is linked to P2X7R dependent Ca2+ signaling and might be due 
to the ability of P2X7R to form a pore.  
Revealing the precise mechanism of TG2 externalization is a crucial task 
given the role of extracellular transamidation activity in disease proceses. This would 
potentially allow pharmacological modulation of TG2 secretion at specific stages of 
disease. It is likely that additional molecules are released through the same non-
classical mechanism but their discovery is slow (Dinarello 2009). Non-conventional 
release triggered by activation of P2X7R might apply to other proteins, as it was 
shown for IL-1β (MacKenzie et al. 2001) and HMGB1 (Lu et al. 2012). This 
pathway may represent an important mechanism for regulating the presence of 
mediators at the sites of inflammation and injury. Moreover, it is likely that other 
members of the transglutaminase family are secreted using the same pathway, 
especially structurally closely related TG3 and TG6. This mechanism may also apply 
to FXIIIa, a protein with a well-definied extracellular function in hemostasis but 
which is also highly expressed in skeletal tissues like TG2 (Nurminskaya and 
Kaartinen 2006). The secretion of TG2 triggered by P2X7R might play a role in 
many diseases linked to inflammation, such as rheumatoid arthritis, osteoarthritis, 
coeliac disease and various types of cancers.  
Another very important question linked to this topic that requires further 
investigation is whether TG2 activation is linked to externalization, or whether it 
occurs independently. Our current understanding suggests that TG2 is rapidly 
converted into the activated form by high extracellular Ca2+ concentrations (Pinkas et 
al. 2007). However, potentially secreted TG2 could remain in GTP/GDP-associated 
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closed conformation and this may depend on the microenvironment encountered in 
the externalization process (Johnson and Terkeltaub 2005). Several lines of recent 
evidence suggest that autocrine signaling in chondrocytes in fact requires 
extracellular GTP/GDP-bound enzyme (Johnson and Terkeltaub 2005). Additionally, 
antibodies against TG2 found in coeliac disease patients display and unexpected 
specificity (Iversen et al. 2013). Clonal antibodies isolated from CD patients were 
shown to bind the one of 4 different regions of the N-terminal part of TG2. Despite 
the fact that theoretically these N-terminal epitopes of TG2 are available in both 
open and closed conformations, antibodies only recognise TG2 when present in free 
form in solution but not when cell surface associated. These data suggest that both 
forms of TG2 are available in the extracellular space and might be mediating 
different responses.  
8.1 Proposed mechanism: Rapid TG2 release is triggered by danger signals in 
osteoarthritis 
 
I propose the hypothesis that ATP-dependent P2X7R activation triggers TG2 release, 
which may occur during development of osteoarthritis (Fig. 8.1). Both, P2X7R-
mediated inflammatory cytokines release (Labasi et al. 2002) and extracellular TG2 
action are likely to be implicated in joint pathology (Huebner et al. 2009). However, 
a link between these events is an entirely novel concept. It is still unclear which cell 
type is the main source of active TG2 released to the extracellular milieu during joint 
disease. Chondrocytes (Johnson et al. 2001), macrophages (Hodrea et al. 2010) as 
well as fibroblasts (Balklava et al. 2002) are all able to externalize TG2 and may 
independently contribute to the enzyme pool. A possible scenario that predisposes 
TG2 for the secretion during osteoarthritis might be the increased ATP 
concentrations released during aberrant mechanical loading of cartilage (Garcia and 
Knight 2010) (Fig. 8.1). Chondrocytes were shown to respond to purinergic signaling 
(Garcia and Knight 2010) and express P2X7R (Knight et al. 2009). This leads to 
TG2 export as well as activation and might promote tissue mineralization and induce 
chondrocyte hypertrophy. As specyfic P2X7R polymorphisms have been linked with 
both rheumatoid arthritis (Al-Shukaili et al. 2011) and osteoarthritis (Sorge et al. 
2012), it is likely that patients with allelic variants of P2X7R may differ with regards 
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to TG2 export. This should be further investigated and may identify specific patient 
populations that are naturally deficient in certain activities of TG2.  
 
 213 
8.2 Current understanding of constitutive TG2 release 
8.2.1 TG2 release via recycling endosomes 
 
Non-conventional export of TG2 by fibroblasts and endothelial cells seems to occur 
in a constitutive manner and involve different membranous organelles (Zemskov et 
al. 2011). It was shown that after three hours of induction of TG2 expression, TG2 
was found co-localized with perinuclear vesicles prior to their export. At the initial 
step of TG2 synthesis, TG2 appear to be targeted into the vesicles expressing the 
recycling endosomal marker (Rab11). Therefore, newly synthesized cytosolic TG2 
needs to somehow fuse with recycling endosomes and be captured inside the 
vesicles. This was verified by the fact that both TG2 and Rab11 were shown to be 
protected from proteolytic degradation due to their endosomal localisation (Zemskov 
et al. 2011). The authors suggested that the fusion process involves an interaction of 
TG2 with phosphoinositides localized on recycling vesicles. The 
590KIRILGEPKQRKK602 sequence motif in TG2 is possibly responsible for the 
interaction with phosphoinositides. However, as this is not a conserved sequence 
motif among other members of the TG family, this type of export would only apply 
to TG2. Mutation of the phosphoinositide binding site present in TG2 on a second β-
barrel domain, apparently lead to reduced TG2 recruitment into recycling endosomes 
and decreased TG2 surface levels (Zemskov et al. 2011). Therefore, the authors 
concluded that this interaction is crucial for proper TG2 export. This is in 
contradiction to data presented by Chou and colleagues (2011). They showed that 
epithelial cells are able to secrete both wild-type TG2 as well as a mutant TG2 
lacking β-barrel 2 into the conditioned medium (Chou et al. 2011). Both enzymes 
were efficiently deposited into the ECM upon serum starvation. In contrast, TG2 
lacking the N-terminal β-sandwich domain was not deposited into the ECM and not 
secreted into the medium (Chou et al. 2011). Other groups have also shown that the 
intact N-terminal part of TG2 is necessary for TG2 trafficking and required for cell 
surface localization (Balklava et al. 2002; Telci et al. 2008) as binding of the N-
terminal part of TG2 to FN facilitates its presence on the cell surface and in the ECM 
(Gaudry et al. 1999). Residues in the N-terminal domain, responsible for the FN 
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interaction were also described (Chou et al. 2011). D94A and D97A point mutations in 
the putative FN binding sequence were shown to inhibit TG2 secretion (Chou et al. 
2011). However, silencing the FN expression had no effect on TG2 export. Thus, the 
authors concluded that TG2 translocation through the membrane is FN-independent 
in epithelial cells (Chou et al. 2011). However, it is not known how these point 
mutations affect TG2 folding and conformation as well as activity and therefore, the 
lack of TG2 may be due to misfolding of the protein. It is possible that constitutive 
TG2 secretion is cell-type specific or different experimental approaches between 
research groups lead to some contradicting findings and this requires further studies.  
8.2.2 TG2 endocytosis from the cell surface  
 
It was also suggested that the pool of TG2 on the cell surface is dynamic. TG2 
association with peripheral endocytic vesicles was proposed, allowing fast TG2 
recycling and trafficking into the cell (Zemskov et al. 2007). In fibroblasts, 
endocytosed TG2 was shown to associate with early endosomes (after 5 min), 
followed by progression to Rab7 positive late endosomes (after 30 min) and eventual 
translocation into lysosomes expressing LAMP-1 (after 90 min). However, the 
previously discussed report on TG2 export (Zemskov et al. 2011) suggests that at the 
initial step of TG2 biosynthesis, TG2 is targeted into the recycling endosomes with 
Rab11 expression (Zemskov et al. 2011). This indicates that a different subset of 
vesicles may be involved in TG2 delivery to the cell surface when compared to 
internalization. These findings makes the model quite complex and does not fully 
explain how these processes are separated. TG2 is believed to share the same 
endocytic pathway with β1 integrin, although only proteolytically cleaved TG2 can 
be detected upon its internalization (Zemskov et al. 2007). TG2 endocytosis is 
dependent on cholesterol and needs dynamin-2 GTPase activity for intracellular 
trafficking. Moreover, TG2 co-localization with transferrin was detected suggesting 
a clathrin-dependent mechanism of endocytosis (Zemskov et al. 2007). However, 
involvement of lipid rafts or caveolae cannot be ruled out, as inhibitors of this type of 
internalization blocked TG2 endocytosis and proteolysis (Zemskov et al. 2007). The 
interaction of the TG2 catalytic domain with low–density lipoprotein receptor-related 
protein 1 (LRP1) is believed to be required for TG2 endocytosis. This observation 
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was based on the fact that LRP1 deficient cells showed an increased cell surface 
transamidation activity. This may constitute a mechanism that regulates TG2 
extracellular activity in fibroblasts. However, another route for TG2 internalization 
was recently discovered in our lab. It might be mediated by its interaction with 
membrane G-coupled receptor, GPR56 (data of Bauer et al. in our lab). TG2 was 
shown to be a ligand for GPR56 and to undergo clathrin-mediated endocytosis upon 
GPR56 binding (Bauer et al). GPR56 and was shown to regulate melanoma 
metastasis by as yet unknown mechanism (Xu et al. 2006). However, TG2 may only 
be one of several potential ligands and the respective interactions are likely to have 
different functional roles. 
8.2.3 TG2 shed form cells in microvesicles and microparticles 
 
Apoptosis, direct membrane blebbing or exosome formation represent different 
pathways for membrane-bound cargo delivery from cell to cell (Al-nedawi et al. 
2009). The release of TG2 in microparticles was already discussed in previous 
chapters and this type of constitutive release has been reported in mouse vascular 
smooth muscle cells (van den Akker et al. 2011). There is also evidence of TG2 
captured inside the shed microvesicles, as seen in cancer cells (Antonyak et al. 
2011). This type of release was potentiated by serum deprivation, or by EGF 
treatment of some cancer cells. It is still unclear how TG2 is specifically targeted 
into these vesicles for export and whether this process is different in normal versus 
cancer cells.  
8.3 Modulators of TG2 availability on the cell surface/ECM 
8.3.1 TG2 release regulated by nitric oxide  
 
Nitric oxide (NO)-dependent S-nitrosylation is a proposed mechanism regulating 
TG2 export in the vascular wall (Santhanam et al. 2010; Jandu et al. 2013). There are 
some recent reports showing that NO inhibits TG2 externalization in vascular 
endothelial cells and fibroblasts (Telci et al. 2009; Santhanam et al. 2010; Jandu et 
al. 2013). NO was previously shown to nitrosylate free cysteine residues of TG2 (Lai 
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et al. 2001). In the presence of Ca2+ ions, the S-nitrosylation was even more 
profound, probably resulting in TG2 “unfolding” that allows for more cysteine 
residues being exposed on the surface of the molecule (Lai et al. 2001). As S-
nitrosylation inhibits TG2 activity, NO is thought to be an important allosteric 
regulator of TG2 activity. Jandu and colleagues show that under conditions 
promoting nitric oxide formation, addition of an NO synthase inhibitor restores TG2 
cell surface localization and its export to ECM in human aorta endothelial cells 
(Jandu et al. 2013). The inhibitor was able to decrease the S-nitrosylation of TG2 in a 
time-dependent manner, which allowed gradual extracellular TG2 accumulation. In 
analogy, addition of NO donor to smooth muscle cells or human fibroblasts not only 
significantly reduced TG2 surface and ECM presence, but also inhibited its 
extracellular cross-linking activity. Telci and colleagues obtained similar results 
when they treated human fibroblasts with an agent continuously releasing NO and 
noticed decreased extracellular TG2 localization and reduced FN deposition in 
treated fibroblasts (Telci et al. 2009). NO treated cells had some TG2 on the cell 
surface but were apparently not able to deposit it into ECM (Telci et al. 2009). There 
might be some differences between fibroblasts and vascular endothelial cells in TG2 
export. Interestingly, the S-nitrosylation of TG2 is reversible by addition of reducing 
agent, such as DTT, which increases the activity of TG2 in epithelial cells 
(Santhanam et al. 2010). However, it is unclear whether S-nitrosylation is reversible 
in situ. Moreover, the gain of TG2 activity is in agreement with other reports 
suggesting that the redox potential clearly affects TG2 extracellular activity 
(Stamnaes et al. 2010). In summary, laminar shear stress reduce TG2 surface levels 
and activity by inducing S-nitrosylation of TG2, and abolishes its deposition into the 
ECM (Santhanam et al. 2010; Jandu et al. 2013). However, it is currently not known 
if this mechanism of regulating TG2 bioavailability in the extracellular space would 
apply to other cell types or is specific to endothelial cells and fibroblasts. 
8.4 Final conclusions 
 
In summary, the results presented in this thesis have advanced our understanding of 
non-conventional export of TG2 from cells. The data provided an excellent basis for 
additional research in this area as it identifies a signal that controls the export 
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mechanism. Although, not answering the question of TG2 membrane translocation it 
characterizes a novel mechanism that triggers TG2 externalization, which was not 
reported before in the literature. This mechanism might exist alongside the other 
proposed mechanisms of constitutive TG2 release. However, an answer to this awaits 
further experimental evaluation.  
Further understanding of how biologically active TG2 is generated is of 
fundamental importance. Firstly, non-conventional protein export is likely a 
conserved pathway shared by potent biological signaling molecules including IL-1β, 
thioredoxin, HMGB-1, FGF2, TG2 and possibly many more. Secondly, 
pharmacological intervention of this pathway has clear potential for therapy and pain 
control in arthritis. Lastly, there is substantial evidence that post-translational 
modifications of specific proteins might be generated by TG2 in the context of the 
osteoarthritis once released. This potentially may serve as a biological indicator 
describing a specific stage of the disease.  
 
I have decided to continue my efforts in this direction of research and developed 
a fellowship application based on my PhD studies. The purpose of the research is to 
understand if TG2 release in cartilage is occurring as a consequence of abnormal 
joint loading or in association with the inflammation, which both processes are 
linked with P2X7R activation. The specific objectives I intend to address in the 
future are:  
• To determine whether P2X7R in response to mechanical loading is sufficient to 
activate TG2 release in human cartilage. 
• To identify whether P2X7R-/- mice are protected from IL-1β mediated TG2 
signaling. 
• To investigate which molecular event downstream of P2X7R activation is 
necessary or sufficient to trigger rapid TG2 externalization. 
• To investigate whether TG2 externalization and enzyme activation are linked 
together or are independently controlled events. 
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Introduction
 Isopeptidase assay for kinetic analysis of transglutaminase 
activity    
 Optimized protocols for FLUOstar OPTIMA and Omega allow for 
rapid implementation and standardization of  measurements
 Assay is amenable to high throughput analysis of regulators/
inhibitors of catalysis
Transglutaminases (TGs) form a family of enzymes that catalyze 
various posttranslational protein modifi cations such as crosslinking,
esterifi cation and deamidation in a Ca2+-dependent manner.1 Their
main function is the formation of covalent Nε-(g-glutamyl)lysine bonds 
within or between polypeptides to stabilize protein assemblies.
The activity of these enzymes is crucial for tissue homeostasis and
function in a number of organ systems, and the lack of or the
excessive crosslinking activity have been linked to human disease 
processes1,2. 
Here we perform kinetic measurements using recombinant TG2 
and a fl uorescent peptide model substrate on a FLUOstar OPTIMA and
FLUOstar Omega in a format suitable for high-throughput analysis. This 
assay principle can be applied to kinetic studies on closely related 
enzymes including TG63 and can be optimised by modifi cation of the 
backbone peptide sequence.
Assay Principle
Abz-APE(g-cad-Dnp)QEA is a quenched fl uorescent probe derived from
a known glutamine donor substrate5 that mimics a crosslinked TG 
reaction product. In this peptide the fl uorophore (2-aminobenzoyl (Abz))
is quenched by a 2,4-dinitrophenyl-cadaverine (cad-Dnp) substituent
on the fi rst Gln residue, essentially replacing the Lys side chain in
Nε-(g-glutamyl)lysine linked peptides (Fig. 1A). TG2-catalysed hydrolysis
of the isopeptide bond releases the cad-Dnp moiety (Fig. 1B) and
consequently generates an increase in light emission at λmax=418 nm
from the Abz group. The thioester enzyme intermediate formed is
subsequently deacylated through either aminolysis or hydrolysis.
Specifi city of the reaction is guided by the amino acid residues that 
surround the reactive Gln residue3.
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Fig 1A: Structure of quenched substrate Abz-APE(g-cad-Dnp)QEA whereby 
2-aminobenzoyl (Abz) and 2,4-dinitrophenyl (Dnp) are fl uorescent 
donor and quenching acceptor group, respectively.
Fig. 1B:  Reaction scheme for TG catalyzed isopeptidase reaction with substrate 
Abz-APE(g-cad-Dnp)QEA in the presence of an excess of unlabeled 
primary amine (R4-NH2, e.g. glycine methylester). R: Abz-AP; R2: QEA; 
 R3: (CH2)4-NH-Dnp; E-SH (TG2 with active site thiol group).
The TG enzymatic reaction is a two-step process. The thioester 
intermediate of the enzyme formed with the substrate in the fi rst step
subsequently reacts with a nucleophile to regenerate active enzyme
and release a ‘crosslinked’ polypeptide. The second step is reversible
and, in the presence of an excess of crosslinked  substrate, TG catalyzes
isopeptide bond hydrolysis4. We have exploited this latter activity
for real-time monitoring of TG activity and characterize the effect of 
potential regulators on TG activity. 
 FLUOstar OPTIMA or FLUOstar Omega (Fig. 3) microplate readers 
 from BMG LABTECH
 Black optical bottom 96-well plates (165305, Nunc)
 Abz-APE(g-cad-Dnp)QEA TG2 substrate (A102; Zedira, Darmstadt, 
 Germany). 50 mM stock in DMSO
 Transglutaminase 2 6, 1 mg/ml stock, cleared by centrifugation at
 14,000 x g for 30 min at 4˚C and concentration derived from 
 OD280 using ε = 1352 cm
2/g; keep on ice and prevent repeated 
 freeze-thawing (similar high quality product is available from 
 Zedira: T002)
Assay buffer
The assay buffer consists of 62.5 mM Tris/HCl, pH 7.4, 125 mM NaCl. 
Add glycine methylester (or alternative amine donor substrate) and 
adjust pH immediately before use (at 37˚C). Include DTT to prevent 
oxidative inactivation of TG.  
Materials and Methods
Germany:  BMG LABTECH GmbH  Tel: +49 781 96968-0 
Australia: BMG LABTECH Pty. Ltd.  Tel: +61 3 59734744 
France:  BMG LABTECH SARL  Tel: +33 1 48 86 20 20 
Japan: BMG LABTECH JAPAN Ltd. Tel: +81 48 647 7217
UK:  BMG LABTECH Ltd.  Tel: +44 1296 336650 
USA:  BMG LABTECH Inc.  Tel: +1 877 264 5227  
 
Internet: www.bmglabtech.com applications@bmglabtech.com
Reported here are optimized experimental conditions for determination 
of TG2 isopeptidase activity with the fluorescent model substrate Abz-
APE(gcad-Dnp)QEA using the FLUOstar OPTIMA/Omega plate readers 
to produce an assay that is rapid, direct and sensitive. Automated 
injection of Ca2+ for enzyme activation combined with the ability to 
continuously measure fluorescence intensity over a considerable time 
period with limited photobleaching facilitates the acquisition of kinetic 
data. Small sample size and plate format make the assay cost-effective 
and adaptable to high-throughput analysis. 
1. Aeschlimann D, Thomazy, V. (2000). Connect Tissue Res. 41:1-27.
2. Iismaa, S, et al., (2009). Physiol. Rev. 89:991-1023.
3. Thomas H, et al., (2013). Amino Acids. 44: 161-177.
4. Parameswaran, KN, et al., (1997). J. Biol. Chem. 272:10311-10317.
5. Hohenadl C, et al., (1995).  J. Biol. Chem. 270: 23415-23420.
6. Hadjivassiliou M, et al., (2008). Ann. Neurol. 64:332-343.
7. Lui S, et al., (2002).  Proc. Natl. Acad. Sci. USA. 99: 2743-2747.
Fig. 2:  Raw data (A) and processed data (B) of substrate Abz-APE(g-cad-Dnp)
QEA conversion at different concentrations of TG2 (2.5 – 20 mg/ml) as 
measured with Optima instrument. Control given represents 20 mg/
ml TG2 without Ca2+ injection. Data processing involved normalization 
for well-specific fluorescence and subtraction of control to account for 
fluorescence bleaching. C: Reaction rate is linearly correlated to enzyme 
concentration (orange, Optima data; green, Omega data). D: Allosteric 
regulation of TG2 by nucleotides. Isopeptidase activity of TG2 measured 
in the presence of different concentrations of nucleotides: GTP, red line; 
GTPgS, yellow line; and ATP, blue line.
After Ca2+ injection an increase in fluorescence can be observed 
dependent on the concentration of enzyme in sample (Fig. 2). 
Results and Discussion
Conclusion
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TG2-mediated substrate conversion is linear for >30 min and initial 
reaction rates can be derived from linear regression of first 15-25 data 
points (Fig. 2A and B). Fluorescence emission of the standard peptide 
Abz-APQQEA was found to correlate linearly with concentration for 
0.13-2.0 mM (gain 2450) on the FLUOstar OPTIMA and 0.016-0.5 mM 
(gain 2450) or 0.03-2.0 mM (gain 1883) on the FLUOstar Omega 
(Fig. 2C). Enzymatic conversion of Abz-APE(g-cad-Dnp)QEA was 
measureable down to 1 mg/ml (~13 nM) for TG2 on the FLUOstar OPTIMA.
The plate format is ideal for investigating the effect of potential 
regulators or inhibitors on catalysis. GTP is a well characterized 
allosteric regulator of TG27. Using the outlined reaction conditions 
and 20 mg/ml TG2 and different concentrations of nucleotides, we 
have determined IC50 concentrations of 2.9 mM, 3.6 mM, and ~1 mM for 
GTP, GTPgS and ATP, respectively, which is in good agreement with 
data in the literature (Fig. 2D).
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Fig. 3:  BMG LABTECH’s FLUOstar Omega multidetection microplate reader
Test protocol 
Prime the FLUOstar injectors with 20 mM CaCl2 for enzyme activation 
(inj. 1) and H2O or 20 mM MgCl2 for control reaction (inj. 2). Pre-warm 
assay buffer and plate to 37˚C and equilibrate instrument chamber at 
37˚C. Dilute substrate Abz-APE(g-cad-Dnp)QEA (1:800) in assay buffer 
and add 80 µl of mixture into wells of the 96-well plate. Add desired 
amount of enzyme, e.g. 1 mg of TG2, and make up volume with H2O to 
90 µl. Transfer plate immediately into the reader and start program.
  
Reaction mixture (final concentrations)
The final assay volume is 100 µl and consists of 1-100 µg/ml TG2, 
50 µM Abz-APE(g-cad-Dnp)QEA, 10-55 mM glycine methylester or 
alternative nucleophile, as well as 1-5 mM DTT. After injection there is 
2 mM CaCl2 present in samples. Detailed discussion can be found here: 
http://www.cardiff.ac.uk/dentl/aeschlimann
Instrument settings
Mode:  Fluorescence Intensity, plate mode
Filters:  Ex320 for excitation and 440-10 for emission
Optics  top
No. of flashes: 20 
Cycles:  90
Cycle time: 40 s (for 12 wells)
Injection cycle: 10
Injection volume: 10 µL
Shaking:  5 s after each cycle
Temperature: 37°C
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Abstract Transglutaminases (TG) form a family of
enzymes that catalyse various post-translational modifica-
tions of glutamine residues in proteins and peptides including
intra- and intermolecular isopeptide bond formation, esteri-
fication and deamidation. We have characterized a novel
member of the mammalian TG family, TG6, which is
expressed in a human carcinoma cell line with neuronal
characteristics and in mouse brain. Besides full-length pro-
tein, alternative splicing results in a short variant lacking the
second b-barrel domain in man and a variant with truncated
b-sandwich domain in mouse. Biochemical data show that
TG6 is allosterically regulated by Ca2? and guanine nucle-
otides. Molecular modelling indicates that TG6 could have
Ca2? and GDP-binding sites related to those of TG3 and TG2,
respectively. Localization of mRNA and protein in the mouse
identified abundant expression of TG6 in the central nervous
system. Analysis of its temporal and spatial pattern of
induction in mouse development indicates an association
with neurogenesis. Neuronal expression of TG6 was con-
firmed by double-labelling of mouse forebrain cells with cell
type-specific markers. Induction of differentiation in mouse
Neuro 2a cells with NGF or dibutyryl cAMP is associated
with an upregulation of TG6 expression. Familial ataxia has
recently been linked to mutations in the TGM6 gene. Auto-
antibodies to TG6 were identified in immune-mediated ataxia
in patients with gluten sensitivity. These findings suggest a
critical role for TG6 in cortical and cerebellar neurons.
Keywords Transglutaminase 6  Sequence  Structural
model  Regulation  Central nervous system  Ataxia
Abbreviations
CNS Central nervous system
DIG Digoxigenin
GFAP Glial fibrillary acidic protein
HD Huntington’s disease
PCR Polymerase chain reaction
RT Reverse transcription
SCA Spinocerebellar ataxia
TG Transglutaminase
Introduction
Transglutaminases (TG) are a family of structurally and
functionally related enzymes that post-translationally
modify proteins by catalysing a Ca2?-dependent transfer-
ase reaction between the c-carboxamide group of a
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peptide-bound glutamine residue and various primary
amines. Most commonly, intra- or intermolecular c-glut-
amyl-e-lysine crosslinks are formed by reaction with the
e-amino group of a lysine residue (Folk and Chung 1973).
The action of these enzymes consequently results in the
formation of covalently crosslinked, often insoluble supra-
molecular structures and has a well-established role in
tissue homeostasis in many biological systems (Aeschlimann
and Thomazy 2000; Lorand and Graham 2003; Iismaa
et al. 2009). Besides crosslinking, peptide-bound glutamine
residues may be modified by TG through reaction of the
acyl-enzyme intermediate with low-molecular-weight
metabolites harbouring amino groups, or through hydro-
lysis or esterification. Conversion through hydrolysis is
comparably slow and occurs preferentially at pH \ 6.5.
Nevertheless, the biological significance of enzymatic
deamidation of glutamine has been illustrated by its role in
T-cell activation in celiac disease (Molberg et al. 1998;
Van de Wal et al. 1998). Transamidation has profound
effects on the biological activity of many substrate proteins
and it has become clear that some TGs preferentially form
intermolecular crosslinks, whereas others catalyse primar-
ily intramolecular reactions (Candi et al. 1995). Such
protein modifications can be dynamic as conversion of the
acyl-enzyme intermediate to the isopeptide bond is
reversible (Parameswaran et al. 1997). TGs are evolution-
arily related to papain-like cysteine proteases, both in terms
of the structure of the core domain and the mechanism of
catalysis, and more distantly to the peptide N-glycanases.
Other enzymes have evolved in lower species that can
catalyse the same transamidation reaction. These, however,
bear no genetic relationship to the TG genes in man and the
mechanism of catalysis is distinct, although it depends on a
reactive thiol in the enzyme active site. These include
Streptomyces microbial TG, bacterial toxins (including
cytotoxic necrotizing factor from E. coli and dermone-
crotic toxin from Bordetella), and thioredoxin/protein-dis-
ulfide isomerase-like enzymes from primitive eukaryotes
(e.g. ERp60-like from nematodes and PDI from Giardia).
Nine different TG genes have been characterized in
mammals (Aeschlimann and Paulsson 1994; Aeschlimann
et al. 1998; Grenard et al. 2001). They exhibit a similar
overall organization, with remarkable conservation of
intron distribution and intron splice types. Detailed com-
parison of the structure of the individual genes shows that
they may be divided into two subclasses, wherein the
TGM2-7 and EBP42 genes contain 13 exons, and the
F13A1 and TGM1 genes contain 15 exons (Grenard et al.
2001). Exon 9 of the former group is separated into two
exons, 10 and 11, in the TGM1 and F13A1 genes, and the
non-homologous N-terminal extensions of factor XIII
a-subunit and TG1 that are absent in other TGs are com-
prised by an additional exon. Several TG gene products
have been characterized in detail using a combination of
mutagenesis and structural studies to elucidate the enzy-
matic mechanism and its regulation. The three-dimensional
structures of three TGs have been solved, i.e. factor XIII a
(Yee et al. 1994), TG2 (Liu et al. 2002) and TG3 (Ahvazi
et al. 2002). All comprise of four domains that are similar
in organization: an amino terminal b-sandwich domain
which forms a functional unit with the core domain; the
catalytic core domain that contains the conserved active
site triad cysteine, histidine and aspartate residues; and two
C-terminal b-barrel domains which are involved in the
regulation of enzyme activity. Molecular modelling and
docking studies on TG3 proposed that binding of two
additional Ca2? ions converts the enzyme to the active
form on the approach of the first substrate (glutamine-
containing polypeptide) (Ahvazi et al. 2004). A recent
X-ray structure of a trapped transamidation intermediate of
TG2 (Pinkas et al. 2007) explained for the first time how a
crosslinked protein complex could be released from the
enzyme after catalysis as well as the considerable increase
in radius of gyration observed by small-angle X-ray scat-
tering for activated TG2 in solution (Mariani et al. 2000).
TG2 undergoes a large conformational change whereby the
b-barrel domains are rotated almost 180 into the plane of
the other two domains, thereby exposing the enzyme active
site (Pinkas et al. 2007).
TGs have been implicated in the pathogenesis of several
neurodegenerative diseases (polyglutamine expansion dis-
eases, Alzheimer’s, Parkinson’s and supranuclear palsy),
but despite extensive investigation over at least two dec-
ades ambiguity remains as to the physiological function of
TGs in the central nervous system (CNS) as well as their
role in pathogenesis (for review see Iismaa et al. 2009;
Jeitner et al. 2009). It has been shown that pathological
length CAG expansions are excellent substrates for TG2
and that TG2 activity is increased in the brains of patients
with Huntington’s disease (HD) and certain forms of spi-
nocerebellar ataxia (SCA) (Lesort et al. 1999). In Alzhei-
mer’s disease TGs have been localised to plaques and
tangles and these contain substrates of TG2 (Kim et al.
1999). Similarly, the presence of TG crosslinked a-syn-
uclein in substantia nigra dopaminergic neurons of Par-
kinson’s disease patients has been demonstrated (Andringa
et al. 2004). The fact that increased levels of the c-glut-
amyl-e-lysine crosslink as well as bis-c-glutamylpolyamine
are found in the affected tissue and in the cerebrospinal
fluid (Zainelli et al. 2003; Nemes et al. 2004; Jeitner et al.
2008) indicates that TG2 and possibly other TG isozymes
extensively modify proteins and possibly also disease-
specific protein aggregates. Mouse models have sub-
stantiated a direct role of TG2 in the pathogenesis of
Huntington’s and other neurodegenerative diseases albeit
the mechanisms involved being somewhat unexpected. HD
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mice (R6/1 and R6/2) lacking TG2 exhibit delayed mor-
tality and behavioural deficits but have increased aggregate
formation (Mastroberardino et al. 2002; Bailey and John-
son 2005). It is therefore possible that TG2 contributes to
the pathogenesis by modulating the size of the aggregates
formed, leading to the formation of smaller aggregates (Lai
et al. 2004) that may be more neurotoxic. In an Alzhei-
mer’s disease model, fibrillar Ab triggers dimerization of
angiotensin II type 2 receptors (AT2) which becomes a
substrate for TG2 and is further oligomerized (AbdAlla
et al. 2009). AT2 oligomerization results in sequestration of
Gaq/11 G protein which impairs M1 muscarinic receptor
function. Excitotoxic neuronal cell death is an important
component of acute injury in the CNS and also chronic
neurodegenerative diseases. Tissue-specific overexpression
of TG2 in mice sensitizes hippocampal neurons to apop-
tosis upon glutamate receptor overstimulation (Tucholski
et al. 2006) and ischemic injury induces rapid upregulation
of TG2 expression (Ientile et al. 2004) consistent with its
regulation by acute-phase injury cytokines. A recent study
provides evidence that TG2 has a broad effect on gene
transcription by regulating chromatin structure through
N-terminal polyamination of histone H3 in a model of HD
and that TG2 inhibition protects striatal neurons from
NMDA-mediated toxicity (McConoughey et al. 2010).
Inflammation is a component of neurodegenerative dis-
eases including HD and mediators such as TNFa may play
a critical role in upregulating TG2 expression locally.
Cytokine-mediated TG2 induction in astrocytes has been
shown for acute spinal cord injury (Monsonego et al. 1998)
and MS lesions (van Strien et al. 2011). It has also become
clear that there is significant complexity in the regulation
of TG activity in the CNS. Two TG2 variants in addition to
the full-length protein have been described in brain
(Monsonego et al. 1998; Citron et al. 2002; Antonyak et al.
2006; Tee et al. 2010). These result from alternative
splicing, giving rise to truncated proteins essentially lack-
ing either b-barrel 2 or both b-barrel domains and having
unique short C-terminal sequences. Expression of these
variants causes distinct changes in regulation of cell dif-
ferentiation and survival as a consequence of differences in
GTP binding of the variant proteins (Antonyak et al. 2006;
Tee et al. 2010). Although the major contribution to TG
activity in the CNS, and cerebral cortex in particular, has
been ascribed to TG2 (Bailey and Johnson 2004), c-glut-
amyl-e-lysine crosslinks are formed in TG2-/- brain
(Mastroberardino et al. 2002). Abundant expression of at
least two other TG isozymes, TG1 and TG3, in the CNS
has been shown (Kim et al. 1999), but the functional
importance of this remains to be investigated. Here we
characterize the hitherto uncharacterized TGM6 gene
product and discuss it in the wider context of CNS
development.
Materials and methods
Detailed descriptions of experimental procedures are given
in ‘‘Supplemental Material’’.
Cell culture
H69 cells (American Type Culture Collection) were main-
tained as floating cell aggregates at a density of
6–30 9 104 cells/ml in RPMI 1640 medium supplemented
with 10% heat-inactivated foetal calf serum (FCS) containing
100 units/ml penicilin and 100 lg/ml streptomycin. HEK293-
EBNA cells were grown in DMEM:Ham’s F-12 medium (1:1)
supplemented with 10% FCS, 250 lg/ml G418 (Invitrogen)
and antibiotics. Neuro 2a cells (European Collection of Cell
Cultures) were maintained in high-glucose DMEM supple-
mented with 10% FCS and antibiotics. For differentiation,
cells were seeded at 5,000 cells/cm2 in 24-well plates and
stimulated for 3 days by reducing FCS to 0.5% and where
indicated, adding 50 ng/ml NGF (Millipore), 1 mM dibutyryl
cAMP (Sigma), or 10 lM retinoic acid (Sigma).
Cloning of human TG6
Overlapping fragments (corresponding to nucleotides
71–502, 409–876, 705–1,442, 1,369–1,720 and 1,666–2,292
in AF540969) of TG6 were amplified by RT-PCR from H69
poly(A)?RNA. The 50-end of the cDNA was isolated by
50-RACE PCR as described (Grenard et al. 2001) and the
transcription initiation site determined by primer extension. A
full-length cDNA for TG6 was constructed by subcloning the
overlapping fragments as described (Hadjivassiliou et al.
2008). The full-length cDNA encoding TG6-L or TG6-S was
subcloned into the pCEP-4 vector for expression in HEK293
EBNA cells (Smyth et al. 2000). Cell strains stably expressing
TG6 were generated by transfection with lipofectamine (10 ll
for 2 lg plasmid DNA) and selection with puromycin, starting
with 0.5 lg/ml puromycin after 48 h and gradually increasing
to 10 lg/ml over a 10 day period.
Northern blotting
5 lg of H69 cell poly(A)?RNA was separated in a 1.2%
agarose gel, transferred to a nylon membrane and probed
with a digoxigenin(DIG)-UTP-labelled single-stranded
RNA probe corresponding to nucleotides 1,484–2,212
(AF540969) of TG6.
Analysis of TG expression in mouse brain and cloning
of mouse TG6
For cloning of mouse TG6, we prepared cDNA from
BALB/c brain and used a series of gene-specific
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oligonucleotides modelled from the human TG6 sequence
to isolate overlapping DNA fragments by PCR. The 50-end
of the sequence was determined using 50-RACE PCR and
yielded besides the full-length mTG6 sequence a transcript
with an alternative exon 1 (AY177607). Real-time PCR to
quantify TG6 mRNA expression was carried out on an ABI
7700 Sequence Detection System using the 50 nuclease
assay with primers 50-CAGCAGTGGTAGGAGTGAC
AG (300 nM) and 50-CTCTTGGAAGGGGTTATGTTG
(600 nM) and labelled (50 6-carboxyfluorescein and 30
6-carboxytetramethylrhodamine) probe 50-CAAGGACAG
CTAAGTATTGAGGTGCCCAG. Reaction conditions
were as previously described except using 4 mM MgCl2
(Stephens et al. 2004).
Molecular modelling
A three-dimensional model of human TG6 was generated
using ProMod II (version 3.70 SP3; Arnold et al. 2006)
with the X-ray derived coordinates of human TG3 in its
activated form (Protein Data Bank code 1L9N, chain A;
Ahvazi et al. 2002) and the GDP-bound form of TG2
(1KV3, chain C; Liu et al. 2002) as a template resulting in
final total energies of -32,300 and -17,400 kJ/mol,
respectively, after optimizing the alignment manually.
ELISA style transamidation assay
TG activity was determined by measurement of the
incorporation of biotin-x-cadaverine (Molecular Probes)
into N,N-dimethylcasein immobilized on the surface of
protein binding 96-well plates essentially as described
(Kleman et al. 1995).
Real-time fluorescence assay for determination of TG
isopeptidase activity
The effect of nucleotides on TG activity [human TG6
(T021; Zedira) or TG2] was quantified by measuring
changes in fluorescence intensity over time at 37C as a
result of cleavage of Abz-APE(c-cad-Dnp)QEA (A102;
Zedira) in the presence of different concentrations of GTP,
GTPcS, GDP, GMP and ATP (Sigma). Fluorescence in the
absence of enzyme activation (no Ca2?) was subtracted and
reaction rates derived by linear regression. To obtain
steady-state kinetics for the replacement reaction, acyl
donor substrate concentration was varied from 3.2 to
170 lM. Product concentration was derived from a con-
centration series of Abz-APQQEA. The kinetic parameters
vmax and KM were obtained through nonlinear regression
[v = (vmax S)/(KM ? S)] and kcat calculated using
kcat = vmax/E0. All experiments were performed at least
twice independently.
In situ hybridization and immunolabelling of mouse
tissue
Sagittal sections of adult BALB/c mouse brain or mouse
embryos at different stages of gestation (E9–E16 and P0)
were hybridized to DIG-labelled 325 bp sense and anti-
sense RNA probes corresponding to the transcript region
encoding the TG6 b-barrels. Binding of the probes was
detected using alkaline phosphatase-conjugated anti-DIG
antibodies and visualized with NBT/BCIP. Polyclonal
antibodies to TG6 were raised in goat against a peptide
comprising residues 482–492 of mouse TG6 conjugated to
hemocyanin (Hadjivassiliou et al. 2008) and affinity puri-
fied over a thiol Sepharose column bearing disulphide-
linked peptide CGWRDDLLEPVTKPS as described
(Aeschlimann and Paulsson 1991). The sequence of this
loop connecting the catalytic core and b-barrel 1 domain is
shared among all TG6 splice variants but highly divergent
between different TGs. The absence of cross-reactivity
with other TG isozymes was established (Hadjivassiliou
et al. 2008). Immunolabelling for TG6 (1 lg/ml) and
b-tubulin III (Sigma T3952, 1:50 diluted) was performed as
previously described using HRP-conjugated secondary
antibodies and AEC (3-amino-9-ethyl carbazole) as a
substrate (Aeschlimann et al. 1993).
Isolation and differentiation of cortical progenitor cells
Cerebral cortex of newborn Balb/c mice was dissected on
ice in Hanks’ balanced salt solution (HBSS) and digested
for 20 min at 37C in 0.1% trypsin, 0.05% DNAse I
(Sigma) in HBSS. The tissue was washed and subsequently
triturated in HBSS/DNAse I solution to dissociate cells.
Cells were washed and subsequently maintained in
DMEM/F12 containing 2% B27 supplement (Invitrogen).
Number of vital cells was determined by trypan blue
exclusion. For FACS analysis, cells were washed in 0.5%
BSA in phosphate-buffered saline, pH 7.4 (PBS), filtered
through 40 lm Falcon cell strainers (Becton–Dickinson) to
remove remaining aggregates, fixed in 2% paraformalde-
hyde in PBS for 20 min on ice, permeabilized and stained
with antibodies to TG6 (20 lg/ml) and cell lineage mark-
ers, glial fibrillary acidic protein (G-A-5, Sigma; 15 lg/ml),
b-tubulin III (SDL.3D10, Sigma; 20 lg/ml) and RIP
(Chemicon, 1:1,000 diluted). For culture (formation of
neurospheres), medium was supplemented with 20 ng/ml
FGF2 (R&D Systems), 20 ng/ml EGF (Sigma) and anti-
biotics and 1 9 106 cells seeded into 35 mm hydrophobic
plastic dishes. For immunocytochemistry, cells were see-
ded at a density of 1 9 105 cells/well in a 12-well plate on
laminin-111 coated [purified from EHS tumour (Aeschli-
mann and Paulsson 1991)] cover slips and grown for
5 days. Cells were fixed in 4% paraformaldehyde,
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permeabilized and labelled with antibodies to TG6 and cell
lineage markers.
Protein analysis
Protein concentrations were determined using the
bicinchoninic acid reagent (Pierce) as described by the
supplier with BSA as a standard. For immunoblotting, pro-
teins were separated on 4–20% SDS–PAGE Tris–glycine
gels under reducing conditions (1% 2-mercaptoethanol),
transferred onto nitrocellulose membranes and stained with
antibodies as described (Aeschlimann et al. 1993).
Results and discussion
TG6 cloning and primary structure
We have previously identified a cluster of TG genes in the
human and mouse genome that contained a novel gene now
termed TGM6 (Grenard et al. 2001). We used RT-PCR to
screen different human cell lines for expression of the
respective gene product. TG6 (previously called TGY)
could not be detected in cells of a wide variety of origins
including mesenchymal, epithelial and hematopoietic cells
suggesting that it has a restricted expression pattern, but its
expression could be verified in a lung small cell carcinoma
cell line, H69, both by RT-PCR and Northern blotting
(Fig. 1a).
A full-length cDNA sequence for TG6 was obtained by
PCR using oligo(dT) primed cDNA from H69 cells and a
series of sequence specific primers based on the presumed
transcribed genomic sequence (Supplemental Fig. 1).
50-RACE PCR was used to identify the position of exon 1
which contains essentially non-coding sequence and
therefore shows no apparent similarity between different
TG genes. Primer extension was used to identify the 50-end
of the cDNA and this located the major transcription ini-
tiation site 455 nt upstream of the translation start codon
(Supplemental Fig. 2). The likely 30-end of the TG6 tran-
script may be inferred from an EST sequence in Gen-
BankTM (AA961594). Based on this, a polyadenylation
signal (ATAAA) could be located 3,887 nt downstream of
the termination codon. This is preceded by a CFIm-binding
site (TGTAA) and followed by a GT-rich sequence known
to bind CstF and therefore conforms to the tripartite ele-
ment required for efficient 30 RNA processing (Venkatar-
aman et al. 2005). The estimated size of the mRNA is
therefore 6,480–6,490 nt which is in good agreement with
the 6.3 kb transcript detected by Northern blotting
(Fig. 1a). A prominent band at *2.2 kb could indicate that
a short transcript may also be abundant but the exact nature
of that remains to be investigated. The obtained sequence
for full-length human TG6 contained an open reading
frame of 2,120 nt. The deduced protein consists of 706
amino acids and has a calculated molecular mass of
79,276 Da. This mass is in good agreement with the size
of the single protein band detected by Western blotting of
keratinocyte protein extract (natively expressed protein) or
when overexpressed in HEK293 cells after transfection
with a TG6 expression construct (Fig. 1d). Recombinant
enzyme displayed Ca2?-dependent transamidation activity
(Fig. 1e).
A shorter transcript which apparently resulted from
alternative splicing of the sequence encoded by exon 12
was also isolated from H69 cells (Fig. 1b). The absence of
exon 12 results in a frame shift and thereby in premature
termination within exon 13 (Supplemental Fig. 3). The
sequence for the short form of TG6 (TG6-S) encoded a
protein consisting of 625 amino acids (Mr 70,480, calcu-
lated). The TG6-S sequence terminates just after the first
C-terminal b-barrel domain and has a unique 14 amino acid
C-terminus (Fig. 1c). Overexpression in HEK293 cells
gives rise to a stable protein of expected size (Fig. 1d)
suggesting that this alternative splicing event may have
biological significance. The b-barrel domains have been
implicated in the regulation of enzyme-substrate interac-
tion and may also be involved in intracellular signalling as
a sequence within the second b-barrel domain of TG2 is
required for binding of PLCd1 (Hwang et al. 1995).
The H69 cell line displays neuronal characteristics
including expression of neuron-specific enolase, brain
isozyme of creatine kinase and L-dopa decarboxylase. We
therefore reasoned that TG6 may be expressed in neurons.
RT-PCR confirmed TG6 expression in mouse brain (see
below). The cDNA sequence for mouse TG6 was isolated
from brain, essentially using the same approach as for
human (Supplemental Fig. 1). We have not determined the
transcription initiation site. However, an EST sequence in
GenBankTM (BY357397) derives from the genomic
sequence upstream of the sequence we have isolated by
RACE PCR indicating that transcription may be initiated at
a position 389 nt upstream of the start codon, a position
similar to that in the human gene in the aligned sequences.
Two consecutive polyadenylation signals are present
1,096 nt downstream of the termination codon (Supple-
mental Fig. 1). Mouse and human TG6 have an 85%
identity on the amino acid level.
Cloning identified two splice variants in mouse brain
lacking either exon 3 or exon 3 together with exon 4
(Fig. 1c). Alternative splicing of exon 3 has been described
by us and others for several TG genes including TG2, TG4,
TG5 and band 4.2 protein and results in a TG with an
altered N-terminal b-sandwich domain (Cohen et al. 1993;
Aeschlimann et al. 1998; Candi et al. 2001; Cho et al.
2010; AK295775 in GenBankTM). TG5 lacking exon 3 has
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no transamidase activity (Candi et al. 2001). Omission of
exon 3 and 4 results in a frame shift and premature ter-
mination before the sequence encoding the catalytic core
domain, giving rise to a hypothetical 66 amino acid poly-
peptide without TG activity.
We could not detect alternative splicing of exon 12 in
mouse brain or neuroblastoma cells. An identical sequence
to H69 cell TG6-S was recently isolated from another
cancer cell suggesting that this splice variant may be
associated with oncogenic transformation. Four distinct
C-terminally truncated versions of TG2 have been identi-
fied. Variants resulting from retention of intron 10 and 6,
respectively, have been isolated from human disease states
(Fraij et al. 1992; Citron et al. 2002). The former, TG2-S,
results in a protein truncated within the sequence encoding
b-barrel 1. Another TG2 short form resulting from splicing
at an alternative 30 site within exon 12 and 50 acceptor site
within exon 13 retains b-barrel 1 but has a distinct short
C-terminal sequence (Monsonego et al. 1998; Citron et al.
2002). This variant was originally identified in rat astro-
cytes, but similar variants, TG2-V1 and TG2-V2, resulting
from use of two alternative 50 acceptor sites within exon 13
have subsequently been demonstrated in different human
primary cells (Lai et al. 2007). However, in mouse brain no
alternatively spliced variants of TG2 could be identified
(Citron et al. 2005). Alternative splicing of exon 11 in
human TG5 gives rise to a variant truncated within b-barrel
1 analogous to TG2-S (Candi et al. 2001). C-terminal
truncation affects allosteric regulation of TG2 by GTP and
has profound effects on cell differentiation and survival
(Monsonego et al. 1998; Antonyak et al. 2006; Tee et al.
2010).
TG6 is a very low abundant transcript as indicated from
directly analysing expression in specific cells and tissues as
well as from whole genome expression profile studies. For
mouse, the GenBankTM database contains a total of 21
independent ESTs. 18 of these are derived from skin and 1
each from retina and brain cortex. EST BB612839 is the
splice variant lacking exon 3 and 4. For man, there is only a
single EST from a lung small cell carcinoma. As a com-
parison, for TG2 the UniGeneTM EST profile lists over
29,000 ESTs in normal human tissues alone.
TG6 origin in evolution
Alignment of TG sequences selected to represent major
branches of animal evolution (Fig. 1f) indicates that the
invertebrate and low chordata proteins are most closely
related to the vertebrate isoforms TG4 and TG1. The factor
XIII a-subunit derives from the same branch as TG1. The
band 4.2 proteins show large divergence between species
indicating low evolutionary pressure for conservation. In
contrast to the mammalian and amphibian sequences, the
three reported avian band 4.2 sequences do contain the
catalytic triad residues indicating that these proteins may
function as active enzyme. Within the vertebrate TGs, the
enzymatically inactive band 4.2 protein and TG2 form
separate branches. The TG5/TG7 and TG3/TG6 pairs, each
encoded by genes located closely together on the same
chromosomes, are most closely related. A closer inspection
reveals that the frog sequences marked xTG5 and xTG6 in
Fig. 1f have ambivalent characteristics, and depending on
the settings of alignment parameters could be also regarded
as xTG7 and xTG3, respectively. Similarly, two bird
sequences are predicted, which share characteristics of the
TG5 and TG7 families. These data suggest that TG5/TG7
and TG3/TG6 arose from tandem gene duplication. We
have previously proposed that two genome duplications in
Fig. 1 Analysis of human TGM6 gene products. a Size of transcripts
expressed in H69 cells. Northern blot containing 5 lg of poly(A?)
RNA from H69 cells that was probed with a 0.7 kb antisense RNA
corresponding to the two C-terminal b-barrel domains of TG6. The
migration position of RNA size markers is indicated on the right and
the full-length TG6 transcript with an arrow. b RT-PCR analysis
identified two transcripts in H69 cells. PCR products spanning the
relevant region of the transcript (left) were separated in a 1% agarose
gel calibrated with the 1-kb ladder (right). These were identified by
sequencing to result from alternative splicing of exon 12 (Supple-
mental Fig. 3). c Schematic illustrating the relationship between gene
organization and protein structure in the TG family. TG4 contains an
additional exon, exon 1B, within intron 1 (Cho et al. 2010) that can
differentially be spliced in and encodes 45 amino acids. The band
4.2L variant contains an extended exon 1 (hatched box) (Sung et al.
1992). Variability in the 50 UTR has been reported in several TGM
genes but does not alter the sequence of the protein encoded.
Polyadenylated transcripts for TG6 isolated from H69 cells (hTG6)
and mouse brain (mTG6) are shown underneath: L denotes full-length
TG6, S TG6 lacking exon 12, d3 TG6 lacking exon 3 and d3,4 TG6
lacking exon 3 and 4. d Detection of TG6 in extracts of human
keratinocytes (lane 1) or HEK293 cells transfected with hTG6-L (lane
2) or hTG6-S (lane 3) expression constructs by Western blotting.
10 lg extracted protein was separated by SDS–PAGE under reducing
conditions, transferred to nitrocellulose membranes and labelled with
antibodies to TG6. Mr standards are indicated on the left. Keratino-
cytes express TG6-L but not TG6-S indicating that alternative
splicing is cell-type dependent. e Transamidation activity of
recombinant hTG6-L. The time-course for the incorporation of
biotin-x-cadaverine into N,N-dimethylcasein with different concen-
trations of TG6 or TG2 was determined. Activity was Ca2?-
dependent and maximal at [Ca2?] [ 1 mM (data for TG6 shown in
insert). The data are shown as mean ± SD. f Protein sequence
relationship of TGs. The dendrogram is based on a multiple sequence
alignment of TGs including coagulation factor XIII a-subunit (F13A)
and eryhtrocyte protein band 4.2 (EB42) from various species
(c chicken, h human, m mouse, x frog, Xenopus tropicalis, z zebra
fish, Danio rerio, dr fruit fly, Drosophila melanogaster, hb honey bee,
Apis mellifera, hc horseshoe crab, Tachypleus tridentatus, gh grass
hopper, Schistocerca americana, hy hydra, Hydra magnipapillata, pw
pork worm, Trichinella spiralis, py Physarum polycephalum, sa sea
anemonae, Nematostella vectensis, sf starfish, Asterina pectinifera, ss
sea squirt, Ciona intestinalis). The TG6 branches adjacent to TG3 are
highlighted by an arrow. All sequences except for the human, mouse
and frog band 4.2 protein contain the Cys, His and Asp residues of the
catalytic triad
c
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early vertebrates may have given rise to ancestral TGM1,
F13A1, TGMn and TGM4 genes and the ‘TGMn’ branch
subsequently further specified through tandem duplication
to form the full complement of TG genes in mammals
(TG2/3/5-7/EPB42; Grenard et al. 2001). The observation
of four principle TG branches for the higher chordata is
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consistent with the hypothesis of at least one whole gen-
ome duplication occurring after the urochordate ascidian
Ciona intestinalis, as it has been proposed based on gen-
ome comparisons of ancestral vertebrates (Dehal and
Boore 2005). More than one TG genes are also present in
some protostome genomes. However, these appear to have
arisen from gene duplication during prototsome speciation
independent from evolution of the TGM genes found in
vertebrates.
TG6 architecture predicted by molecular modelling
Based on the high sequence similarity between TG6 and
TG3 (overall sequence identity: 50 with 59% within the
catalytic core domain), we used the high-resolution X-ray
derived human TG3 structure (activated form with three
bound calcium ions) as a template for generating a model
of human TG6-L (Fig. 2a). The flexible solvent exposed
loop, which is not resolved in the X-ray structure connects
the last a-helical region of the catalytic core to the first
b-strand of the b-barrel 1 domain. The active site catalytic
triad residues C274, H333 and D356 are at the base of a
cavity, which is bound by the catalytic core and b-barrel 1
domains, and buried in a hydrophobic pocket, as in the case
of TG3 (Fig. 2b). Consistent with biochemical data and the
interpretation of the TG3 structure (Folk and Chung 1973;
Ahvazi et al. 2002; Ahvazi and Steinert 2003), it can be
assumed that the sulfhydryl group of C274 can form a
thiolate-imidazolium ion pair with H333. The second
nitrogen atom of the H333 ring is in hydrogen-bonding
distance to the side chain oxygen atom of D356. The indole
rings of the two tryptophan residues W238 and W330 are
buried near the surface as in TG3 (W236, W327). It has
been proposed that as a suitable glutamyl substrate
approaches, an oxyanion intermediate forms with the for-
mer tryptophan, which results in break-down of the sub-
strate to release NH3 and forms a thiol-acyl intermediate
with the enzyme. This intermediate is attacked by the
e-amine of a lysyl substrate to form another tetrahedral
oxyanion intermediate with the latter tryptophan resulting
in a cross-linked product (Pedersen et al. 1994). As in the
TG3 structure, the corresponding hydroxyl oxygen of Y538
from the b-barrel 1 domain is within hydrogen-bonding
distance of C274 and W238 and is located in the loop of
the sequence motif I536–T539 that obstructs the entrance
to the active site. The pair of serine residue S469;S470 in
TG3, which serve as cleavage site for proteolytic activation
by cathepsin L (Cheng et al. 2006), is not found in TG6
though cleavage by another enzyme cannot be ruled out.
However, TG6 has a high specific activity in the absence of
proteolytic processing (Fig. 1d). A redox-sensitive Cys
switch that is involved in oxidative inactivation of TG2
through formation of a vicinal disulfide bond (Cys370–
Cys371) (Stamnaes et al. 2010a) is not replicated in TG6 in
the same form as Cys230 is replaced by a serine residue.
Nevertheless, TG6 is profoundly sensitive to oxidative
inactivation.
Regulation of TG6 by co-factors
It is well established that transamidation activity of TGs
requires binding of calcium ions (Folk and Chung 1973).
As expected, activation of TG6 requires Ca2?-binding and
TG6 was found to display a similar concentration-
dependence for activation as TG2 (Fig. 1e). In the case of
factor XIII a, the activated enzyme contains a single
calcium ion in a position near to the catalytic site (Fox
et al. 1999) though its binding does not markedly alter the
structure. For the zymogen form of TG3, a single tightly
bound calcium ion has been found, but two further ions
are bound upon proteolytic activation (Ahvazi et al.
2002). In our model of TG6, the highest affinity binding
site 1 observed for TG3 is well conserved bringing the
main chain carbonyl oxygen atoms of A223, N226, N228
and the side chain oxygens of N226, and D230 into
coordinating distance of the TG3 inferred calcium ion
position (Fig. 2c). A second calcium-binding site can be
inferred to be formed by residues close to the C-terminal
end of the catalytic core domain adjacent to the loop
which joins the b-barrel 1 domain. The main chain oxy-
gen atom of T417, and side-chain oxygens of N396, E445
and E450 are in a position to coordinate a calcium ion. In
the case of TG3, calcium access to the related site in the
zymogen form is hampered by the flexible loop (residues
462–471), which must be cleaved to allow entry. We do
not yet know whether such a cleavage occurs in the case
of TG6, though it could be speculated that the 11 residues
longer loop might be more flexible to allow entry to this
site, and this is supported by the high specific activity of
the intact TG6 (Fig. 1e). A third calcium-binding site
reported for activated TG3 is found adjacent to the cat-
alytic triad histidine residue within a loop the position of
which is shifted upon activation. The residues involved in
calcium coordination are all conserved within the TG6
sequence and structural modelling suggests a corre-
sponding orientation with the main chain carbonyl of
S309 and side chain oxygen atoms of D303, D305, D327
and N307 as putative calcium acceptor sites.
It has been shown for TG2 (Achyuthan and Greenberg
1987; Im et al. 1990), TG3 (Boeshans et al. 2007) and TG5
(Candi et al. 2004) that enzymatic activity is inhibited by
purine nucleotides. Ca2?-binding and nucleotide binding
occur at different sites and stabilize distinct conformations
of TGs. The affinity of GTP is substantially reduced in the
presence of extracellular Ca2? concentrations allowing
enzyme activation. In contrast to ATP, the affinity for GTP
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and Mg-GTP is high and therefore of biological signifi-
cance. Besides inhibiting transamidation activity intracel-
lularly, independent functions of GTP binding and
hydrolysis in intracellular signalling have been proposed
for TG2 (Im et al. 1990; Stephens et al. 2004; Iismaa et al.
2009).
Fig. 2 Model of the structure of human TG6-L and its interaction
with nucleotides. a The overall structure as modelled based on the
calcium activated TG3 form is shown. Cylinders and arrows denote
a-helical and b-strand conformations, respectively. The four domains
(b sandwich, residues 3–136; catalytic core, res. 137–462; b-barrel 1,
res. 494–605; b-barrel 2, res. 606–706) are depicted in different
colours. The position of the three bound calcium ions of TG3 is
shown by numbered yellow spheres. The residues of the catalytic triad
are depicted in space-filling style. The flexible loop (res. 463–492)
connecting the catalytic core with the b-barrel 1 domain has been
deleted as the corresponding part is not resolved in the TG3 X-ray
structure. b The residues of the catalytic triad and the adjacent
tryptophan and tyrosine residues, the positions of which are proposed
to be modulated by calcium (yellow spheres) binding, are shown as
ball-and-stick and stick models, respectively. The side chain oxygen
of Y538 is in hydrogen-bonding distance to the sulphur atom of C274.
c Oxygen atoms of TG6 residues, which are within 3.5 A˚ distance of
the calcium ion sites of the TG3 template, are shown as red spheres.
Further calcium coordination could arise from water molecules not
included in the modelling. d Transamidation activity (measured as
isopeptide replacement activity) of TG6 (closed symbols; solid lines)
and TG2 (open symbols, dashed lines) was measured in the presence
of various concentrations of nucleotides, and half-maximum activity
is indicated by a dotted line: GTP, black; GTP in the presence of
1 mM Mg2?, orange; GTPcS, green; GDP, magenta; GMP, blue; and
ATP, red. Symbols indicate representative values of duplicate
independent measurements. e The putative nucleotide-binding pocket
was inferred from the GDP-bound TG2 structure. A semitransparent
surface showing the electrostatic potential (blue positive, red
negative) is overlaid over the residues surrounding a GDP molecule
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We therefore determined the transamidation activity
of TG6 in the presence of various nucleotides (Fig. 2d)
using a quenched fluorescent substrate, Abz-APE(c-cad-
Dnp)QEA, for real-time monitoring as suggested by
Lorand and co-workers (Parameswaran et al. 1997). Folk’s
work has shown that the reaction occurs in a two-step
mechanism whereby the active site thiol is transiently
acylated by the c-carboxamide group of the peptide-bound
glutamine to form a stable acyl-enzyme intermediate. The
second step involves either hydrolysis to convert Q to E or
aminolysis by reaction with a primary amine to form the
isopeptide bond and this is rate-limiting (Folk and Chung
1973). This reaction is reversible and steady-state kinetics
can be performed by coupling isopeptide hydrolysis to a
second reaction driven by an excess amine donor substrate.
Given that the reactive nucleophilic form of the substrate is
the neutral amine, maximum substrate conversion is
achieved with amines deprotonated at physiological pH
such as glycinemethylester or ethylene diamine (pKa \ 7)
(Leblanc et al. 2001). The sequence of the fluorescent
substrate is based on the amine acceptor site of osteonectin/
BM-40/SPARC for TG2 (Hohenadl et al. 1995). Never-
theless, the kinetic parameters given in Table 1 show that
this peptide is a better substrate for TG6 than for TG2.
When compared with TG2, a *50-fold higher concentra-
tion of GTP (200 lM) is required for half-maximal inhi-
bition of TG6, whereas for ATP (*1 mM) similarly high
concentrations are needed. The non-hydrolyzable GTP
analogue GTPcS is a more effective inhibitor than GTP as
has been reported for TG2 (Achyuthan and Greenberg
1987). Activity of TG6 is inhibited to a similar degree by
GTP and GDP both in the absence and presence of
1 mM Mg2?, but the affinity for GMP is low. Taken
together, these data suggest that TG6 has the potential to
function as a guanine nucleotide exchange factor in
receptor signalling similar to TG2.
Based on the GDP-bound form of human TG2 (PDB
code 1KV3, chain C, Liu et al. 2002), we modelled a
putative corresponding nucleotide-binding pocket between
the catalytic and b-barrel 1 domains (Fig. 2e). Such a TG6
GDP-binding site would be delineated by residues K170
and H171 from the catalytic domain, and K498 to P505 as
well as K600 to E605 from the b-barrel 1 domain. The
e-amino groups of lysine residues 170, 498, 500 and 600
envelop the phosphate groups of GDP, whereas V501–
P505 and L604 surround the guanine group which is
stacked by the imidazole ring of H171. In TG2, R478 and
R580 form two ion pairs with the GDP a- and b-phos-
phates. These residues are replaced by K500 and K600 in
TG6. S482 and Y583 of TG2, which form hydrogen bonds
with the N1 and N2 atoms of the guanine base are replaced
by P505 and T603, respectively, in TG6 of which the main
chain oxygen of T603 hydrogen bonds to N1 and N2, and
its oxygen to O6. Although the fold around a putative GDP
molecule can be well adopted by TG6, the reduced number
of interactions could be the cause for the observed decrease
in nucleotide affinity (Fig. 2d).
Substrate specificity
There is a large degree of overlap in glutamine donor
substrates of TG6, TG3, and TG2. On the level of fine
specificity, however, clear differences exist. In peptides,
TG2 has a highly sequence-dependent targeting (Gorman
and Folk 1984; Vader et al. 2002; Hitomi et al. 2009),
whereas TG6 shows tolerance to a broader spectrum of
sequence changes in the neighbouring amino acids
(Stamnaes et al. 2010b). The most significant influence on
substrate properties is exerted by proline residues. None
of the enzymes can modify glutamine residues directly
followed by proline (-QP-), whereas proline at position
?2 (-QXP-) exerts a positive influence. Furthermore,
while all three enzymes readily target -PQ- sequences,
proline in position -2 (-PPQ-) has a detrimental effect on
recognition by TG2, but not TG6 or TG3. An indication
that different positions may have a greater impact on
Fig. 3 TG6 expression in mouse development. a Amplification of
TGs from mouse whole brain cDNA. Products amplified with primers
specific for TG1 (lane 1, 182 bp), TG2 (2, 177 bp), TG3 (3, 157 bp),
TG5 (5, 135 bp), TG6 (6, 171 bp), and TG7 (7, 126 bp) could be
detected but not TG4 (lane 4), factor XIII a-subunit (lane 8) and band
4.2 protein (lane 9). Products were analysed by electrophoresis in a
1% agarose gel calibrated with the 1-kb ladder. b TG6 expression in
the developing and mature mouse brain. In situ hybrization was
carried out with antisense (b) and sense (c) DIG-labelled TG6 RNA
probes on serial sagittal sections of a newborn mouse or adult mouse
brain (dark brown labelling with alkaline phosphatase and NBT/
BCIP). A section stained with luxol fast blue/cresyl violet a shows the
myelin and nuclei of nerve cells. C cortex, Cer cerebellum, ChP
choroid plexus, Hip hippocampus, Mid mid brain, St striatum, Tha
thalamus. Higher magnification images demonstrate labelling of cells
in the cerebral cortex at P0 (d) and in mature brain (e) through layers
II–VI, in Purkinje cells of the cerebellum (g) and keratinocytes in the
epidermis and forming the hair shaft (h). Immunostaining of P0 serial
section with antibodies recognizing the hinge region of TG6 confirms
protein expression within the cell layers forming the motor cortex
(red brown labelling with HRP and AEC) (f) and cells within grey
matter of the spinal cord (FITC) (i). WM white matter, GM grey
matter. c Sections of mouse embryo at the indicated developmental
stages were hybrized with the antisense TG6 RNA probe. Images a–
c depict a sagittal section through the developing head and images d–
f a close-up of the telencephalon. A schematic illustrating the
development of the cerebral cortex together with hematoxylin/eosin
stained sections of the developing cerebral cortex at E11 and E16 is
given in g. The cortical plate (CP) which will give rise to the
multilayered neocortex (layers I–VI) develops between the marginal
zone (MZ) and subplate (SP) which is derived from the preplate (PP).
Pyramidal neurons within layer V/VI differentiate first and are
positive for b-tubulin III by E16. Immunostaining for TG6 labels CP
and layers V/VI of neocortex at E16 (g) whereas TG6 RNA
expression is predominant in CP (f). IZ intermediate zone, SVZ
subventricular zone, VZ ventricular zone
c
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substrate recognition by the different enzymes comes
from the observed differences in relation to altered pep-
tide length N- or C-terminal to the reactive glutamine
residue. TG6 and TG2 are profoundly sensitive to the
C-terminal sequence, whereas reactivity of TG3 with
peptide substrates is primarily influenced by the sequence
N-terminal to the glutamine residue (Stamnaes et al.
2010b). TG6 can both deamidate (Stamnaes et al. 2010b)
and transamidate (Fig. 1d) glutamine residues, but it has
not been determined yet for TG6 whether the type of
modification that occurs preferentially is influenced by the
sequence context as has been demonstrated for TG2
(Boros et al. 2006).
TG6 is associated with neuronal differentiation
in the central nervous system
RT-PCR from mouse brain cDNA using specific primers
for TG6 and also the other members of the TG family
revealed expression of TG1, TG2, TG3, TG5, TG6 and
TG7 (Fig. 3a). These results are consistent with demon-
stration of expression of TG1, TG2, TG3, and TG5 in the
brain (Kim et al. 1999; Bailey and Johnson 2004; Bailey
et al. 2004) and together with cell biological studies points
to a highly complex regulation of TG genes in the CNS. To
obtain a clearer understanding of TG6 expression on the
cellular level, in situ hybridisation was performed on sag-
ittal newborn mouse sections. An antisense RNA fragment
corresponding to the C-terminal end of TG6 was used as a
probe as this area has the least similarity between the dif-
ferent TGs and a similar human probe gave no cross-
hybridisation with other TG gene products in Northern
blotting. In situ hybridisation revealed that TG6 expression
is widespread in the brain (Fig. 3b), most prominently
within the cell layers containing the neuronal cell bodies of
the cerebral cortex (particularly layers II–IV containing
granular neurons and pyramidal cells) (image d), olfactory
lobe (data not shown; see Fig. 3c, image c) and the cere-
bellum (Purkinje cells) (image g). TG6 expression was
detected in the spinal cord (image i) and in the retinal cells
of the eye (data not shown). TG6 was expressed in tissues
other than the CNS, most prominently in the skin (image h)
and other stratified squamous epithelia. Interestingly, these
cells derive embryologically from a common ectodermal
progenitor. Immunolabelling with antibodies confirmed
TG6 protein expression (image f).
Given the prominent expression of TG6 in the CNS in
the developed organism, we were interested to identify
whether the induction of TG6 expression correlated with
any specific events in development. While the CNS is the
first organ system to develop and to differentiate, it is also
one of the last to be completed. The primary parts of the
mouse brain can be identified soon after the neural groove,
neural plate and head process stage at E7.5, and by day E14
has the typical anatomical layout of a mammalian brain.
The neocortex is a highly organized six-layered structure
that contains hundreds of different neuronal cell types and
various subsets of glia. Progenitors residing in the ven-
tricular zone produce the neurons of the different neocor-
tical layers in a tightly controlled temporal order between
about days E11 and E17.5 (Molyneaux et al. 2007). In situ
hybridisation was therefore carried out on stage E11, E13
and E16 embryos (Fig. 3c). The walls of the primitive
brain divide into an inner ependymal, an intermediate
mantel, and outer marginal layer by E10, whereby the
ependymal layer that ultimately forms the lining of the
ventricles of the brain is the thickest layer. At E11, active
proliferation of neuroblastic cells occurs in the walls of the
entire CNS and these begin to occlude some of the neural
cavities. Up to E11, the major neuroblastic activity is
occurring behind the hindbrain where cranial ganglia V to
IX develop. Little TG6 expression can be detected in the
brain at E11 while labelling can be seen in the developing
spinal cord (Fig. 3c, image a, arrow). By E13, TG6
expression is apparent in several parts of the brain and
strong expression can now be detected in regions under-
going neuronal differentiation such as the mesencephalon
(image b, arrow). From E13 to 16, the major neuroblastic
activity occurs in the telencephalon where cells from the
mantle layer migrate into the overlying marginal zone to
form the neocortex which will become the outer grey
matter of the cerebral hemispheres. At E13, TG6 expres-
sion is detected in a thin layer of the neocortex, presumably
progenitor cells constituting the preplate (image e). By
E16, TG6 is highly expressed in the outer layers of the
neocortex (image f). TG6 mRNA expression is most
prominent within the area of the cortical plate where
neuronal differentiation occurs to form layers II–IV (image
Table 1 Kinetic parameters of TG2 and TG6 for the replacement reaction of Abz-APE(c-cad-Dnp)QEA at 37C, pH 7.4, in the presence of an
excess glycinemethylester
vmax (M/s) kcat (/s) KM (M) kcat/KM (/M s)
TG2 0.83 ± 0.14 9 10-9 3.2 ± 0.5 9 10-3 110 ± 23 9 10-6 0.30 ± 0.07 9 102
TG6 2.6 ± 0.4 9 10-9 10.1 ± 1.6 9 10-3 49 ± 12 9 10-6 2.1 ± 0.6 9 102
Calculations were based on a molecular mass of 77 and 79 kDa for TG2 and TG6, respectively. The data are shown as mean ± SD
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f). TG6 protein is most prominent within layers V/VI
where postmitotic neurons can be labelled for b-tubulin III
at this stage (image g). Induction of TG6 expression
appears to correlate both spatially and temporally with
neurogenesis. In contrast, in situ hybridisation with a TG5
antisense RNA probe showed widespread expression
throughout the CNS by E11 (data not shown).
Towards the latter stages of corticogenesis, astrocytes
differentiate from radial glia. To clarify whether TG6
expression was associated with neurogenesis or astrocyte
differentiation, progenitors were isolated from P0 stage
mouse cortex and expanded in suspension culture as
neurospheres (Murayama et al. 2002). To induce neuronal
differentiation, progenitors were seeded on a laminin-111
substrate in the absence of mitogen for 5 days and subse-
quently labelled for TG6 and cell lineage markers. Cells of
the neuronal lineage were identified using antibodies
against b-tubulin III (Tuj-1), astrocytes with antibodies to
glial fibrillary acidic protein (GFAP) and oligodendrocytes
with RIP-antibodies (Sergent-Tanguy et al. 2003). Immu-
nocytochemistry confirmed expression of TG6 in neuronal
cells and its absence from the astroglial and oligoden-
droglial lineage (Fig. 4a). To exclude de novo expression
of TG6 in neurons as a consequence of culture conditions,
freshly isolated cells from the cerebral cortex of newborn
mice were double-labelled with antibodies to TG6 and to
the above cell lineage markers and analysed by FACS. 81%
of cells were positive for TG6 and 58% for b-tubulin III,
with 99% of b-tubulin III positive cells also positive for
TG6. Physical parameters can be used to distinguish neu-
rons, astrocytes and microglial cells as they differ in size
and morphology (Sergent-Tanguy et al. 2003). Therefore,
we plotted forward scatter (FSC), representing cell size, as
a function of fluorescence intensity for TG6 labelling.
Within the broad distribution of cells expressing TG6, two
clusters of cells of different size were apparent and were
gated (Supplemental Fig. 4, R1 and R2). Further analysis
of gated cells for expression of cell lineage markers
showed that both clusters were exclusively positive for
b-tubulin III indicating that they are derived from the
neuronal lineage and represent different neuronal popula-
tions (Supplemental Fig. 4).
Neuro2A is a mouse neural crest-derived cell line that
has been extensively used to study neuronal differentia-
tion, and specification into different neuronal lineages is
possible (Tremblay et al. 2010). We initially confirmed
that non-lineage-specific differentiation in low serum
induced TG6 expression and subsequently used a number
of differentiation factors to induce lineage-specific dif-
ferentiation (Fig. 4b). Non-cholinergic differentiation with
neurotrophin NGF was associated with strong upregula-
tion of TG6. TG6 expression was also induced upon
dopaminergic differentiation using dibutyryl cAMP,
whereas TG6 was not upregulated in cells treated with
retinoic acid, a known inhibitor of dopaminergic differ-
entiation. Quantitative PCR indicated that TG6 expression
was upregulated twofold upon serum starvation and
fourfold by dibutyryl cAMP. Dopamine neurons are
formed in the olfactory lobe and retina during embryonic
development, two areas where strong TG6 expression was
seen in in situ hybridization (Fig. 3). However, the
highest level of TG6 expression in Neuro 2a cells was
observed upon induction of cell death by metal ion che-
lation suggesting that the strong TG6 expression observed
during cerebral cortex development may relate in parts to
association with programmed cell death rather than neu-
ronal differentiation.
Cerebellar ataxia as consequence of genetic defects
in TGM6 gene or acquired autoimmunity to TG6
Celiac disease (CD) is a common T cell-mediated auto-
immune disorder characterized by its linkage to specific
human lymphocyte antigen alleles, HLA-DQ2 and -DQ8
(Jabri and Sollid 2009). In susceptible individuals, con-
sumption of gluten triggers a CD4? T-cell response to
gliadin as well as a B cell response to gliadin and self
antigens. TG2 contributes to disease development in at
least two ways: first, by deamidating gluten peptides,
thereby increasing their reactivity with HLA-DQ2/DQ8,
which potentiates the T-cell response (Molberg et al. 1998;
Van de Wal et al. 1998). Second, TG2 is the major auto-
antigen targeted by the B cell response (Dietrich et al.
1997). Although the T-cell response in the mucosa of the
small intestine is the key player in disease development,
gluten sensitivity is a systemic disease and autoantibodies
may play a role in extraintestinal pathogenesis (Caja et al.
2011). This is supported by the recent demonstration of
circulation derived anti-TG3 autoantibodies inducing a
dermatitis herpetiformis-like pathology in human skin-
grafted SCID mice (Zone et al. 2011). Neurological
disorders have also been recognised as a form of extrain-
testinal manifestation of gluten sensitivity, with cerebellar
involvement (gluten ataxia) and peripheral nerve involve-
ment (gluten neuropathy) being the most common pre-
sentations (Hadjivassiliou et al. 2010). We have shown that
gluten ataxia patients develop autoantibodies that are spe-
cific to TG6 (Hadjivassiliou et al. 2008). Furthermore,
antibodies isolated from celiac disease patients are fre-
quently reactive with human and mouse neurons. However,
this neuronal reactivity is specific for antibodies that are
crossreactive between the closely related TG2, TG3 and
TG6 enzymes and is not mediated by TG2 as it is preserved
in a TG2-/- background (Boscolo et al. 2010). This
is consistent with TG2 being primarily associated with
the vasculature in non-disease brain (Aeschlimann and
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Paulsson 1991; Hadjivassiliou et al. 2008; Boscolo et al.
2010) and suggests that TG6 may be the neuronal auto-
antigen recognised in these patients. To test whether
patient-derived autoantibodies directly contribute to
pathology we attempted passive disease transfer. Serum
immunoglobulin from gluten ataxia patients, as well as
clonal anti-TG immunoglobulins derived using phage dis-
play, caused deficits in motor coordination but not anxiety
when injected intraventricularly in mice (Boscolo et al.
2010). The fact that isolated anti-TG immunoglobulins
induce dramatic ataxia-like deficits in mice indicates
selective neurotoxicity of anti-TG antibodies once exposed
to the CNS and suggests that antibodies may play a role in
disease transfer to the CNS. However, both scFv crossre-
active between different TGs and TG2-specific scFv
compromised motor coordination in mice.
Fig. 4 a Confirmation of neurons as the primary source for TG6
expression in the mouse cerebral cortex. Progenitor cells from
newborn mouse forebrain were grown as neurospheres and subse-
quently differentiated by culture in defined medium for 5 days on a
laminin-111 substrate and double stained for TG6 (TRITC) and
different cell markers (FITC): b-tubulin III isoform for neurons (a),
GFAP for astrocytes (b, c). Co-expression of TG6 with b-tubulin III is
highlighted by colour mixing (yellow, a). TG6 shows discrete
subcellular distribution in large protein complexes or vesicles
surrounding the nucleus and also in neurites (d, arrows). Left images
in a, b and inset in d provide DIC images of the field of view shown
under fluorescence illumination. Size bar 40 lm (a). b TG6 expres-
sion is upregulated concomitant with differentiation of Neuro 2a
mouse neuroblastoma cells. Neuro 2a cells were grown with 10%
FCS (a) or induced to differentiate by serum starvation (0.5% FCS)
(b) or serum starvation in combination with NGF (50 ng/ml) (c) or
dibutyryl cAMP (1 mM) (d) stimulation. After 3 days, cells were
labelled with antibodies to TG6 (alexa fluor 568, bottom panels) and
nuclei counterstained with Hoechst 34580. Upper panels provide DIC
images of the field of view to illustrate changes in cell morphology.
Size bar 10 lm (a)
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Cerebellar ataxias are a complex and heterogeneous
group of neurodegenerative diseases characterized by
progressive imbalance and limb movement deficits. About
20% of cerebellar ataxias display a familial inheritance
pattern. So far, 30 different genetic loci have been linked to
different SCA subtypes and 19 causative genes identified.
Among those are CAG repeat expansion diseases including
SCA1–3, 6–8, 12, 17, 31 and DRPLA and non-repeat
mutations such as SCA 5, 11, 13–16, 27 and 28. A recent
paper identified mutations in TGM6 in two Chinese fami-
lies with autosomal dominant ataxia using linkage analysis
and exome sequencing (Wang et al. 2010). Taken together
with our demonstration of neuronal expression of TG6 and
the presence of autoantibodies to TG6 in immune-mediated
ataxia, this suggests that TG6 may play an important role in
neurons involved in motor control. The mutations identi-
fied in TGM6 are single nucleotide exchanges leading to
alteration of amino acid residues that are strictly conserved
in TG6 among different species (D327G, L517W). Struc-
tural modelling suggests that the former substitution could
interfere with Ca2? binding at site 3 (Fig. 2c) and may
therefore compromise enzyme activation, whereas the
deleterious effect of the latter substitution remains obscure.
It is also not clear why mutation of a single allele should
produce a dominant ataxia phenotype. Haploinsufficiency
is possible but one might also speculate that the problem is
unrelated to the catalytic function and could be caused by
difficulties in folding of mutant proteins and this may
ultimately be neurotoxic. It is also interesting to note that
alternative splicing or mutations in TG2 that affect its
regulation by GTP have been shown to have dramatic
effects on neuronal differentiation and to be pro-apoptotic
in different cell types (Antonyak et al. 2006; Tee et al.
2010).
In order to gain a better understanding of the TG6-
related pathology further work needs to address the phys-
iological function of TG6 in the CNS. Given that TG6
similar to TG2 is a protein that can be detected in the cell
cytosol as well as at the cell surface it may have inde-
pendent intra- and extracellular functions that may employ
the enzyme’s ability to bind GTP or act as a Ca2?-depen-
dent crosslinking enzyme, respectively. Recent progress in
the development of more isozyme-specific inhibitors may
facilitate the elucidation of the context within which TG6
is activated and plays a critical role.
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Appendix 4 
Sequencing data P2X7Rstop clone 3                                                                    
 
T7 forward result: 
 
                           10        20        30        40        50      
gi_33877741_  T-----MPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQRK 
              :     :::::::::::::::::::::::::::::::::::::::::::::::::::::: 
P2X7Rstop cl  TLGTFTMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQRK 
                      10        20        30        40        50        60 
 
                 60        70        80        90       100       110      
gi_33877741_  EPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEGQ 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
P2X7Rstop cl  EPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEGQ 
                      70        80        90       100       110       120 
 
                120       130       140       150       160       170      
gi_33877741_  EQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAVE 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
P2X7Rstop cl  EQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAVE 
                     130       140       150       160       170       180 
 
                180       190       200       210       220       230      
gi_33877741_  EAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDI 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
P2X7Rstop cl  EAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDI 
                     190       200       210       220       230       240 
 
                240       250       260       270       280       290      
gi_33877741_  FRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFR 
              ::::::::::::::::::::::::::::::::::::::::::::::.       :      
P2X7Rstop cl  FRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDR-------P----- 
                     250       260       270       280 
 
 
 
P2X7R-for-3 results: 
                                                10        20        30     
P2X7Rstop cl  --------------------------ENILPGLNITCTFHKTQNPQCPIFRLGDIFRETG 
                                        .::::::::::::::::::::::::::::::::: 
gi_33877741_  ALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETG 
                     190       200       210       220       230       240 
 
                  40        50        60        70        80        90     
P2X7Rstop cl  DNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYY 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  DNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYY 
                     250       260       270       280       290       300 
 
                 100       110       120       130       140       150     
P2X7Rstop cl  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
                     310       320       330       340       350       360 
 
                 160       170       180       190       200       210     
P2X7Rstop cl  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
                     370       380       390       400       410       420 
 
                 220       230       240       250       260       270     
P2X7Rstop cl  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
                     430       440       450       460       470       480 
 
                 280       290       300                                   
P2X7Rstop cl  GSCLPSQLPESHRCLEELCCRKKPGACITTSEL--------------------------- 
              :::::::::::::::::::::::::::::::::                            
gi_33877741_  GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
 
pCR3.1-BGH reverse result: 
 
P2X7Rstop cl  --------------------------------------------------------AKYY 
                                                                      :::: 
gi_33877741_  DNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYY 
                     250       260       270       280       290       300 
 
                  10        20        30        40        50        60     
P2X7Rstop cl  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
                     310       320       330       340       350       360 
 
                  70        80        90       100       110       120     
P2X7Rstop cl  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
                     370       380       390       400       410       420 
 
                 130       140       150       160       170       180     
P2X7Rstop cl  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
                     430       440       450       460       470       480 
 
                 190       200       210       220       230       240     
P2X7Rstop cl  GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
                     490       500       510       520       530       540 
 
                 250       260       270       280       290       300     
P2X7Rstop cl  STNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY*LESR 
              ::::::::::::::::::::::::::::::::::::::::::::::::::::::::     
gi_33877741_  STNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY---- 
                     550       560       570       580       590           
 
                 310       320       330  
P2X7Rstop cl  GPFEGKPIPNPLLGLDSTRTGHHHHHH 
                                   
gi_33877741_  --------------------------- 
 
 
turquoise = V5-His tag                                   
              
 
Sequencing data P2X7R-V5-His clone 3                                                                    
 
T7 forward result: 
                      10        20        30        40        50        60 
P2X7R clone   LKLGTFTMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQR 
                    :::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  ------TMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQR 
                            10        20        30        40        50     
 
                      70        80        90       100       110       120 
P2X7R clone   KEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEG 
                  60        70        80        90       100       110     
 
                     130       140       150       160       170       180 
P2X7R clone   QEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAV 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  QEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAV 
                 120       130       140       150       160       170     
 
                     190       200       210       220       230       240 
P2X7R clone   EEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGD 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  EEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGD 
                 180       190       200       210       220       230     
 
                     250       260       270       280       290       300 
P2X7R clone   IFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNF 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  IFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNF 
                 240       250       260       270       280       290     
 
                     310       320                                         
P2X7R clone   RYAKYYKENNVEKRTLIKVFGIR------------------------------------- 
              :::::::::::::::::::::::                                      
gi_33877741_  RYAKYYKENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDF 
                 300       310       320       330       340       350   
 
P2X7R-for-3 results: 
 
P2X7R clone   ------------------------------------------------------------ 
                                                                    
gi_33877741_  TMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQRKEPVIS 
                      10        20        30        40        50        60 
 
                                                                    
P2X7R clone   ------------------------------------------------------------ 
                                                                    
gi_33877741_  SVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEGQEQRLC 
                      70        80        90       100       110       120 
 
                                                                    
P2X7R clone   ------------------------------------------------------------ 
                                                                    
gi_33877741_  PEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAVEEAPRP 
                     130       140       150       160       170       180 
 
                                                10        20        30     
P2X7R clone   --------------------------ENILPGLNITCTFHKTQNPQCPIFRLGDIFRETG 
                                        .::::::::::::::::::::::::::::::::: 
gi_33877741_  ALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETG 
                     190       200       210       220       230       240 
 
                  40        50        60        70        80        90     
P2X7R clone   DNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYY 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  DNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYY 
                     250       260       270       280       290       300 
 
                 100       110       120       130       140       150     
P2X7R clone   KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
                     310       320       330       340       350       360 
 
                 160       170       180       190       200       210     
P2X7R clone   SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
                     370       380       390       400       410       420 
 
                 220       230       240       250       260       270     
P2X7R clone   SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
                     430       440       450       460       470       480 
 
                 280       290       300       310                         
P2X7R clone   GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRK------------------------ 
              ::::::::::::::::::::::::::::::::::::                         
gi_33877741_  GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
                     490       500       510       520       530       540 
 
pCR3.1-BGH reverse result: 
 
                  10        20        30        40        50        60     
P2X7R clone   KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYS 
                     310       320       330       340       350       360 
 
                  70        80        90       100       110       120     
P2X7R clone   SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGR 
                     370       380       390       400       410       420 
 
                 130       140       150       160       170       180     
P2X7R clone   SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQC 
                     430       440       450       460       470       480 
 
                 190       200       210       220       230       240     
P2X7R clone   GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  GSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVD 
                     490       500       510       520       530       540 
 
                 250       260       270       280       290       300     
P2X7R clone   STNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPYLESR 
              ::::::::::::::::::::::::::::::::::::::::::::::::::::::::     
gi_33877741_  STNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY---- 
                     550       560       570       580       590           
 
                 310       320       330  
P2X7R clone   GPFEGKPIPNPLLGLDSTRTGHHHHHH 
                                   
gi_33877741_  --------------------------- 
 
turquoise = V5-His tag     
Sequencing data P2X7Rstop clone 6                                                                    
 
T7 forward result: 
 
  10        20        30        40        50        60 
P2X7Rstop cl  LLKLGTFTMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQ 
                      :::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  --------MPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQ 
                              10        20        30        40        50   
 
                      70        80        90       100       110       120 
P2X7Rstop cl  RKEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTE 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  RKEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTE 
                    60        70        80        90       100       110   
 
                     130       140       150       160       170       180 
P2X7Rstop cl  GQEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEA 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  GQEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEA 
                   120       130       140       150       160       170   
 
                     190       200       210       220       230       240 
P2X7Rstop cl  VEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  VEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLG 
                   180       190       200       210       220       230   
 
                     250       260       270       280       290       300 
P2X7Rstop cl  DIFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYN 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  DIFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYN 
                   240       250       260       270       280       290   
 
                     310                                                   
P2X7Rstop cl  FRYAKYYKENNVEKRTLIK----------------------------------------- 
              :::::::::::::::::::                                          
gi_33877741_  FRYAKYYKENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFID 
                   300       310       320       330       340       350   
 
 
P2X7R-for-3 results: 
 
 
   10        20        30       
P2X7Rstop cl  ------------------------TRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGD 
                                      :::::::::::::::::::::::::::::::::::: 
gi_33877741_  LLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGD 
                     190       200       210       220       230       240 
 
                40        50        60        70        80        90       
P2X7Rstop cl  NFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYYK 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYYK 
                     250       260       270       280       290       300 
 
               100       110       120       130       140       150       
P2X7Rstop cl  ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                     310       320       330       340       350       360 
 
               160       170       180       190       200       210       
P2X7Rstop cl  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
                     370       380       390       400       410       420 
 
               220       230       240       250       260       270       
P2X7Rstop cl  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
                     430       440       450       460       470       480 
 
               280       290       300       310                           
P2X7Rstop cl  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVL----------------- 
              :::::::::::::::::::::::::::::::::::::::::::                  
gi_33877741_  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
                     490       500       510       520       530       540 
 
 
                               
 
   
pCR3.1-BGH reverse result: 
 
   30        40        50       
P2X7Rstop cl  --------------------------KIDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                                        :.:::::::::::::::::::::::::::::::: 
gi_33877741_  ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                     310       320       330       340       350       360 
 
                60        70        80        90       100       110       
P2X7Rstop cl  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
                     370       380       390       400       410       420 
 
               120       130       140       150       160       170       
P2X7Rstop cl  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
                     430       440       450       460       470       480 
 
               180       190       200       210       220       230       
P2X7Rstop cl  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
                     490       500       510       520       530       540 
 
               240       250       260       270       280       290       
P2X7Rstop cl  TNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY*LESRG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::      
gi_33877741_  TNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY----- 
                     550       560       570       580       590           
300       310       320 
P2X7Rstop cl  PFEGKPIPNPLLGLDSTRTGHHHH 
                                
gi_33877741_  ------------------------ 
 
 
turquoise = V5-His tag    
Sequencing data P2X7R-V5-His clone 6                                                                  
 
T7 forward result: 
  
 
                      10        20        30        40        50        60 
P2X7R clone   LKLGTFTMPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQR 
                     ::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  -------MPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQR 
                             10        20        30        40        50    
 
                      70        80        90       100       110       120 
P2X7R clone   KEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  KEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEG 
                   60        70        80        90       100       110    
 
                     130       140       150       160       170       180 
P2X7R clone   QEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAV 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  QEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAV 
                  120       130       140       150       160       170    
 
                     190       200       210       220       230       240 
P2X7R clone   EEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGD 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  EEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGD 
                  180       190       200       210       220       230    
 
                     250       260       270       280       290       300 
P2X7R clone   IFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNF 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  IFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNF 
                  240       250       260       270       280       290    
 
                     310                                                   
P2X7R clone   RYAKYYKENNVEKRTLIK------------------------------------------ 
              ::::::::::::::::::                                           
gi_33877741_  RYAKYYKENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDF 
                  300       310       320       330       340       350    
 
 
P2X7R-for-3 results:	  	  	  
   10        20        30        
P2X7R clone   -----------------------TTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGD 
                                     ::::::::::::::::::::::::::::::::::::: 
gi_33877741_  LLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGD 
                     190       200       210       220       230       240 
 
               40        50        60        70        80        90        
P2X7R clone   NFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYYK 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NFSDVAIQGGIMGIEIYWDCNLDRWFHHCHPKYSFRRLDDKTTNVSLYPGYNFRYAKYYK 
                     250       260       270       280       290       300 
 
              100       110       120       130       140       150        
P2X7R clone   ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                     310       320       330       340       350       360 
 
              160       170       180       190       200       210        
P2X7R clone   NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
                     370       380       390       400       410       420 
 
              220       230       240       250       260       270        
P2X7R clone   LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
                     430       440       450       460       470       480 
 
              280       290       300                                      
P2X7R clone   SCLPSQLPESHRCLEELCCRKKPGACITTS------------------------------ 
              ::::::::::::::::::::::::::::::                               
gi_33877741_  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
                     490       500       510       520       530       540 
pCR3.1-BGH reverse result: 
 
      30        40        50          
P2X7R clone   -------------------------GKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                                       ::::::::::::::::::::::::::::::::::: 
gi_33877741_  ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSS 
                     310       320       330       340       350       360 
 
             60        70        80        90       100       110          
P2X7R clone   NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  NCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRS 
                     370       380       390       400       410       420 
 
            120       130       140       150       160       170          
P2X7R clone   LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  LQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCG 
                     430       440       450       460       470       480 
 
            180       190       200       210       220       230          
P2X7R clone   SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
gi_33877741_  SCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDS 
                     490       500       510       520       530       540 
 
            240       250       260       270       280       290          
P2X7R clone   TNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPYLESRG 
              :::::::::::::::::::::::::::::::::::::::::::::::::::::::      
gi_33877741_  TNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY----- 
                     550       560       570       580       590           
 
            300       310       320      
P2X7R clone   PFEGKPIPNPLLGLDSTRTGHHHHHQ 
                                  
gi_33877741_  -------------------------- 
 
 
turquoise: VS-His tag 	  
